• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    compounds useful as trpm8 modulators. the present invention includes compounds useful as trpm8 modulators, such as compounds of formula (I), and the subgenus and species thereof; personal products containing these compounds; and use of these compounds and personal products, particularly use to enhance or induce chemostasic sensations, such as feelings of chilliness or coldness.
    公开号:BR112013011188B1
    申请号:R112013011188-7
    申请日:2011-11-04
    公开日:2022-01-04
    发明作者:Alain Noncovich；Andrew Patron；Jane Ung；Chad Priest
    申请人:Senomyx, Inc；
    IPC主号:
    专利说明:

    CROSS REFERENCE TO RELATED REQUEST
    This application claims priority benefit on provisional application US 61/410,634, filed on November 5, 2010 and entitled "Compounds Useful as Agonists of hTRPM8", and provisional application US 61/443,490, filed on February 16, 2011 and entitled "Compounds Useful as Agonists of hTRPM8", the contents of which are hereby incorporated by reference in their entirety for all purposes. FIELD OF THE INVENTION
    The present invention relates to compounds useful as modulators of TRPM8. FUNDAMENTALS OF THE INVENTION
    The present invention provides compounds useful as modulators of the Transient Melastatin Receptor Potential Channel 8 (TRPM8). TRPM8 is a channel involved in the sensation of chemostasis, such as ice-cold temperatures, as well as the sensation of known cooling agents such as Menthol and Icillin. However, many of the currently known TRPM8 modulators have deficiencies with respect to strength and/or duration of effect, skin and/or mucosal irritation, odor, taste, solubility, and/or toxicity. SUMMARY OF THE INVENTION
    In one embodiment, the present invention provides a compound having Structural Formula (I):
    or a salt or solvate thereof; wherein Ar is optionally substituted aryl, optionally substituted carbocyclyl, or optionally substituted heteroaryl; X1-X2 is O-CR2aR2b, CHR3-CHR4, CR5=CR6, or cycloalkyl; or alternatively Ar-X1-X2- is a bicyclic heteroaryl;R2a, R2b, R3, R4, R5, and R6 are independently hydrogen or lower alkyl;hAr is a five- or six-membered heteroaryl R1 and optionally substituted alkyl, optionally substituted heteroalkyl , optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl.
    In another embodiment, the present invention provides a personal product comprising a compound of the present invention, or a salt or solvate thereof.
    In another embodiment, the present invention provides a method for modulating transient receptor potential channel melastatin 8 member (TRPM8) comprising contacting the receptor with a compound of the present invention, or a salt or solvate thereof.
    In another embodiment, the present invention provides a method of modulating the cooling sensation of a composition comprising combining the composition with a compound of the present invention, or a salt or solvate thereof, to form a modified composition.
    In another embodiment, the present invention provides a method of inducing a feeling of cooling in a human or animal comprising contacting the human or animal with a compound of the present invention, or a salt or solvate thereof. DETAILED DESCRIPTION OF THE INVENTION
    Various embodiments and advantages of the present invention will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the invention. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as described. Definitions
    The terms “one” and “one” do not denote a quantity limitation, but, on the other hand, denote the presence of at least one of the referenced item. The term “or” or “c/or” is used as a function word to indicate that two words or expressions are to be taken together or individually. The terms “comprising”, “containing”, “including”, and “containing” should be interpreted as open-ended terms (ie mean “including but not limited to”). The endpoints of all ranges directly to the same component or property are inclusive and independently combinable.
    The term "present compound(s)" or "compound(s) of the present invention" refers to compounds included by structural formulas disclosed herein and includes any subgenres and specific compounds within these formulas whose structures are disclosed herein. Compounds can be identified by their chemical structures and/or chemical name. When the chemical structure and the chemical name conflict, the chemical structure determines the identity of the compound. The compounds described herein may contain one or more chiral centers and/or double bonds and therefore may exist as stereoisomers, as double bond isomers (i.e. geometric isomers), enantiomers or diastereoisomers. Thus, the chemical structures described herein include all possible enantiomers and stereoisomers of the illustrated compounds including the stereoisomerically pure form (eg, geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their enantiomeric or stereoisomeric components using separation techniques or chiral synthesis techniques well known to those skilled in the art. The compounds may further exist in various tautomeric forms including the enol form, the keto form and mixtures thereof. Thus, the chemical structures described herein include all possible tautomeric forms of the compounds illustrated. The compounds described herein further include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that can be incorporated into the compounds of the invention include, but are not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 17O, ele. The compounds can exist in unsolvated forms as well as solvated forms, including hydrated forms and as N-oxides. In general, compounds can be hydrated, solvated or N-oxides. Certain compounds may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention. Furthermore, it should be understood, when partial structures of compounds are illustrated, the parentheses indicate the point of attachment of the partial structure to the rest of the molecule. The term "tautomer" as used herein refers to isomers that change one another more easily so that they can exist together in equilibrium. "Alkyl," by itself or as part of another substituent, refers to a hydrocarbon radical. branched, straight-chain or cyclic saturated monovalent derivative derived by the removal of a hydrogen atom from a single carbon atom of a parent alkane. The term "alkyl" includes "cycloalkyl" as defined hereinbelow. Typical alkyl groups include, but are not limited to, methyl; ethyl; propyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butanis such as butan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-1-yl (isobutyl), 2-methyl-propan-2-yl (Z-butyl), cyclobutan-1 -il, etc.; and the like. In some embodiments, an alkyl group comprises from 1 to 20 carbon atoms (C1-C20 alkyl). In other embodiments, an alkyl group comprises from 1 to 10 carbon atoms (C1 -C10 alkyl). In still other embodiments, an alkyl group comprises from 1 to 6 carbon atoms (C1 -C(, alkyl).C1 -Cf, alkyl is further known as "lower alkyl".
    Note that when an alkyl group is still attached to another atom, it becomes an "alkylene" group. In other words, the term "alkylene" refers to a divalent alkyl. For example, -CH2CH3 is an ethyl, while -CH2CII2- is an ethylene. That is, "alkylene," by itself or as part of another substituent, refers to a saturated or unsaturated, branched, straight-chain or cyclic divalent hydrocarbon radical derived by the removal of two hydrogen atoms from a hydrogen atom. single carbon or two different carbon atoms of an alkane, alkene or alkyne parent. The term "alkylene" includes "cycloalkylene" as defined hereinbelow. The term "alkylene" is specifically intended to include groups containing any degree or level of saturation, i.e. groups containing exclusively carbon-carbon single bonds, groups containing one or more carbon-carbon double bonds, groups containing one or more carbon-carbon triple bonds -carbon and groups containing mixtures of carbon-carbon single, double, and triple bonds. In some embodiments, an alkylene group comprises from 1 to 20 carbon atoms (C1-C20 alkylene). In other embodiments, an alkylene group comprises from 1 to 10 carbon atoms (C 1 -C 10 alkylene). In still other embodiments, an alkylene group comprises from 1 to 6 carbon atoms (C1 -Cr, alkylene). "Alkenyl," by itself or as part of another substituent, refers to a branched, straight-chain or cyclic monovalent unsaturated hydrocarbon radical containing at least one carbon-carbon double bond derived from the removal of a hydrogen atom from a single carbon atom of a parent alkene. The term "alkenyl" includes "cycloalkenyl" as defined hereinbelow. The group can be in the es or trans conformation around the double bonds. Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-cn-2-yl, prop-2-en-1-yl (allyl), prop-2-cn-2-yl, cycloprop-1-en -1-yl; cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-cn-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2- en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, e/c.; and the like. "Alkynyl," by itself or as part of another substituent, refers to a branched, straight-chain or cyclic unsaturated monovalent hydrocarbon radical containing at least one carbon-carbon triple bond derived from the removal of a hydrogen atom from a single atom. carbon of an alkyne parent. Typical alkynyl groups include, but are not limited to, ethynyl; propyns such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.-, butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but- 3-in-1-yl, etc.; and the like. "Alkoxy," by itself or as part of another substituent, refers to a radical of the formula -O-R199, where R199 is alkyl or substituted alkyl as defined herein. "Acyl" by itself or as part of another substituent refers to a radical -C(O)R200, where R200 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, substituted heteroarylalkyl or heteroarylalkyl as defined herein. Representative examples include, but are not limited to, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl, and the like. "Aryl," by itself or as part of another substituent, refers to a monovalent aromatic hydrocarbon group derived from the removal of a hydrogen atom from a single carbon atom of a parent aromatic ring system, as defined herein. Groups typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, αs-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphen, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like. aryl comprises from 6 to 20 carbon atoms (C6-C20 aryl) In other embodiments, an aryl group comprises from 6 to 15 carbon atoms (CG-CIS aryl) In still other embodiments, an aryl group comprises from 6 to 15 carbon atoms 15 carbon atoms (C(,-Cio aryl ). "Arylalkyl," by itself or as part of another substituent, refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal carbon atom or sp, is substituted with a aril, as defined here. That is, arylalkyl can still be considered as an alkyl substituted by aryl. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan- l-il and the like. When specific alkyl moieties are intended, the nomenclature arylalkanyl, arylalkenyl and/or arylalkynyl is used. In some embodiments, an arylalkyl group is (C6-C30) arylalkyl, for example, the alkanyl, alkenyl, or alkynyl moiety of the arylalkyl group is (C1-C10) alkyl and the aryl moiety is (C6-C20) aryl. In other embodiments, an arylalkyl group is (C1 -C20 ) arylalkyl, for example, the alkanyl, alkenyl alkynyl moiety of the arylalkyl group is (C1 -C6 )alkyl and the aryl moiety is (C6 -C12 ) aryl. In still other embodiments, an arylalkyl group is (C6-C15) arylalkyl, for example, the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-C5) alkyl and the aryl moiety is (C6-C10) aryl. "Carbocyclic," or "Carbocyclyl," by itself or as part of another substituent, refers to a cyclic saturated or partially saturated, but non-aromatic, monovalent hydrocarbon radical, including cycloalkyl, cycloalkenyl, and cycloalkynyl as defined herein. Typical carbocyclyl groups include, among others, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane, and the like. In some embodiments, the cycloalkyl group comprises from 3 to 10 ring atoms (C3-C10 cycloalkyl). In other embodiments, the cycloalkyl group comprises from 3 to 7 ring atoms (C3-C7 cycloalkyl). The carbocyclyl may further be substituted by one or more heteroatoms including, but not limited to, N, P, O, S, and Si, which are attached to the cycloalkyl carbon atoms via a monovalent or multivalent bond. "Heteroalkyl," by itself or as part of other substituents, refers to alkyl groups in which one or more of the carbon atoms are each, independently of the other, substituted with the same or different heteroatoms or heteroatomic groups. Typical groups of heteroatoms or heteroatoms that can replace carbon atoms include, but are not limited to, -O-, -S-, -N-, -Si-, -NH-, -S(O)-, -S(O) 2-, -S(O)NH-, -S(O)2NII- and the like and combinations thereof. Heteroatoms or heteroatomic groups may be substituted at any position within the alkyl group. Typical heteroatomic groups that may be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -OS-, -NR20lR202-, =NN=, -N=N-, -N =N-NR2()3R2()4, -PR205-, -P(O)2-, -POR206-, -OP(O)2-, -SO-, -SO2-, -SnR2(,7R201i- and the like, where R201 , R202 , R203 , R204 , R20 , R206 , R207 and R2( are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cyclohetcroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl "Heterocyclyl," or "Heterocyclyl," alone or as part of another substituent, refers to a carbocyclic radical in which one or more carbon atoms are independently substituted with the same or different heteroatom Heterocyclyl may further be substituted by one or more heteroatoms including, but not limited to, N, P, O, S, and Si, which bond to the the carbon ones of the heterocyclyl via monovalent or multivalent bonding. Typical heteroatoms to replace carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Typical heterocyclyl groups include, among others, groups derived from epoxides, azirines, thiranes, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidone, quinuclidine, and the like. In some embodiments, the heterocyclyl group comprises 3 to 10 ring atoms (3 to 10 membered heterocyclyl). In other embodiments, the heterocyclyl group comprises 5 to 7 ring atoms (5 to 7 membered heterocyclyl). A cycloheteroalkyl group may be substituted on a heteroatom, for example a nitrogen atom, with a (C1 -C5 ) alkyl group. As specific examples, N-methyl-imidazolidinyl, N-methyl-morpholinyl, N-methyl-piperazinyl, N-methyl-piperidinyl, N-methyl-pyrazolidinyl and N-methyl-pyrrolidinyl are included within the definition of "heterocyclyl." A heterocyclyl group may be attached to the remainder of the molecule through a ring carbon atom or a ring hetero atom. "Halo," by itself or as part of another substituent, refers to a -F, -Cl, -Br or -I radical. "Heteroaryl," by itself or as part of another substituent, refers to a monovalent heteroaromatic radical derived from the removal of a hydrogen atom from a single atom of a parent heteroaromatic ring system, as defined herein. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, β-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine , oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene , triazole, xanthene, and the like. In some embodiments, the heteroaryl group comprises from 5 to 20 ring atoms (5 to 20 membered heteroaryl). In other embodiments, the heteroaryl group comprises 5 to 10 ring atoms (5 to 10 membered heteroaryl). Exemplary heteroaryl groups include those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole and pyrazine. "Heteroarylalkyl" by itself or as part of another substituent refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is substituted with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclaturum heteroarylaleanyl, heteroarylalkenyl and/or heteroarylalkynyl is used. In some embodiments, the heteroarylalkyl group is a 6- to 21-membered heteroarylalkyl, for example, the alkanyl, alkenyl, or alkynyl moiety of the heteroarylalkyl is (C1 -C6 )alkyl and the heteroaryl moiety is a 5- to 15-membered heteroaryl. In other embodiments, the heteroarylalkyl is a 6- to 13-membered heteroarylalkyl, for example, the alkanyl, alkenyl or alkynyl moiety is (C1-C3) alkyl and the heteroaryl moiety is a 5- to 10-membered heteroaryl. "Protecting group" refers to a grouping of atoms that when attached to a reactive functional group on a molecule masks, reduces, or prevents reactivity of the functional group. Examples of protecting group can be found in Green et al., "Protective Groups in Organic Chemistry", (Wiley, 2nd ed. 1991) and Harrison et al., "Compendium of Synthetic Organic Methods", Vols. 1-8 (John Wiley and Sons, 1971-1996). Representative amino protecting groups include, among others, formyl, acetyl, trifluoroacetyl. benzyl, benzyloxycarbonyl ("CBZ"), /e/7-butoxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilyl-ethanesulfonyl ("SES"), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitro-veratryloxycarbonyl (“NVOC”) and the like. Representative hydroxy protecting groups include, among others, those where the hydroxy group is acylated or alkylated such as benzyl ethers, and trityl as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers. "Salt" refers to a salt of a compound, which has the desired pharmacological activity of the parent compound, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvid acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid , 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacctic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, for example, an alkali metal ion, an alkaline earth metal ion, or an aluminum ion; or coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. "Solvate" means a compound formed by solvation (the combination of solvent molecules with solute molecules or ions), or an aggregate consisting of a solute ion or molecule, i.e., a compound of the present invention, with one or more molecules of solvent. When water is the solvent, the corresponding solvate is "hydrated". "N-oxide", also known as amine oxide or amine-N-oxide, means a compound which is derived from a compound of the present invention via oxidation of an amine group of the compound of the present invention. An N-oxide typically contains the functional group R3N+-0 (sometimes written as R3N=O or R3N—>0). "Substituted," when used to modify a specified group, means that one or more hydrogen atoms of the specified group or radical are each, independently of the other, substituted with the same or different substituent. Useful substituent groups for substituting saturated carbon atoms on the specified group or radical include, but are not limited to -Rd, halo, -O', =O, -ORb, -SRb, -S', =S, -NR^R^, =NRb, =N-ORb, trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(())2Rb, -S(O)2NRb, - S(O)2O', -S(O)2ORb, -OS(O)2Rb, -OS(O)2O', -OS(O)2ORb, -P(O)(O')2, -P( O)(ORb)(O'), -P(O)(ORb)(ORb), -C(O)Rb, -C(S)Rb, -C(NRb)Rb, -C(O)O' , -C(O)ORb, -C(S)ORb, -C(O)NRcRc, -C(NRb)NRcRc, -OC(O)Rb, -OC(S)Rb, -OC(O)O' , -OC(O)ORb, -OC(S)ORb, -NRbC(O)Rb, -NRbC(S)Rb, -NRbC(O)O', -NRbC(O)ORb, -NRbC(S)ORb -NRbC(O)NRcRe, -NRbC(NRb)Rb and -NRbC(NRb)NRLRL, where Rd is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; each Rb is independently hydrogen or Rd; and each RL is independently Rb or alternatively the two Rcs may be taken together with the nitrogen atom to which they are attached form a 4, 5, 6 or 7 membered cycloheteroalkyl which may optionally include from 1 to 4 of the same or different heteroatom additional from the group consisting of O, N and S. As specific examples, -NRCRC is intended to include -NH 2 , -NU-alkyl, N-pyrrolidinyl and N-morpholinyl. As another specific example, a substituted alkyl is intended to include -alkylene-O-alkyl, -alkylene-heteroaryl, -alkylene-cycloheteroalkyl, -alkylene-C(O)ORb, -alkylene-C(O)NRbRb, and -CH2-CH2 -C(O)-CH3.O one or more substituent groups, taken together with the atoms to which they are attached, can form a cyclic ring including cycloalkyl and cycloheteroalkyl.
    Similarly, substituent groups useful for substituting unsaturated carbon atoms in the specified group or radical include, but are not limited to, -Ra, halo, -O', -ORb, -SRb, -S', -NRRCC, trihalomethyl, -Cf3, -CN, -OCN, -SCN, -NO, -NO2, -N3, -S(O)2Rb, -S(O)2O', -S(O)2ORb, -OS(O)2Rb, -OS( O)2O', -OS(O)2ORb, -P(O)(O')2, -P(O)(ORb)(O'), -P(O)(ORb)(ORb), -C (O)Rb, -C(S)Rb, -C(NRb)Rb, -C(O)O', -C(O)ORb, -C(S)ORb, -C(O)NRcRc, -C (NRb)NRcRc, -OC(O)Rb, -OC(S)Rb, -OC(O)O', -OC(O)ORb, -OC(S)ORb, -NRbC(O)Rb, -NRbC (S)Rb, -NRbC(O)O', -NRbC(O)ORb, -NRbC(S)ORb, -NRbC(O)NReRc, -NRbC(NRb)Rb and -NRbC(NRb)NRcRc, where Ra , Rb and Rc are as previously defined.
    Useful substituent groups for replacing nitrogen atoms in heteroalkyl and cycloheteroalkyl groups include, but are not limited to, -Ra, -O', -ORb, -SRb, -S', -NRRCC, trihalomethyl, -CF3, -CN, -NO, - NO2, -S(O)2Rb, -S(O)2O', -S(O)2ORb, -OS(O)2Rb, -OS(O)2O', -OS(O)2ORb, -P(O )(O')2, -P(O)(ORb)(O'), -P(0)(ORb)(ORb), -C(O)Rb, -C(S)Rb, -C(NRb )Rb, -C(O)ORb, -C(S)ORb, -C(O)NRcRc, -C(NRb)NRcRc, -OC(O)Rb, -OC(S)Rb, -OC(O) ORb, -OC(S)ORb, -NRbC(O)Rb, -NRbC(S)Rb, -NRbC(O)ORb, -NRbC(S)ORb, -NRbC(O)NRcRc, -NRbC(NRb)Rb and -NRbC(NRb)NRcRc, where Ra, Rb and Re are as previously defined.
    Substituent groups from the above lists useful for replacing other specified groups or atoms will be apparent to those skilled in the art.
    The term "substituted" specifically provides for and permits one or more substitutions that are common in the art. However, it is generally understood by those skilled in the art that substituents should be selected so as not to adversely affect the useful characteristics of the compound or adversely interfere with its function. Suitable substituents may include, for example, halogen groups, perfluoroalkyl groups, perfluoroalkoxy groups, alkyl groups, alkenyl groups, alkynyl groups, hydroxy groups, oxo groups, mercapto groups, alkylthio groups, alkoxy groups, aryl or heteroaryl groups, aryloxy or heteroaryloxy groups , arylalkyl or heteroarylalkyl groups, arylalkoxy or heteroarylalkoxy groups, amino groups, alkyl and dialkylamino groups, carbamoyl groups, alkylcarbonyl groups, carboxyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups, dialkylaminocarbonyl groups, arylcarbonyl groups, aryloxycarbonyl groups, alkylsulfonyl groups, arylsulfonyl groups, cycloalkyl groups, cyano groups, C1 -C6 alkylthio groups, arylthio groups, nitro groups, keto groups, acyl groups, boronate or boronyl groups, phosphate or phosphonyl groups, sulfamyl groups, sulfonyl groups, sulfinyl groups, and combinations thereof. In the case of substituted combinations, such as "substituted arylalkyl," either the aryl or alkyl group may be substituted, or both aryl and alkyl groups may be substituted with one or more substituents. Furthermore, in some cases, appropriate substituents may combine to form one or more rings as known to those skilled in the art.
    The term "optionally substituted" denotes the presence or absence of the substituent group. For example, optionally substituted alkyl includes both unsubstituted alkyl and substituted alkyl. Substituents used to replace a specified group may be further substituted, typically by one or more of the same or different groups selected from the various groups specified above. "Carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a compound is administered.
    A “personal product” as used herein refers to any product that is used by or useful to a person or animal, optionally in contact with the person or animal during its intended use, for example in surface contact such as skin. or mucosal contact with the person or animal during its intended use.
    As used herein, an "ingible composition" includes any substance which, alone or in combination with another substance, can be taken by mouth whether intended for consumption or not. The ingestible composition includes both "food or beverage" and "non-edible products". By "food or beverage" is meant any edible product intended for consumption by humans or animals, including solids, semi-solids, or liquids (e.g., beverages). The term “non-edible products” or “non-edible composition” includes any product or composition that can be taken by humans or animals for purposes other than consumption or as food or drink. For example, the non-edible product or non-edible composition includes supplements, nutraceuticals, functional food products (e.g., any fresh or processed product claimed to have health promoting and/or disease-preventing properties beyond the basic nutritional function of providing nutrients ), over-the-counter medications and medications, oral care products like toothpastes and mouthwashes, cosmetics like sweetened lip balms, and other personal care products that may or may not contain any sweeteners.
    A "incredibly acceptable carrier or excipient" is a medium and/or composition that is used to prepare a desired dispersed dosage form of the inventive compound, to administer the inventive compound in a dispersed/diluted form, such that the biological effectiveness of the compound inventiveness is maximized. The medium and/or composition may be in any form depending on the intended use of the product, for example solid, semi-solid, liquid, paste, gel, lotion, cream, foam, suspension, solution, or any combination thereof (such as a liquid containing solids). Incredibly acceptable carriers include many common food ingredients such as water at neutral, acidic, or basic pH, fruit or vegetable juices, vinegar, marinades, beer, wine, plain water/fatty emulsions such as milk or condensed milk, edible oils and fats, fatty acids and their alkyl esters, low molecular weight oligomers of propylene glycol, glyceryl esters of fatty acids, and dispersions or emulsions of such hydrophobic substances in aqueous media, salts such as sodium chloride, wheat flours, solvents such as ethanol, edible diluents solids such as vegetable powders or flours, or other liquid carriers; dispersing or suspending aids; surface active agents; isotonic agents; thickening or emulsifying agents, preservatives; solid binders; lubricants and the like.
    A "taste" here refers to a subject's perception of taste, which includes sweet, sour, salty, bitter, and umami (also known as cospice). The subject can be a human or an animal.
    A "Flavorizing agent" herein refers to a compound or the incredibly acceptable salt or solvate thereof that induces a taste or taste in an animal or human. The flavoring agent may be natural, synthetic, or synthetic.
    A "modulator" herein refers to a compound that can regulate TRPM8 activity. Such regulation includes activating TRPM8, blocking TRPM8, or potentiating/reducing TRPM8 activation. That is, modulators include agonists, antagonists, enhancers, etc. .
    The term "chemostasis" or "feeling of chemostasis" herein refers to body surface sensitivity, e.g., skin and/or mucosal surfaces that arise when the body surface is exposed to heat or cold or when chemical compounds activate receptors associated with senses that mediate pain, touch, and thermal/cold perception. Particularly these chemical-induced reactions do not fit into the traditional sense categories of taste and smell. Examples of chemostatic sensation include the pepper burn-like irritation, the coldness of menthol in mouthwashes and topical pain relievers, the sting or tingling of carbonation in the nose and mouth, and the induction of tears from onions. That is, chemostatic sensations can arise by direct chemical activation of ion channels in sensory nerve fibers, eg TRPM8. Due to the presence of chemoresponsive nerve fibers in all skin types, chemostatic sensations can be aroused from anywhere on the surface of the body as well as from mucosal surfaces in the nose, mouth, eyes, etc.
    A "chemostasis sensation modifier" or "chemostasis sensation modifying agent" herein refers to a compound, or a salt or solvate thereof, that modulates, including enhances or potentiates, induces, or blocks, chemostatic sensation in an animal or a human.
    An "amount that modulates the sensation of chemostasis" herein refers to an amount of a compound of the present invention that is sufficient to alter (induce, increase, or reduce) the chemostatic sensation in a personal product, sufficiently to be perceived by a subject. animal or human. In many embodiments of the invention, at least about 0.001 ppm of the present compound would need to be present for most animal or human subjects to perceive a modulation of chemostatic sensation in a personal product comprising the present compound. A wide concentration range that could typically be employed to economically provide a desirable degree of chemostatic sensation modulation may be from about 0.001 ppm to 1000 ppm, or from about 0.01 ppm to about 500 ppm, or from about dc 0.05 ppm to about 300 ppm, or from about 0.1 ppm to about 200 ppm, or from about 0.5 ppm to about 150 ppm, or from about 1 ppm to about 100 ppm.
    An "amount that induces a sensation of chemostasis" or "amount that increases a sensation of chemostasis" herein refers to an amount of a compound that is sufficient to induce or enhance a chemostatic sensation as perceived by an animal or a human. of an amount that induces/increases chemostatic sensation can be from about 0.001 ppm to 100 ppm, or a narrow range of about 0.1 ppm to about 10 ppm. Alternative ranges of amounts that increase/induce chemostatic sensation may be from about 0.01 ppm to about 30 ppm, from about 0.05 ppm to about 15 ppm, from about 0.1 ppm to about 5 ppm, or from about 0.1 ppm to about of 3 ppm. Compound modalities
    In one embodiment, the present invention provides a compound having Structural Formula (I):
    or a salt or solvate thereof; wherein Ar is optionally substituted aryl, optionally substituted carbocyclyl, or optionally substituted heteroaryl; X'-X2 is O-CR2aR2b, CHR3-Cl1R4, CR5=CR6, or cycloalkyl; or alternatively Ar-X'-X"- is a bicyclic heteroaryl;R2d, R2b, R3, R4, R5, and R6 are independently hydrogen or lower alkyl;hAr is an optionally substituted five-membered heteroaryl containing one or more heteroatoms selected from nitrogen, oxygen, and sulfur, and R1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl.
    In one embodiment of Formula (I), Ar is optionally substituted aryl, and the optionally substituted aryl is optionally substituted phenyl.
    In one embodiment of Formula (1), Ar is optionally substituted heteroaryl, wherein the heteroaryl is a five- or six-membered heteroaryl containing one or more heteroatoms selected from nitrogen, oxygen, and sulfur. In certain embodiments, the optionally substituted heteroaryl is an optionally substituted group selected from the group consisting of pyrrolyl, furanyl. thienyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, isoxazolyl, isoliazolyl, pyridyl, pyrimidyl, and triazinyl.
    In one embodiment of Formula (I), the optional substituent as mentioned above is one or more groups selected from the group consisting of alkyl, heteroalkyl, alkenyl, alkoxy, hydroxyl, amino, N-alkylamino, N-dialkylamino, halo, nitro, cyano, acyl, carboxyl, carboxyl ester, or amide; or two substituents, together with the atoms to which they are attached, form an optionally substituted carbocyclyl or heterocyclyl containing one or more heteroatoms selected from nitrogen, oxygen, and sulfur. In one embodiment of Formula (I), R2b, R3, R4 , R5, and R6 are all hydrogen.
    In one embodiment of Formula (I), hAr is selected from the group consisting of pyrrolyl, furanyl, thienyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, isoxazolyl, and isothiazolyl, each of which is optionally substituted.
    In one embodiment of Formula (I), R 1 is optionally substituted alkyl, wherein the alkyl is linear, branched, cyclic, or a combination thereof.
    In one embodiment of Formula (I), R1 is optionally substituted aryl or optionally substituted heteroaryl. Examples of aryl and heteroaryl include, among others, phenyl, pyrrolyl, furanyl, thienyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidyl, and triazinyl, each of which is optionally substituted.
    In one embodiment of Formula (I), X'-X2 is O-CIF, O-CII(CI13), or O-CH(CH2CH3). In one embodiment of Formula (I), X'-X2 is CFI2-CH2 or CH=CH. In one embodiment of Formula (I), X'-X2 is cyclopropyl, cyclobutyl, or cyclopentyl.
    In one embodiment of Formula (I), the compound may be represented by a Structural Formula (II):
    whereinAr is optionally substituted aryl, optionally substituted carbocyclyl, or optionally substituted heteroaryl;Y is oxygen or sulfur;Z is nitrogen or CR;R is hydrogen or lower alkyl;X'-X2 is O-CR2aR2b, CHR3-CHR4, CR5= CR6, OR cycloalkyl; R2a, R2h, R3, R4, R5, and R6 are independently hydrogen or lower alkyl; R1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carboethyl, or optionally substituted heterocyclyl; n is 0, 1, 2, or 3; Each R2 is independently optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, alkoxy, hydroxyl, amino, N-alkylamino, N-dialkylamino, halo, nitro, cyano, acyl, carboxyl, carboxyl ester, or amide.
    In one embodiment of Formula (II), the compound may be represented by a Structural Formula (III):
    wherein Ar is optionally substituted aryl, optionally substituted carbocyclyl, or optionally substituted heteroaryl; X'-X2 and O-CR2aR2b, CIIR3-CHR4, CR5=CR6, OR cycloalkyl;R2a, R2b, R3, R4, R5, and R6 are independently hydrogen or lower alkyl; Z1 and Z2 are independently nitrogen or CH, provided that Z1 and Z2 are not both nitrogen; and R1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl.
    In one embodiment of Formula (HI), Ar is optionally substituted aryl; and X'-X2 and O-CR2aR2b, CII2-CII2, or CH=CH; R2,1 and R2b are independently hydrogen or lower alkyl; R1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl.
    In one embodiment of Formula (III), Ar is optionally substituted phenyl. In one embodiment of Formula (III), Ar is optionally substituted heteroaryl; and X'-X2 is O-CR2aR2b, CH2-CH2, or CH=CH; R2a and R2b are independently hydrogen or lower alkyl; R1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl.
    In one embodiment of Formula (III), R 1 is optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl.
    In one embodiment of Formula (III), R2a and R2b are hydrogen. In one embodiment of Formula (III), R2a is hydrogen, and R2b is lower alkyl.
    In one embodiment of Formula (I), the compound may be represented by a Structural Formula (IV):
    wherein X is a bicyclic heteroaryl; hAr is an optionally substituted five-membered heteroaryl containing one or more heteroatoms selected from nitrogen, oxygen, and sulfur; and R1 is optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl.
    In one embodiment of Formula (1), hAr is thienyl or furanyl. In one embodiment of Formula (I), X is optionally substituted benzofuranyl.
    In one embodiment of Formula (I), R1 is optionally substituted alkyl, optionally substituted aryl, or optionally substituted heteroaryl.
    In some specific embodiments of the present invention, the present compounds are selected from the group consisting of the compound of Table A and Table B below:
























    The compounds of the present invention, or a salt or solvate thereof, can be used as modulators, for example agonists, of the TRPM8 receptor in personal products to modulate, for example, induce chemostatic sensations, particularly sensations of cold or coolness.
    The present compounds are important to the flavor and fragrance industries because they enhance or induce/generate a feeling of coolness or coldness that is generally associated with freshness and cleanliness.
    As TRPM8 receptor modulators, the present compounds further have repellent effect on insects, therapeutic effect in antitumor treatments (e.g. an influence of prostate tumors), activity in the treatment of inflammatory pain/hypcralgesia, and efficacy (as TRPM8 antagonists) in treatment of bladder syndrome or overactive bladder.
    The personal product may be provided as a composition, which comprises one or more of the present compound and optionally at least one carrier. The composition may be in any physical form, such as a solid, semi-solid, plaster, solution, suspension, lotion, cream, foam, gel, paste, emulsion, or a combination thereof. Examples of the composition include, but are not limited to, a pharmaceutical composition, an ingestible composition, a chemostasis concentrate, a personal care composition, and a combination thereof. In one embodiment of the present invention, the composition comprises a chemostatic sensation that modulates the amount of the present compound. In another embodiment of the present invention, the composition comprises a chemostatic sensation that induces an amount of the present compound. In certain modalities, the chemostatic sensation is a feeling of cold or chilliness. In one embodiment of the composition, the present compound is in a concentration ranging from about 0.0001 ppm to 100,000 ppm. In another embodiment of the composition, the present compound is in a concentration ranging from about 0.001 ppm to 10,000 ppm. In another embodiment of the composition, the present compound is in a concentration ranging from about 0.01 ppm to 1000 ppm. In another embodiment of the composition, the present compound is in a concentration ranging from about 0.1 ppm to 500 ppm. In another embodiment of the composition, the present compound is in a concentration ranging from about 1 ppm to 500 ppm. In another embodiment of the composition, the present compound is in a concentration ranging from about 10 ppm to 500 ppm. In another embodiment of the composition, the present compound is in a concentration ranging from about 1 ppm to 400 ppm.
    The present ingestible composition typically comprises one or more compounds of the present invention and at least one ingestible acceptable carrier. The ingestible composition includes both "food or beverage" and "non-edible products". By "food or beverage" is meant any edible product intended for consumption by humans or animals, including solids, semi-solids, or liquids (eg, beverages). The term "non-edible products" or "non-edible composition" includes nutraceutical compositions, dietary supplements, nutritional compositions, and functional food products (e.g., any fresh or processed food that has health-promoting and/or disease-preventing properties in addition to of the basic nutritional function of providing nutrients).
    In one embodiment, the present compounds are added to food or beverage products or formulations. Examples of food and beverage products or formulations include, but are not limited to, toppings, meringues, or icings for edibles or any entity included in the Soup category, dry processed food category, beverage category, ready meal category, preserved food category or canned, frozen processed food category, chilled food category, snack food category, baked goods category, confectionery category, dairy category, ice cream category, meal replacement category, pasta and noodles category, and category of sauces, toppings, and condiments, infant food category, and/or spreads category.
    In general, the soup category refers to canned/prepared, dehydrated, instant, chilled, IU ff and frozen soup. For purposes of this definition soup(s) means a food prepared from meat, poultry, fish, vegetables, grains, fruit and other ingredients, cooked in a liquid which may include visible pieces of some or all of these ingredients. It should be clear (like a broth) or thick (like a thick soup), smooth, pureed or chunky, ready-to-serve, semi-condensed or condensed and can be served hot or cold, as a first course or as a main course. a meal or as a snack between meals (drunk as a beverage). Soup can be used as an ingredient to prepare other meal components and can range from broths (consommé) to sauces (cream or cheese-based soups). kitchen aids such as: powders, granules, doughs, concentrated liquid products, including broth concentrates, broths and broth-like products in pressed cubes, tablets or powder or in granulated form, which are sold separately as a finished product or as an ingredient in from a recipe product, sauces and mixes (regardless of technology); (ii) solution meal products such as: freeze-dried dehydrated soups, including dehydrated soup mixes, dehydrated instant soups, dehydrated ready-to-cook soups, ambient or dehydrated ready-to-cook meal preparations, individual meals and entrees including pasta dishes, potato and rice; and (iii) meal preparation products such as: condiments, marinades, salad dressings, salad toppings, sauces, baked goods, pasta mixes, shelf-stable spreads, barbecue sauces, liquid recipe mixes, concentrates, sauces or blends of sauces, including salad dressing mixes, sold as a finished product or as an ingredient within a product, whether dehydrated, liquid or frozen.
    The beverage category generally means beverages, beverage blends and concentrates, including but not limited to carbonated and non-carbonated beverages, alcoholic and non-alcoholic beverages, ready-to-drink beverages, liquid concentrate formulations for preparing beverages such as soft drinks, and powdered drinks. The beverage category also includes alcoholic beverages, soft drinks, sports drinks, isotonic drinks, and hot drinks. Alcoholic beverages include, but are not limited to, beer, cider/pcrry, FABs, wine, and spirits. Soft drinks include, among other gases, such as cola and non-cola; fruit juice such as juice, nectars, juice drinks and fruit flavored drinks; bottled water, which includes sparkling water, mineral water, and purified/table water; functional drinks, which can be carbonated or even and include sports drinks, energy drinks or elixirs; concentrates, such as liquid and powder concentrates in ready-to-drink measure. Beverages, hot or cold, include, among others, coffee or iced coffee, such as fresh, instant, and blended coffee; tea or iced tea, such as black, green, white, oolong, and flavored tea; and other beverages including flavor, malt or plant based powders, granules, blocks or tablets mixed with milk or water.
    The snack food category generally refers to any food that can be an informal light meal including but not limited to sweet and savory snacks and snacks. Examples of snack foods include, but are not limited to fruit snacks, chips/crisps, extruded snacks, corn tortilla/chips, popcorn, pretzels, peanuts and other sweet and savory snacks. Examples of snacks include but are not limited to granola/muesli bars, morning bars, energy bars, fruit bars and other snack bars.
    The baked goods category generally refers to any edible product to prepare that involves exposure to heat or excessive sunlight. Examples of baked goods include, but are not limited to breads, sweet rolls, cookies, muffins, cereal, toast, pastries, waffles, tortillas, cookies, pies, bagels, pies, quiches, cake, any baked goods, and any combination thereof.
    The ice cream category generally refers to a frozen dessert containing cream and sugar and flavoring. Examples of ice cream include, but are not limited to: popsicles; ice cream in pots; frozen yogurt and artisanal ice cream; soy beans, oats, fava beans (eg red fava beans and beans), and rice-based ice cream.
    The confectionery category generally refers to an edible product that is sweet in taste. Examples of confectionery include, but are not limited to, candies, jellies, chocolate, sugar confections, gums, and the like, and any combination of products.
    The meal replacement category generally refers to any food intended to replace a regular meal, particularly for people with health or fitness concerns. Examples of meal replacements include, but are not limited to, weight loss products and convalescent products.
    The ready-to-eat category generally refers to any food that can be served without extensive preparation or processing. The ready-meal includes products that have “proficiency” recipes added to them by the manufacturer, resulting in a high degree of speed, completeness, and convenience. Examples of ready meals include, but are not limited to, canned/prescribed, frozen, dried, chilled ready meals; dinner mixes; frozen pizza; chilled pizza; c prepared salads.
    The Pasta and Noodle category includes any pasta and/or noodles including but not limited to canned, dry and chilled/fresh pasta; and plain, instant, chilled, frozen noodles.
    The canned/preserved foods category includes, but is not limited to, canned/preserved meat and meat products, fish/seafood, vegetables, tomatoes, beans, fruit, ready meals, soup, pasta, and other canned/preserved foods.
    The frozen processed foods category includes but is not limited to frozen processed red meat, processed poultry, processed fish/seafood, processed vegetables, meat substitutes, processed potatoes, baked goods, desserts, ready meals, pizza, soup, noodles, and other frozen foods.
    The dry processed food category includes, but is not limited to, rice, dessert mixes, dry ready meals, dehydrated soup, instant soup, dry pasta, plain noodles, and instant noodles.
    The cold processed food category includes, but is not limited to, chilled processed meats, chilled processed meats, processed fish/seafood products, lunch kits, fresh cut fruit, ready meals, pizza, prepared salads, soup, noodles and fresh pasta .
    The sauces, toppings and condiments category includes, but is not limited to, tomato pastes and purees, broths/bouillon cubes, herbs and seasonings, monosodium glutamate (MSG), table sauces, soy-based sauces, pasta sauces, wet/cooking, dry sauces/powder mixes, ketchup, mayonnaise, mustard, salad dressings, vinaigrettes, spreads, pickles, and other sauces, toppings and condiments.
    The infant food category includes, among others, milk or soy-based formulas; and prepared, dried and other infant foods.
    The category of spreads includes, among others, jellies and preserves, honey, chocolate spreads, peanut-based spreads, and yeast-based spreads.
    The category of dairy products generally refers to an edible product produced from mammalian milk. Examples of dairy products include, but are not limited to, drinkable dairy products, cheese, yogurt and sour milk drinks, and other dairy products.
    Additional examples for edible composition, particularly food and beverage products or formulations, are provided as follows. Exemplary edible compositions include one or more of confectionery, chocolate confectionery, lozenges, candies, packaged chocolate bars, boxed assortments, standard boxed assortments, wrapped twist miniatures, seasonal chocolate, toy chocolate, alfajores, other chocolate confectionery , peppermints, standard mints, energy candies, hard candies, lozenges, gummies, jelly beans and chewing gum, caramels and nougats, medicated confectionery, lollipops, licorice, other sugar confectionery, gum, gum, sugared gum, sugar-free gum , functional gums, chewing gums, breads, packaged/industrial breads, unpackaged/artisanal breads, doughs, pies, packaged/industrial pies, unpackaged/artisanal pies, cookies, chocolate covered cookies, sandwich cookies, filled cookies, cookies savory and crackers, bread substitutes, breakfast cereals, rte cereals, family breakfast cereals, flakes, muesli, other cereals, cereals children's foods, hot cereal, ice cream, popsicles, single-serve dairy ice cream, single-serve water-based ice cream, multi-pack dairy ice cream, multi-pack water-based ice cream, ice cream to go, dairy ice cream to go, desserts ice cream, bulk ice cream, water based ice cream to go, frozen yogurt, artisan ice cream, dairy products, milk, fresh/pasteurized milk, whole/pasteurized milk, semi-skimmed/pasteurized milk, long life/uht milk, whole milk long life/uht, semi-skimmed/uht long life milk, long life/uht skimmed milk, goat's milk, condensed/evaporated milk, simple condensed/evaporated milk, other flavored condensed milks, functional, flavored milk-based beverages , dairy-only flavored milk drinks, fruit juice flavored dairy drinks, soy milk, curdled milk drinks, fermented dairy drinks, coffee whiteners, powdered milk, powdered dairy drinks with m flavor, creams, cheese, processed cheese, processed cheese in paste, non-paste processed cheese, unprocessed cheese, unprocessed cheese in paste, hard cheese, packaged hard cheese, unpacked hard cheese, yogurt, plain/plain yogurt, yogurt flavored, fruity yogurt, probiotic yogurt, yogurt drinks, regular yogurt drink, probiotic yogurt drink, chilled and storable desserts, dairy-based desserts, soy-based desserts, chilled snacks, fresh and quark cheese, fresh flat cheese and quark, flavored fresh cheese and quark, salted fresh cheese and quark, sweet and savory snacks, fruit snacks, chips/crisps, extruded crackers, corn tortilla/chips, popcorn, pretzels, nuts, other sweet and savory snacks, candy bars cereal, granola bars, breakfast bars, energy bars, fruit bars, other snack bars, meal replacement products, slimming products, convalescent drinks, pro meals canned ready meals, frozen ready meals, dry ready meals, chilled ready meals, dinner mixes, frozen pizza, chilled pizza, soup, canned soup, dehydrated soup, instant soup, chilled soup, hot soup, frozen soup, pasta, canned pasta, dry pasta, chilled/frozen noodles, noodles, plain noodles, instant noodles, instant cup/bowl noodles, instant pouch noodles, chilled noodles, snack noodles, canned food, canned meat and meat products, fish/fruit canned seafood, canned vegetables, canned tomatoes, canned beans, canned fruit, canned ready meals, canned soup, canned pasta, other canned foods, frozen food, frozen processed red meat, frozen processed poultry, frozen processed fish/seafood, frozen meal replacements, frozen potatoes, baked potato chips, other baked potato products, non-cooked frozen potatoes baked goods, frozen bakery products, frozen desserts, frozen ready meals, frozen pizza, frozen soup, frozen noodles, other frozen foods, dry food, dessert mixes, dry ready meals, dehydrated soup, instant soup, dry pasta, plain noodles, instant noodles, instant noodles in cups/bowl, instant noodles in pouches, chilled food, chilled processed meats, chilled fish/seafood products, chilled processed fish, chilled coated fish, chilled smoked fish, chilled lunch kit, ready meals chilled, chilled pizza, chilled soup, chilled/fresh pasta, chilled noodles, oils and fats, olive oil, vegetable and seed oil, cooked fats, butter, margarine, spreadable oils and fats, spreadable functional oils and fats, sauces, toppings condiments, tomato pastes and purees, bouillon/stock cubes, bouillon cubes, gravy granules, broth liquids, herbs and peppers, fermented sauces, soy-based sauces, pasta sauces, wet sauces, dry sauces/powder mixes, ketchup, mayonnaise, regular mayonnaise, mustard, salad dressing, regular salad dressing, low-calorie salad dressing, vinaigrettes, dressings, preserves, other dressings, toppings and condiments, infant foods, milk-based formulas, standard milk-based formulas, milk-based infant formulas, hypoallergenic milk-based formulas , prepared infant foods, dry infant foods, other infant foods, spreads, jellies and jams, honey, chocolate spreads, nut-based bases, and yeast-based pastes. Exemplary edible compositions further include confectionery, bakery, ice cream, dairy, sweet and savory cookies, cereal bars, meal replacement products, ready meals, soups, pasta, noodles, canned foods, frozen foods, dry foods, chilled foods, oils and fats, infant foods, or pastes or a mixture thereof.
    In one embodiment, the pharmaceutical composition comprises one or more compounds of the present invention and at least one pharmaceutically acceptable carrier. The pharmaceutical composition includes both prescription medication and over-the-counter medication. The present compound may or may not be the therapeutically active ingredient in the pharmaceutical composition. The pharmaceutical composition may be used by any mode of administration known to the person skilled in the art, particularly by topical administration, such as application of analgesic cream to the surface of the skin. In general, over-the-counter (OTC) and oral care product generally refers to a product for home care and/or personal use that can be sold without a prescription and/or a visit to a medical professional. Examples of OTC products include, but are not limited to, vitamins and dietary supplements; topical analgesics and/or anesthetics; cough, cold, and allergy remedies; antihistamine and/or allergy medications; and combinations thereof. Vitamins and dietary supplements include, but are not limited to, vitamins, dietary supplements, nutritious tonic/bottled drinks, child-specific vitamins, dietary supplements, any other product of or relating to or providing nutrition, and combinations thereof. Topical analgesics and/or anesthetics include any topical cream/ointment/gel used to relieve superficial or deep pain, eg muscle pain; dental gel; adhesives with analgesic ingredient; and combinations thereof. Cough, cold, allergy remedies include, but are not limited to, decongestants, cough remedies, pharyngeal preparations, drug confections, antihistamines, and child-specific cough, cold and allergy remedies; and products in combination. Antihistamine and/or allergy remedies include but are not limited to any systemic treatment for hay fever, nasal allergies, insect bites. Examples of an oral hygiene product include, but are not limited to, oral cleaning strips, toothpaste, toothbrushes, mouthwashes, denture care, mouth fresheners, mouthwashes, household teeth whiteners and dental floss.
    As used herein, a "personal care composition" refers to a composition to be applied directly to the skin, mucosa, or other surface area of the body. Examples of a personal care composition include, but are not limited to, an oral care composition such as toothpaste, chewing gum, breath freshener, dentifrices, and mouthwashes; a skin or hair care composition such as sunscreen cream, sunburn lotions, shaving cream, plasters, shampoos, conditioners, face cleanser, soaps, bath oils or bubble bath, antiperspirants, c deodorants; a cosmetic composition, such as moisturizer, lip balms, foundations, etc.; an insect repellent composition; or an insecticidal composition.
    In one embodiment of the invention, the present compounds are provided in a concentrated chemostatic formulation, for example, suitable for further processing to produce a ready-to-use (i.e., ready-to-serve) product. By a "chemostasis concentrate formulation", it is meant that a formulation that was to be reconstituted with one or more dilution media must become a ready-to-use composition. The term “ready-to-use composition” is used interchangeably herein with “ingestible composition”, which denotes any substance which, alone or together with another substance, can be taken by mouth whether intended for consumption or not. In one embodiment, the ready-to-use composition includes a composition that can be directly consumed by a human or animal. The chemostasis concentrate formulation is typically used by mixing with or diluted by one or more dilution medium, for example any consumable or ingestible ingredient or product, to impart or modify a chemostatic sensation to the dilution medium. Said use process is generally referred to as reconstitution. The reconstitution can be conducted in a domestic environment or in an industrial environment. For example, a frozen fruit juice concentrate can be reconstituted with water or other aqueous medium by a consumer in a kitchen to obtain the ready-to-use fruit juice beverage. In another example, a mouthwash concentrate can be reconstituted with water or other aqueous medium by a manufacturer on large industrial scales to produce the ready-to-use mouthwash. Since the chemostasis concentrate formulation has the present compound and optionally a flavoring agent and/or flavor modifying agent in a higher concentration than the ready-to-use composition, the chemostasis concentrate formulation is typically not suitable for use. consumed directly without reconstitution. There are many benefits of using and producing a chemostasis concentrate formulation. For example, one benefit is the reduction in weight and volume for shipping as the chemostasis concentrate formulation can be reconstituted at the time of use by the addition of an appropriate solvent, solid or liquid.
    In one embodiment, the chemostasis concentrate formulation comprises i) a chemostatic sensation modifying ingredient, a compound of the present invention; ii) a carrier; and iii) optionally at least one adjuvant. The term "chemostatic sensation-modifying ingredient" denotes that the compound of the present invention acts as a modulator of a chemostatic sensation (such as a modulator of a cold or cooling sensation) in the formulation. The term "carrier" denotes a generally inactive accessory substance, such as solvents, binders, or other inert media, which is used in combination with the present compound and one or more optional adjuvants to form the formulation. For example, water or starch can be a carrier for a flavor concentrate formulation. In some embodiments, the carrier is the same as the dilution medium to reconstitute the chemostasis concentrate formulation; and in other embodiments, the carrier is different from the dilution medium. The term "carrier" as used herein includes, but is not limited to, ingestibly acceptable carrier.
    The term "adjuvant" denotes an additive that supplements, stabilizes, maintains, or improves the intended function or effectiveness of the active ingredient, such as the compound of the present invention. In one embodiment, the at least one adjuvant comprises one or more flavoring agents. The flavoring agent can be of any flavor known to one skilled in the art or to consumers, such as the flavor of chocolate, coffee, tea, mocha, French vanilla, peanut butter, chai, or combinations thereof. In another embodiment, the at least one adjuvant comprises one or more sweeteners. In another embodiment, the at least one adjuvant comprises one or more ingredients selected from the group consisting of an emulsifier, a stabilizer, an antimicrobial preservative, an antioxidant, vitamins, minerals, fats, starches, protein concentrates and isolates, salts, and combinations. of the same. Examples of emulsifiers, stabilizers, antimicrobial preservatives, antioxidants. vitamins, minerals, fats, starches, protein concentrates and isolates, and salts are described in US 6,468,576, the contents of which are incorporated herein by reference in their entirety for all purposes.
    In one embodiment, the present chemostasis concentrate formulation may be in a form selected from the group consisting of liquid including solution and suspension, solid, foamy material, paste, gel, cream, and a combination thereof, as a liquid containing a certain amount of solid contents. In one embodiment, the chemostasis concentrate formulation is in the form of a liquid including the aqueous and non-aqueous base. The present chemostasis concentrate formulation may be gaseous or non-gaseous.
    The chemostasis concentrate formulation may further comprise a freeze point depressant, nucleating agent, or both as the at least one adjuvant. The freezing point depressant is an incredibly acceptable compound or agent that can depress the freezing point of a liquid or solvent to which the compound or agent is added. That is, a liquid or solution containing the freezing point depressant has a lower freezing point than the liquid or solvent without the freezing point depressant. In addition to reducing the onset of freezing point, the freezing point depressant can also reduce the water activity of the flavor concentrate formulation. Examples of freezing point depressants include, but are not limited to, carbohydrates, oils, ethyl alcohol, polyol, e.g., glycerol, and combinations thereof. Nucleating agent denotes a remarkably acceptable compound or agent which is capable of facilitating nucleation. The presence of a nucleating agent in the flavor concentrate formulation can improve the oral feel of frozen slushes from a frozen slush and to help maintain the physical properties and performance of the slush at freezing temperatures by increasing the number of ice crystallization centers. . Examples of nucleating agents include, but are not limited to, calcium silicate, calcium carbonate, titanium dioxide, and combinations thereof.
    In one embodiment, the chemostasis concentrate formulation is formulated to have a low water activity for extended shelf life. Water activity is the ratio of the vapor pressure of water in a formulation to the vapor pressure of pure water at the same temperature. In one embodiment, the chemostasis concentrate formulation has a water activity of less than about 0.85. In another embodiment, the chemostasis concentrate formulation has a water activity of less than about 0.80. In another embodiment, the chemostasis concentrate formulation has a water activity of less than about 0.75.
    In one embodiment, the chemostasis concentrate formulation has the present compound in a concentration that is at least 2 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the compound present in a concentration that is at least 5 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the present compound in a concentration that is at least 10 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the present compound in a concentration that is at least 15 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the compound present in a concentration that is at least 20 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the compound present in a concentration that is at least 30 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the present compound in a concentration that is at least 40 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the compound present in a concentration that is at least 50 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the present compound in a concentration that is at least 60 times the concentration of the compound in a ready-to-use composition. In one embodiment, the chemostasis concentrate formulation has the present compound in a concentration that is up to 100 times the concentration of the compound in a ready-to-use composition.
    The person product can be supplied as a textile product. Examples of textile product include, but are not limited to, shirts, pants, socks, towels, etc. The present compound can be applied to the textile product in any suitable method known to a person skilled in the art. For example, the present compound can be associated with fabric by spin coating, printing, in the form of microencapsulation, direct incorporation into a fabric material (e.g., extrusion), covalent coupling of appropriate derivatives of the modulators (via spacer groups/ ligands, with the help of which the molecule is reversibly or irreversibly linked to the packaging material).
    Personal product can be provided as packaging materials. Examples of packaging materials include a paper and plastic wrap, which can be in various processing forms including fibers, fabrics, and moldings. The present compound can be applied to the packaging material in any suitable method known to one skilled in the art. For example, the present compound can be associated with the packaging material by spin coating, printing, in the form of microencapsulation, direct incorporation into the packaging material (e.g. extrusion), covalent coupling of appropriate derivatives of the modulators (via spacer groups/ suitable linkers, with the aid of which the molecule is reversibly or irreversibly linked to the packaging material.
    The compounds of the present invention can be used to modulate transient receptor potential channel melastatin 8 member (TRPM8) by contacting the receptor as a compound of the present invention. This modulation process can be conducted in vitro or in vivo. In one embodiment, the compound is a TRPM8 receptor agonist.
    The compounds of the present invention may further be formulated in a precursor to the compositions described above. By "precursor" is meant a substance or composition from which another composition, such as those described above, is formed. For example, the present compounds may be provided as a concentration formulation or composition which may be further mixed or diluted to form another composition suitable for consumption or personal use.
    The present compounds can be used to modify a chemostatic sensation of a composition by contacting the present compounds with the composition to form a flavor-modified composition. In one embodiment, the present compounds can impart or impart a chilled taste to a composition.
    In one embodiment, the present invention provides a method of modulating the coolness or cooling sensation of a composition comprising combining the composition with a compound of the present invention, or a salt or solvate thereof, to form a modified composition.
    In one embodiment, the present invention provides a method of inducing a feeling of coldness or chilliness in a human or animal by contacting the human or animal with a compound of the present invention. Biological Assay
    A mammalian cell line that specifically expresses 11TRPM8 was used in biological assays in association with testing the present compounds with taste or cold sensation properties (Servant et al. US 2007/0259354 A1 and references cited therein). Typical concentrations of the compounds tested were 100 μM, 50 μM, 10 μM, 1 μM, and 0.5 μM. The present compounds demonstrated strong activity as 11TRPM8 agonists. The assay results for the compounds are illustrated in Table 1 below. Specifically, the Examples listed in Table 1, i.e., Compounds A1 to Compounds U10 are the specific compounds, i.e., Examples, as described above.



    sensory studies
    Two typical sensory studies are described below followed by a table summarizing the sensory results of selected compounds of the invention (Table 6). Brake line scale test with example 26 (15 μM): Formulation:
    All samples prepared with low sodium buffer (LSB) pH ~7.1 and contain 0.1% ethanol. General Protocol:
    Compounds are rated on a 15-point inline scale where 45 μM WS-3 (N-Ethyl-p-menthane-3-carboxamide) is rated 5 in cold intensity. In most cases our compounds are tested to determine at what concentration the cooling intensity is equivalent to 45 μM WS-3. In each test, the panelist is presented with a 0 μM control sample, a 45 μM WS-3 control sample and the experimental compound sample and asked to rate the cooling intensity of each sample. Panelists are also asked to rate the bitterness. In the table below there was no significant bitterness detected unless otherwise noted. Also, in the table below, n represents the number of tests completed for a given experiment (# panelists x # repetitions). Conclusions:
    Panelists found that 15 μM Compound Z1 was significantly more refreshing than 0 μM WS-3 (p<0.05) and not significantly different in cooling than 45μM WS-3 (p>0.05). There was no significant extraneous bitter taste in any of the samples (p>0.05). Analysis for 15μM Compound Z1 from a sample cup from the test was 70% of the expected value, while bottle analysis of the solution was within the expected range. Table 2. Average Cooling, n = 30 (15 Panelists x 2 rep). Tukey dc value = 1.103 (a = 0.05).

    Cold line scale test with Compound F1 (3 μM in LSB): Formulation:
    All samples prepared with low sodium buffer (LSB) pH ~7.1 and contain 0.1% ethanol. Conclusions:
    Panelists found that 3 μM Compound F1 was significantly more refreshing than 0μM WS-3 (p<0.05) and not significantly different in cooling than 10 45μM WS-3 (p>0.05). significant in any of the samples (p>0.05).Table 4. Medium Cooling, n = 28 (14 Panelists x 2 rep). Tukey's value = 1,359 (a = 0.05).
    Table 5. Medium Bitterness, n = 28 (14 Panelists x 2 rep). Tukey value = 0.51 7

    Table 6. Selected sensory results for compounds of the invention.


    Biological test results of several compounds further indicated that the present compounds in which the hAr is a five-membered heteroaryl are surprisingly much more potent than those compounds in which the hAr is a non-five-membered aryl or heteroaryl. Exemplary data are provided in Tables 7 and 8 below.

    *According to WO2011/061330 A2 E Table C 3-14. Preparation and Examples Standard procedures and chemical transformation and related methods are well known to a person skilled in the art, and such methods and procedures have been described, for example, in standard references such as Fiesers ' Reagents for Organic Synthesis, John Wiley and Sons, New York, NY, 2002; Organic Reactions, vols. 1-83, John Wiley and Sons, New York, NY, 2006; March J. and Smith M., Advanced Organic Chemistry, 6th ed., John Wiley and Sons, New York, NY; and Larock RC, Comprehensive Organic Transformations, Wiley-VCII Publishers, New York, 1999. All texts and references cited herein are incorporated by reference in their entireties. Reactions using compounds containing functional groups can be carried out on compounds with functional groups that can be protected. A "protected" compound or derivative means derivative of a compound where one or more reactive sites or sites or functional groups are blocked with protecting groups. Protected derivatives are useful in preparing the compounds of the present invention or themselves; the protected derivatives may be the biologically active agent. An example of a comprehensive text listing appropriate protecting groups can be found in TW Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999. Synthesis of example compounds shown is illustrated in the following schemes and procedures. General synthetic schemes and related procedures used to prepare the exemplary compounds are presented hereafter. Scheme 1
    If not commercially available or otherwise described, all secondary amines were prepared by reductive amination similar to example 6a or 21b using one of the standard reducing agents and general conditions known to those skilled in the art such as: NaBIR, LiAlIR, Na/ OAchBH (STAB), Na(CN)BH3, 2-picolino borane complex, 5-ethyl-2-methylpyridine borane (PEMB) or their equivalents, and DCM (dichloromethane), DCE (dichloroethane), EtaO (diethyl ether), THF (tetrahydrofuran), dioxane, MeOH, EtOH, MeCN, AcOH alone or in binary or tertiary combinations thereof. One skilled in the art can readily derive the synthesis of the present compounds from the descriptions below in accordance with the methods and principles discussed above. When commercially available, selected compounds were purchased from the following vendors: Enamine, Chemidiv, Princeton, Chembridge.
    N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 6. 2-(p-Tolyloxy)acetyl chloride (500 mg, 2.68 mmol. 2.0 eq) was added to a solution of pyridine (0.217 mL, 2.68 mmol, 2.0 eq) in dichloromethane . A'-(thiophen-2-ylmethyl)-177-pyrazol-5-amine (240 mg, 1.34 mmol, 1.0 eq) was added to the stirred mixture at room temperature. The reaction was stirred overnight at room temperature. The mixture was diluted with dichloromethane and washed with water and brine followed by drying with sodium sulfate. The salts were filtered and washed with dichloromethane. The filtrate was concentrated and the residue was rediluted in ethanol. Sodium hydroxide (tablets, 268 mg, 6.7 mmol, 5.0 eq) was added. The mixture was stirred at room temperature. Upon completion by LC-MS, the volatiles were removed and the residue was redissolved in ethyl acetate and washed with water and brine. The organic layer was dried with sodium sulfate. The crude product was purified by column chromatography (ethyl acetate in hexanes) to give 126 mg of product. The procedure was repeated on the same scale and yielded 241 mg after column chromatography. The two batches were combined and re-purified by HPLC (acetonitrile in water). The collected fractions were combined and the volatiles were removed by rotary evaporation. The residue was dried three times in ethanol (10 mL, 200 proofs) resulting in 288 mg (0.8796 mmol) of white solid as the desired product. Yield 16%. 'hl NMR (400 MHz, DMSO-d6) δ 2.21 (s, 3H), 4.59 (br s, 2H), 4.98 (br s, 2H), 6.23 (br s, 1H) , 6.67 (br d, J = 8.5 Hz, 2H), 6.91 (br m, 2H), 7.04 (br d, .7 = 8.1 Hz, 2H), 7.41 ( m, HI), 7.78 (brs, 1H), 12.88 (brs, HI); M+H(328.1).N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine; Example 6a.l//-pyrazol-5-amine (2.0 g, 1.0 cq, 24.07 mmol) and thiophene-2-carbaldehyde (2.23 mL, 1.0 eq, 24.07 mmol) were combined in methanol and stirred at room temperature with magnesium perchlorate (0.5 eq, 2.69 g) overnight. Volatiles were subsequently removed by rotary evaporation and the residue was rediluted in ethyl acetate and washed with water then brine followed by drying with sodium sulfate. The salts were filtered and washed with ethyl acetate. The filtrate was concentrated to dryness followed by high vacuum treatment. The dry residue was redissolved in anhydrous dichloromethane (30 mL) and the system was purged with nitrogen and sealed. The solution was cooled to 0°C in an ice bath. LiAlH4 (1.0 M in diethyl ether, 24.07 mmol, 24.07 mL, 1.0 eq) was added to the solution slowly, changing the color of the solution from yellow to orange. The mixture was stirred overnight as the temperature increased to room temperature. The reaction was quenched with 1.0 N aqueous sodium hydroxide solution at 0°C. Most of the volatiles were evaporated and the remaining aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine and then dried over sodium sulfate. The crude product was purified by column chromatography (ethyl acetate and hexanes) to give 1.97 g of yellow oil as the desired intermediate, A-(thiophen-2-ylmethyl)-1,7-pyrazol-5-amine. 11 NMR (400 MHz, CDCl3 ) δ 4.55 (s, 2H), 6.95 (dd, .7 - 5.1, 3.5 Hz, 1H), 6.99 - 7.01 (m, 111), 7.20 (dd, .7 = 5.1, 1.3 Hz, 1H), 7.33 (d, .7 = 2.4 Hz, 1H).
    N-ethyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 21.
    To a round bottom flask was added N-(thiophen-2-ylmethyl)ethanamine (0.92g, 5mmol) in dichloromethane (20ml) followed by 2-(p-tolyloxy)acetyl chloride (0.93g , 5mmol) in 5mL of dichloromethane and triethylamine (0.84mL, 6mmol). The reaction mixture was poured into water, extracted with dichloromethane (x 3), washed with 1M NaOH, 1M HCl and brine, dried over MgSO4 and evaporated in vacuo. The compound was purified on the biotage (dichloromethane.-ethyl acetate 0-20% gradient); the clear fractions were combined and concentrated. The final compound was then concentrated 3 times from the ethanol. 1.259 g (4.35mmol, 87%) of compound were obtained in purity greater than 97%. 'H NMR (400 MHz, DMSO-d6, T=80°C) δ 'id NMR (400 MHz, DMSO) δ 1.11 (br s, 3H), 2.24 (s, 3H), 3.37 (q, α/= 7.1 Hz, 2H), 4.71 (br s, 2H), 4.76 (s, 2H), 6.82 (d, α7 = 8.5 Hz, 2H), 6.97 (br s, 111), 7.04 (br s, 111), 7.07 (d, .7 = 8.5 Hz, 211), 7.40 (br s, 111); M+H(290.1).
    2-(p-Tolyloxy)acetyl chloride; Example 21a
    To a stirred suspension at 0°C of 4.00 g of the acid (24.07 mmol; 1.0 eqmol) in 40.0 mL of dichloromethane was added 2.20 mL of oxalyl chloride (25.27 mmol ; 1.05 eqmol) and then 56 uL of dimethylformamide (0.7221 mmol; 0.03 eqmol). The ice bath was removed and the reaction was stirred at room temperature until gas evolution ceased (bubbling monitor). All volatiles were then evaporated in vacuo. The crude liquids obtained contained some very fine precipitates, so the pure liquid was passed through a Celite plate which was purged with hexanes. Again, all volatiles were then evaporated in vacuo to obtain a clear liquid that showed only one compound in the 'fl-NMR analysis. The 4.129 g (22.36 mmol; 93%) obtained was used in the next step without further purification. δ H NMR (400 MHz; CDCℓ) δ 2.30 (s, 3H), 4.92 (s, 211), 6.84 - 6.76 (m, 211), 7.15 - 7.08 (m , 211).N-(thiophen-2-ylmethyl)ethanamine; Example 21b
    To a round bottom flask cooled to 0°C was added ethyl amine hydrochloride (4.58 g, 56.17 mmol) and thiophene-2-carbaldehyde (5.0 mL, 53.50 mmol) in methanol (20. 0 mL), followed by triethylamine (7.83 mL, 56.17 mmol) and the reaction was stirred for 30 minutes. Sodium triacetoxyborohydride (15.87 g, 74.90 mmol) was added in one portion with vigorous stirring. The ice bath was removed and the flask was attached to a bubbler to allow gas evolution and expansion. The reaction was stirred overnight at room temperature. Most of the volatiles were evaporated in vacuo. The reaction mixture was quenched by the addition of 1N NaOH, and the product was extracted with dichloromethane. The organic extract was washed with brine and dried with MgSO4. The volatiles were evaporated to give the crude product free base N-(thiophen-2-ylmethyl)ethanamine (5.85 g, 41.42 mmol, 77%), which resulted >97% purity by 11-NMR analysis, so it was used in the next step without further purification. δ11 NMR (400 MHz, CDCl 3 ) δ 1.13 (t, δ7 = 7.1 Hz, 3H), 2.71 (q, δ7 = 7.2 Hz, 2H), 4.00 (d, J=0.7 Hz, 2H), 6.90 - 6.97 (m, 2H), 7.21 (dd,.7=5.0, 1.3 Hz, 1H).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 1.
    Prepared similarly to example 6 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. Yield: 27%. *H NMR (400 MHz, CDCl3 ) δ 2.04 (m, 2H), 2.81 (m, 4H), 4.59 (br s, 2H), 5.07 (br s, 2H), 6, 09 (br s, 1H), 6.62 (br d, J = 8.4 Hz, 1H), 6.71 (br s, 1H), 6.91 (m, 2H), 7.05 (br d , J = 8.2 Hz, 1H), 7.21 (dd, J = 5.0, 1.3 Hz, 1H), 7.53 (d, .7 = 2.4 Hz, 1H), 10, 16 (br s, 1H); M+H(354.1).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-(4-methyl-1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 2.
    Prepared similarly to example 6 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and 4-methyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-5 -the mine. Yield: 48%. 1 H NMR (400 MHz, CDCl3 ) δ 1.97 (s, 3H), 2.00 - 2.09 (m, 2H), 2.82 (m, 5H), 4.32 (br s, 2H) , 4.92 (br s, 2H), 6.60 (br dd, .7= 8.2, 2.5 Hz, 1H), 6.68 (br d, 2.4 Hz, 1H), 6, 86 (br dd, .7= 3.4, 1.2 Hz, 1H), 6.91 (dd, .7= 5.1, 3.4 Hz, 1H), 7.06 (br d, .7 = 8.2 Hz, 1H), 7.24 (dd, Δ7=5.1, 1.2 Hz, 1H), 7.32 (br s, 1H), 9.98 (br s, 1H); M+H(368.1).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 3.
    Prepared similarly to example 6 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine . Yield: 40%. 1 H NMR (400 MHz, DMSO-6 ) δ 1.98 (m, 2H), 2.77 (m, 4H), 4.49 (s, 2H), 4.87 (s, 2H), 6, 54 (br dd, .7 = 8.2, 2.5 Hz, 1I I), 6.64 (br d, J= 2.0 Hz, 1H), 6.88 (br d, .7 = 2, 4 Hz, 1H), 6.94 (dd, J = 5.1, 3.4 Hz, 1 IF), 7.06 (br d, .7 = 8.2 Hz, HI), 7.45 (dd , .7= 5.1, 1.2 Hz, 1H), 7.62 (br s, 211), 12.98 (br s, HI); M+H(354.1).
    N-(oxazol-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 4.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl N-(thiophen-2-ylmethyl)oxazol-2-amine chloride. δ 11 NMR (400 MHz, CDCl3 ) δ 2.27 (s, 3H), 5.01 (s, 2H), 5.25 (s, 2H), 6.76 - 6.70 (m, 2H), 6.91 (dd, J = 5.1, 3.5 Hz, 1H), 7.08 - 7.01 (m, 3H), 7.21 (dd, .7 = 5.1, 1.2 Hz , HI), 7.52 (d, .7 = 1.0 Hz, 1H); M+H(329.1).
    10 2-(2,3-dihydro-1H-inden-5-yloxy)-N-(3,5-dimethyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 7.
    Prepared similarly to example 6 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and 3,5-dimethyl-N-(thiophen-2-ylmethyl)-1H- pyrazol-4-amine. Yield 54%. 1 H NMR (400 MHz, CDCl3 ) δ 1.91 (s, 6H), 2.01-2.10 (m, 2H), 2.82 (m, 4H), 4.2515 (s, 211), 4.89 (br s, 2H), 6.60 (dd, .7= 8.2, 2.5 Hz, 1H), 6.68 (d, .7= 2.3 Hz, HI), 6, 84 - 6.87(m, 1H), 6.90 (dd, .7=5.1, 3.5Hz, 1H), 7.06 (d, .7=8.2Hz, HI), 7 .24 (dd, J=5.1, 1.2 Hz, 1H); M+H(382.2).
    N-(3,5-dimethyl-1U-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide;20 Example 8.
    Prepared similarly to example 6 from 2-(p-tolyloxy)acetyl chloride and 3,5-dimethyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. Yield 83%. 111 NMR (400 MHz, DMSO-d6) δ 1.79 (s, 611), 4.23 (br s, 211), 4.67 (br s, III), 4.84 (br s, 111) , 6.61 - 6.70 (m, 2H), 6.80 (dd, .7= 3.4, 1.2 Hz, HI), 6.91 (dd, .7= 5.1, 3, 4 Hz, HI), 7.03 (m, 2H), 25 7.46 (dd, α7 = 5.1, 1.2 IIz, III), 12.36 (br s, 1H); M+H(356.1).
    N-(3-methyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 9.
    Prepared similarly to example 6 from 2-(p-tolyloxy)acetyl chloride and 3-methyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. δ 11 NMR (400 MHz, DMSO) δ 1 H NMR (400 MHz, CDCl 3 ) δ 1.96 (s, 3H), 2.24 (s, 3H), 4.32 (br s, 2H), 4, 91 (br s, 2H), 6.69 (d, J = 8.6 Hz, 2H), 6.84 - 6.87 (m, 1H), 6.89 (dd, .7= 5.1, 3.5 Hz, 1H), 7.01 (d, .7 = 8.6 Hz, 2H), 7.22 (dd, .7 = 5.1, 1.2 Hz, 1H), 7.31 ( br s, 1H); M+H(342.1).
    2-(benzo[d][1,3]dioxol-5-yloxy)-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 12.
    Prepared similarly to example 6 from 2-(benzo[d]|1,3]dioxol-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. Yield 28%. δ H NMR (400 MHz, CDCl 3 ) δ 4.53 (s, 2H), 5.06 (s, 2H), 5.86 (s, 2H), 6.05 (br d, .7 = 2.1 Hz, 1H), 6.21 (dd, .7= 8.5, 2.5 Hz, 1H), 6.44 (d, .7= 2.5 Hz, 1H), 6.60 (d, . .7 = 8.5 Hz, 1H), 6.90 (m, 2H), 7.20 (dd, .7 = 5.0, 1.3 Hz, HI), 7.50 (d, .7 = 2.4 Hz, 1H), 10.96 (br s, 1H); M+H(358.1).
    2-(benzo|d|[1,3|dioxol-5-yloxy)-N-(3,5-dimethyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 13.
    Prepared similarly to example 6 from 2-(benzo[d]]1,3-dioxol-5-yloxy)acetyl chloride and 3,5-dimethyl-N-(thiophen-2-ylmethyl)-111 -pyrazol-4-amine. δ 11 NMR (400 MHz, CDCl 3 ) δ 1.91 (s, 611), 4.21 (s, 2H), 4.88 (br s, 211), 5.90 (s, 211), 6.20 (dd, .7= 8.5, 2.6 Hz, 111), 6.45 (d, .7= 2.5 Hz, 1H), 6.64 (d, .7= 8.5 Hz, 111), 6.85 (br dd, .7 = 2.0, 1.4 Hz, 1H), 6.90 (dd, .7 = 5.1, 3.4 Hz, 1H), 7.24 ( dd, J= 5.1, 1.3 Hz, 1H), 9.91 (br s, 1H); M+H(386.1).
    4-(N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamido)-1H-pyrazol-2-onium chloride; Example 14.257 mg of N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide from example 15 was dissolved in EtOH (2.0 mL) and then a 2.0M solution of HCl in Et2O was added: a white solid precipitated out of solution. After decanting, the liquids were removed with a pipette and the salt obtained was washed with three aliquots of Et2O. The crystals were then dissolved in EtOH (approximately 5.0 mL) and concentrated on the rotary evaporator. This step was repeated a total of three times. The solids were left overnight under high vacuum. In this way, 120 mg of the desired product was obtained. δ 2.22 (s, 3H), 4.51 (s, 2H), 4.91 (s, 2H), 5.85 (m , 2H), 6.70 (br d, J = 7.7, 2H), 6.90 (br s, 1H), 6.94 (m, 1H), 7.04 (br d, .7 = 7 .7, 2H), 7.39 (dt, .7=1.1, 5.0, III), 7.57 (br s, 2H); M+H(328.1).
    N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 15.
    Prepared similarly to example 6 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)-HI-pyrazol-4-amine. Yield 60%. *H NMR (400 MHz, hCDC) δ 2.25 (s, 3H), 4.42 (s, 2H), 4.95 (s, 2H), 6.71 (d, ./= 8.2 Hz , 2H), 6.88 (d, J= 2.4 Hz, III), 6.92 (dd, J= 5.1, 3.5 Hz, 1H), 7.03 (br d, .7 = 8.2 Hz, 2H), 7.24 (dd, .7=5.1, 1.2 Hz, 1H), 7.41 (brs, 211). M+H(328.1).
    N-(isoxazol-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 16.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)isoxazol-3-amine. Yield 60%. *H NMR (400 MHz, DMSO-d6) δ 2.21 (s, 3H), 4.96 (br s, 2H), 5.19 (br s, 2H), 6.71 (d, J=8 .6 Hz, 2H), 6.94 (m, 2H), 7.05 (m, 3H), 7.45 (dd, .7=5.1, 1.3 Hz, 1H), 8.95 ( d, .7=1.9 Hz, 1H); M+H(329.1).
    N-(1-(cyanomethyl)-1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide;Example 17.N-(oxazol-2-yl)- N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide (example 4) (430 mgs, 1.313 mmol) was dissolved in N,N-dimethylformamide. Sodium hydride (60% in mineral oil, 55 mgs, 1.38 mmol) was added at 0°C and a bubbler was turned on to observe gas evolution. The reaction was stirred with gradual warming to room temperature until gas evolution ceased. 2-Bromoacetonitrile (92 μL, 1.38 mmol) was added at room temperature and the reaction was stirred overnight. Upon completion by TLC (5:5 ethylhexanes acetate), the reaction was carefully quenched with water at 0°C. The reaction mixture was concentrated by rotary evaporation. The residue was taken up in water and extracted with ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. The crude material was purified by column chromatography (ethyl acetate and hexanes). (Yield 64%, the other possible N-alkylation isomer was obtained as a by-product; data not reported). *H NMR (400 MHz, DMSO-d6) δ 2.26 (s, 3H), 4.65 (broad, s, 2H), 4.96 (s, 2H), 5.05 (s, 2H), 6.09(wide, s, 1H), 6.73(d, 2H, J=8.8Hz), 6.91(m, 2H), 7.03 (d, 2H, J=8.4Hz), 7.21(dd, 1H, J1=4.8Hz, J2=1.2Hz), 7.50(wide, s, 1H). Additional two-dimensional NMR studies confirmed the structure assigned to the correct isomer; M+H(329.1).
    2-(benzo[d][1,3]dioxol-5-yloxy)-N-(3-methyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 18.
    Prepared similarly to example 6 from 2-(benzo[d| 1,3]dioxol-5-yloxy)acetyl and 3-methyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-4- the mine. 1 H NMR (400 MHz, CDCl 3 ) δ 1.96 (s, 3H), 4.28 (br s, 2H), 4.91 (br s, 211), 5.87 (s, 2H), 6, 18 (dd, .7=8.5, 2.6 Hz, III), 6.42 (d, .7= 2.5 Hz, 1H), 6.62 (d, .7= 8.5 Hz, 1H), 6.83 -6.86 (m, 111), 6.89 (dd, J=5.1, 3.5Hz, 1H), 7.22 (dd, J=5.1, 1, 3 Hz, 1H), 7.31 (br s„ 1H); M+H(372.1).
    2-(benzo[d][1,3]dioxol-5-yloxy)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 20.
    Prepared similarly to example 6 from 2-(benzo[d][1,3]dioxol-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. Yield 73%. δ 11 NMR (400 MHz, CDCl3 ) δ 4.38 (s, 2H), 4.94 (br s, 2H), 5.90 (s, 2H), 6.21 (dd, J = 8.5, 2.6 Hz, 1H), 6.45 (d, .7= 2.5 Hz, 1H), 6.64 (d, J= 8.5 Hz, 1H), 6.88 (br s, 1H) , 6.92 (dd, .7 = 5.1, 3.5 Hz, 1H), 7.24 (dd, J= 5.1, 1.3 Hz, HI), 7.41 (br s, 2H ), 10.37 (br s, 1H); M+H(358.1).
    N-cyclopropyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 22.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)cyclopropanamine. *H NMR (400 MHz, DMSO-d(„ T=50°C) δ 0.87(m, 4H), 2.23 (s, 3H), 2.72 (br m, 1H), 4.66 (br s, 211), 4.93 (br s, 2H), 6.79 - 6.72 (m, 2H), 6.98 (br m, 2H), 7.09 - 7.02 (m, 2H), 7.42 (br dd, J = 5.0, 1.0 Hz, 1H); M+H(302.1).
    N-allyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 23.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)prop-2-en-1-amine. δ11 NMR (400 MHz, DMSO-d(„ T=80°C) δ 2.24 (s, 311), 3.98 (d, .7=5.5 Hz, 2H), 4.68 (br s, 2H), 4.77 (br s, 2H), 5.18 (d, J= 15.3 Hz, 211), 5.80 (br s, III), 6.78 - 6.83 (m , 2H), 6.95 - 7.00 (br m, 111), 7.03 (br s, III), 7.05 - 7.10 (m, 211), 7.42 (brd, .7= 4.6 Hz, 1H), M+1 1(302.1).
    N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide; Example 24.
    Prepared similarly to example 21 from 3-p-tolylpropanoyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. Yield 76%. δ H NMR (400 MHz, DMSO-d6) δ 2.22 (s, 3H), 2.36 (t, ./ = 7.8 Hz, 2H), 2.72 (t, J = 7.8 Hz , 2H), 4.84 (s, 2H), 6.78 - 6.85 (m, III), 6.91 (dd, J = 5.1, 3.4 Hz, 1H), 6.97 ( d, J = 8.1 Hz, 2H), 7.02 (d, . / = 7.9 Hz, 2H), 7.24 (d, , / =- 1.7 Hz, 1H), 7.41 (dd, J = 5.1, 1.2 Hz, III), 7.57 (s, 1H), 12.89 (s, 1H); M+H(326.1).
    2-(4-methoxyphenoxy)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 25.
    Prepared similarly to example 6 from 2-(4-methoxyphenoxy)acetyl chloride and 2-(4-methoxyphenoxy)acetyl chloride. 1 H NMR (400 MHz, CDCR) δ 3.74 (br s, 3H), 4.40 (br s, 2H), 4.95 (br s, 2H), 6.78 (br s, 3H), 6.88 (br m, 1H), 6.92 (dd, J= 5.1, 3.5 Hz, 1H), 7.24 (dd,.7= 5.1, 1.3 Hz, 1H) , 7.41 (s, 2H); M+H(344.1).
    N-propyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 28.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)propan-1-amine. *H NMR (400 MHz, DMSO-do, T=80°C) δ 0.84 (t, J = 7.4 Hz, 3H), 1.55 (br s, 2H), 2.24 (s, 3H), 3.25 - 3.31 (br m, 2H), 4.71 (br s, 211), 4.76 (s, 2H), 6.81 (d, J= 8.6 Hz, 2H ), 6.97 (br s, 1H), 7.04 (br s, 111), 7.05 - 7.10 (m, 2H), 7.40 (brs, III); M+H(304.1).
    N-allyl-2-(benzo[d][1,3|dioxol-5-yloxy)-N-(thiophen-2-ylmethyl)acetamide; Example 30. This compound was purchased from Enamine. M+H(332.1).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 34.
    Prepared similarly to example 21 from 2-(2,3-dihydro-1H-5-inden-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. 1 H NMR (400 MHz, DMSO-d6) δ 1.98 (m, 2H), 2.68 - 2.83 (m, 5H), 4.45 (br s, 2H), 5.04 (br s , 2H), 6.48 (br s, 1H), 6.60 (br s, 1H), 6.84 (br s, III), 6.91 (dd, J= 5.1, 3.4 Hz , 1H), 7.05 (br d, .7 = 8.1 Hz, 1H), 7.36 - 7.50 (m, 2H), 7.70 (ddd, .7 = 8.1.2, 5, 1.5 Hz, 1H), 8.44 (dd, .7 = 2.6, 0.6 Hz, 1H), 8.53 (br s, III); M+H(365.1).
    2-(3-methoxyphenoxy)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 35.
    Prepared similarly to example 6 from 2-(3-methoxyphenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)-1H-1-pyrazol-4-amine. 1 H NMR (400 MHz, 15 CDCl 3 ) δ 3.73 (s, 3H), 4.43 (s, 2H), 4.94 (s, 2H), 6.36 (ddd, .7=8.2 , 2.4, 0.7 Hz, 1H), 6.41 (t, .7= 2.4 Hz, 1I-I), 6.50 (ddd, .7= 8.3, 2.4, 0 .7 Hz, 1H), 6.85 - 6.93 (m, 2H), 7.11 (t, .7 = 8.2 Hz, 1H), 7.23 (dd, .7=5.1, 1.3 Hz, 1H), 7.41 (s, 2H), 11.24 (brs, III); M+H(344.1).
    N-(pyridin-4-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 36.20 Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-4-amine. δ111 NMR *H NMR (400 MHz, DMSO-d6) δ 2.20 (s, 3H), 4.66 (br s, 211), 5.11 (s, 211), 6.63 (d, . 7 = 8.6 Hz, 2H), 6.85 - 6.95 (m, 2H), 7.03 (d, .7 = 8.6 Hz, 211), 7.33 - 7.39 (m, 2H), 7.40 - 7.46 (m, III), 8.54 - 8.61 (m, 2H); M+11(339.1).
    N-isopropyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 38.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)propan-2-amine. Room temperature 'fl-NMR showed a mixture of rotamers in ratio -2:1: *H NMR (400 MHz, DMSO-d6) δ 1.12 (minor) (d, J= 6.8 Hz, 6H), 1 .17 (major) (d, J=6.6 Hz, 6H), 2.21 (minor) (s, 3H), 2.23 (major) (s, 3H), 4.20 - 4.06 ( minor) (m, 1H), 4.50 - 4.34 (major) (m, 1H), 4.58 (major) (s, 2H), 4.66 (minor) (s, 2H), 4, 72 (minor) (s, 2H), 4.82 (major) (s, 2H), 6.70 (minor) (d, J = 8.1 Hz, 2H), 6.81 (major) (d, J = 8.5 Hz, 2H), 6.89 (major) (dd, J = 5.0, 3.5 Hz, 1H), 7.14 - 6.95 (m, 3H), 7.33 ( major) (dd, ./ = 5.1, 1.0 Hz, 1H), 7.48 (minor) (d, ./ = 4.8 Hz, 1H); Mi-H(304.1).
    N-(bicyclo[2.2.1]heptan-2-ylmethyl)-N-(1H-pyrazol-3-yl)-2-(p-tolyloxy)acetamide;Example 39.
    Prepared similarly to example 6 from 2-(p-tolyloxy)acetyl chloride and N-(bicyclo[2,2,1]heptan-2-ylmethyl)-1H-pyrazol-3-amine. Yield 18%. 1 H NMR (400 MHz, CDCI 3 )δ0.81 (ddd, δ = 13.1.5.2, 2.9 Hz, 1H), 0.96 - 1.06 (m, 1H), 1.26 -1.51 (m, 5H), 1.70 (m, 1H), 1.76-1.86 (m, 1H), 2.10 (br t, J = 4.0 Hz, 1H), 2 .24 (s, 3H), 2.94 (br s, 1H), 4.34 (q, J=15.0 Hz, 2H), 4.52 (m, III), 6.21 (d, . / = 2.4 Hz, 1H), 6.71 (d, J= 8.6 Hz, 2H), 7.01 (d, J= 8.6 Hz, 2H), 7.62 (d, J= 2.4 Hz, 1H); M+H(340.2).
    N-ethyl-N-(thiophen-3-ylmethyl)-2-(p-tolyloxy)acethamide; Example 41.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-3-ylmethyl)ethanamine. Room temperature 'H-NMR showed a mixture of rotamers in ratio -2:1: '11 NMR (400 MHz, DMSO-d6) δ 0.98 (smallest) (t,./ - 7.1 Hz, 3H), 1.11 (major) (t, δ = 7.1 Hz, 3H), 2.21 (minor) (s, 311), 2.23 (major) (s, 3H), 3.31 - 3, 24 (m, 2H), 4.47 (major) (s, 2H), 4.54 (minor) (s, III), 4.75 (minor) (s, 1H), 4.80 (major) ( s, 2H), 6.74 (minor) (d, .7 = 8.5 Hz, 2H), 6.81 (major) (d, J = 8.6 Hz, 2H), 6.97 (major) (dd, .7 = 4.9, 1.1 Hz, 1H), 7.11 - 7.02 (m, 3H), 7.32 (major) (d, .7 = 1.8 Hz, 1H) , 7.42 (minor) (d, .7=1.9 Hz, 1H), 7.48 (major) (dd, .7=4.9, 3.0 Hz, 1H), 7.56 ( minor) (dd,.7 = 4.9, 3.0 Hz, 1H); M+H(290.1).
    N-(bicyclo[2,2,1]heptan-2-ylmethyl)-N-(1H-pyrazol-3-yl)-2-(p-tolyloxy)acetamide; Example 43.
    Prepared similarly to example 21 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-2-amine. *H NMR (400 MHz, DMSO-d6) δ 1.89 - 2.06 (m, 2H), 2.75 (dd, δ7 = 15.7, 7.7 Hz, 4H), 4.76 (s, 211), 5.20 (s, 2H), 6.47 (dd, J = 8.2, 2.5 Hz, 1H), 6.58 (d, J = 2.3 Hz, 1H), 6, 86 - 6.95 (m, 2H), 7.03 (d, .7 = 8.2 Hz, 1H), 7.31 (ddd, .7 = 7.4, 4.9, 0.9 Hz, 1H), 7.39 (dd, .7=4.9, 1.4Hz, 1H), 7.46 (d, .7=8.2Hz, 1H), 7.88 (ddd, .7 = 8.1, 7.5, 2.0 Hz, III), 8.46 (ddd, .7 = 4.9, 1.9, 0.8 Hz, 1H); M+H(365.1) .
    2-phenoxy-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 45.
    Prepared similarly to example 21 from 2-phenoxyacetyl chloride and N-(thiophen-2-ylmethyl)aniline. 1 H NMR (400 MHz, DMSO-d6) δ 4.44 (br s, 211), 5.01 (br s, 2H), 6.74 (br d, .7 = 8.0 Hz, 2H), 6.84 (br s, 1H), 6.89 - 6.95 (m, 2H), 7.22 - 7.29 (m, 4H), 7.36-7.45 (m, 4H); M+H(324.1).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide;Example 47.
    Prepared similarly to example 21 from 2-(2,3-dihydro-1II-inden-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)aniline. δ11 NMR (400 MHz, DMSO-d6) δ 1.98 (m, 211), 2.70 - 2.88 (m, 4H), 4.38 (br s, 211), 5.00 (br s , 2H), 6.49 (br d, J= 8.3 Hz, 1H), 6.59 (br s, 1H), 6.83 (br s, 1H), 6.91 (dd, .7 = 5.0, 3.5 Hz, 1H), 7.05 (br d, .7 = 8.2 Hz, 1H), 7.25 (d, .7 = 7.1 Hz, 2H), 7.33 -7.47 (m, 411); M+H(364.1).
    N-(bicyclo[2,2,1]heptan-2-ylmethyl)-3-phenyl-N-(1H-pyrazol-3-yl)propanamide;Example 50.
    Prepared similarly to example 6 from 3-phenylpropanoyl chloride and N-(bicyclo[2,2,1]heptan-2-ylmethyl)-HI-pyrazol-3-amine. Yield 9%. 1 H NMR (400 MHz, hCDC) δ 0.71 (ddd, .7 = 13.0, 5.3, 2.9 Hz, 1H), 0.90 - 1.01 (m, 1H), 1, 24 - 1.50 (m, 6H), 1.62 - 1.78 (m, 311), 2.05 - 2.09 (m, 1H), 2.33 (m, 2H), 2.84 - 2.93 (m, 3H), 4.41 - 4.50 (m, 1H), 6.01 (d, .7 = 2.4 Hz, 1H), 7.05 - 7.12 (m, 2H ), 7.19-7.12 (m, 1H), 7.25-7.19 (m, 2H), 7.54 (d, .7 = 2.4 Hz, 1H); M+11(324.2).
    N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 51.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. *FI NMR (400 MHz, DMSO-d6) δ 2.20 (s, 3H), 4.46 (br s, 2H), 5.04 (br s, 2H), 6.62 (br s, .7 = 6.7 Hz, 2H), 6.84 (br s, 1H), 6.91 (dd,.7= 5.1, 3.4Hz, 1H), 7.03 (br d, .7= 8 .3 Hz, 211), 7.41 - 7.49 (m, 2H), 7.71 (ddd, .7 = 8.1, 2.5, 1.6 Hz, 1H), 8.47-8 .42 (m, HI), 8.54 (br d, .7-3.5 Hz, 1H); M+H(339.1).
    N-ethyl-N-((5-methylthiophen-2-yl)methyl)-2-(p-tolyloxy)acetamide; Example 54.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-((5-methylthiophen-2-yl)methyl)ethanamine. Yield: 38%. Room temperature 1II-NMR showed a mixture of rotamers in ratio ~2:1: 'II NMR (400 MHz, DMSO-d6) δ 1.00 (smallest) (t, .7 = 7.1 Hz, 3H), 1 .13 (major) (t, .7 = 7.1 Hz, 311), 2.23 (s, 3H), 2.38 (major) (s, 3H), 2.41 (minor) (s, 3H ), 3.29 (m, 2H), 4.54 (major) (s, 211), 4.65 (minor) (s, 2H), 4.76 (s, 2H), 6.64 - 6, 57 (major) (br m, 1H), 6.68 (minor) (br m, 1H), 6.84 - 6.75 (m, 3H), 6.87 (minor) (d,.7 = 3.3 Hz, 111), 7.07 (br d, .7 = 8.5 Hz, 2H).
    N 2-(4-ethylphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 59.
    Prepared similarly to example 21 from 2-(4-ethylphenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. *H NMR (400 MHz, CDCI 3 ) δ 1.18 (t, .7 = 7.6 Hz, 1H), 2.56 (q, .7 = 7.6 Hz, 1H), 4.38 (s, 1H), 5.04 (s, 1H), 6.64 (d, .7 = 8.3 Hz, 1H), 6.80 (dd, .7 = 3.2, 0.8 Hz, 1H), 6.89 (dd, .7= 5.1, 3.5 Hz, 1H), 7.04 (d, .7= 8.4 Hz, 1H), 7.24 (dd, .7 = 5.1 , 1.2 Hz, 1H), 7.40 - 7.28 (m, 1H), 8.36 (s, 1H), 8.61 (s, 1H); M+H(353.1).
    N-(1-methyl-1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide;Example 60.
    Prepared similarly to example 6 from 2-(p-tolyloxy)acetyl chloride and 1-methyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. Yield 62%. *H NMR (400 MHz, DMSO-d6) δ 2.21 (s, 3H), 3.53 (s, 3H), 4.39 (brd, δ7 = 17.3, 2H), 4.77 ( brd,.7=14.9, 1H), 5.06 (brd, J=14.1, 1H), 6.15 (d, .7=1.8, 1H), 6.67 (d, .7=8.4, 2H), 6.90 (br d, .7=2.7, 1H), 6.95 (dd, .7=3.5, 5.1, 1H), 7.05 (d, J=8.4, 2H), 7.44 (d, J=1.8, 1H), 7.49 (dd, .7=1.2, 5.1, 1H); M+H(324.2).
    N-(bicyclo|2,2,1]heptan-2-ylmethyl)-2-phenoxy-N-(1H-pyrazol-3-yl)acethamide;Example 66.
    Prepared similarly to example 6 from 2-phenoxyacetyl chloride and N-(bicyclo[2,2,1]heptan-2-ylmethyl)-1H-pyrazol-3-amine. Yield 18%. δ 11 NMR (400 MHz, CDCI3 ) δ 0.81 (ddd, δ7 = 13.2, 5.2, 3.0 Hz, 1H), 1.07 -0.96 (m, 1H), 1, 24-1.51 (m, 511), 1.86 - 1.65 (m, 3H), 2.10 (brs, 1H), 2.94 (brs, 1H), 4.38 (q, , 7=15.1Hz, 1H), 4.58-4.45 (m, 1H), 6.22 (d, .7=2.4Hz, 1H), 6.79 - 6.84 (m, 2H), 6.89 - 6.94 (m, 1H), 7.18 - 7.25 (m, 2H), 7.63 (d, .7 = 2.4 Hz, HI); M+H(326.1).
    2-(benzo[d][1,3]dioxol-5-yloxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 70.
    Prepared similarly to example 21 from 2-(benzo[d][1,3]dioxol-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. Yield 94%. *H NMR (400 MHz, DMSO-d6) δ 4.46 (br s, 2H), 5.05 (br s, 2H), 5.94 (s, 2H), 6.16 (br s, 1H) , 6.45 (br s, 1H), 6.75 (d, .7 = 8.5 Hz, III), 6.85 (br s, 1H), 6.91 (dd, .7 = 5.1 , 3.4 Hz, 1H), 7.45 (dd, .7= 5.1, 1.3 Hz, HI), 7.53 (dd, .7= 8.2, 4.9 Hz, 1H) , 7.80 (br d, .7 = 8.1 Hz, 1H), 8.51 (brs, 1H), 8.58 (br d, 7 = 3.7 Hz, 1H); M+H(369.1).
    N-ethyl-2-(4-fluorphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 72.
    Prepared similarly to example 21 from 2-(4-fluorophenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)ethanamine. Yield 66%. Room temperature 'H-NMR showed a mixture of rotamers: 'II NMR (400 MHz, DMSO-d6) δ 7.51 - 7.49 (lower) (m, 1H), 7.43 - 7.41 (higher) (m, III), 7.14 - 7.09 (m, 2H), 7.07 - 7.00 (m, 1H), 6.97 - 6.87 (m, 3H), 4.84 (m , 2H), 4.75 (minor) (s, 2H), 4.64 (major) (s, 2H), 3.41 - 3.25 (m, 2H), 1.14 (major) (t, J = 7.1 Hz, 3H), 1.03 (minor) (t, .7 = 7.1 Hz, 3H); M+H (294.1).
    N-sec-butyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 79.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl and N-(thiophen-2-ylmethyl)butan-2-amine chloride. Room temperature 1 I-NMR showed a mixture of rotamers in ~2:1 ratio: 1 H NMR (400 MHz, DMSO-d6) δ 0.74 (m, 3H), 1.14 (m, 3H), 1, 39 - 1.79 (m, 211), 2.22 (m, 3H), 3.73 - 4.28 (m, 1H), 4.42 - 4.85 (m, 411), 6.69 - 6.81 (m, 2H), 6.88 (dd, J = 5.1, 3.4 Hz, 1H), 6.97 - 7.13 (m, 3H), 7.41 (m, 1H ); M+H(318.1).
    2-(4-chlorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 80.
    Prepared similarly to example 21 from 2-(4-chlorophenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)aniline. 1 H NMR (400 MHz, DMSO-d6) δ 4.44 (br s, 2H), 4.98 (br s, 2H), 6.72 - 6.84 (m, 3H), 6.89 (dd , J = 4.8, 3.6 Hz, HI), 7.26 (dd, .7 = 8.1, 4.0 Hz, 4H), 7.31-7.45 (m, 4H); M+H(358.1).
    N-phenyl-N-(thiazol-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 82.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiazol-2-ylmethyl)aniline. 111 NMR (400 MHz, DMSO-d6) δ 2.19 (s, 3H), 4.44 (br s, 2H), 5.11 (br s, 2H), 6.62 (br d, J = 7.6 Hz, 2H), 7.02 (d, J=8.3 Hz, 2H), 7.49 - 7.33 (m, 5H), 7.69 (br s, 211); M+H(339.1).
    N-methyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 85.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-methyl-1-(thiophen-2-yl)methanamine. Room temperature 11-NMR showed a mixture of rotameters in a ratio of ~3:1: 1 H NMR (400 MHz, DMSO-d6) δ 2.23 (br s, 311), 2.83 - 2.97 (m , 3H), 4.64 - 4.83 (m, 4H), 6.79 (m, 211), 6.97 (dd, .7 = 5.1, 3.4 Hz, 1H), 7.01 -7.11 (m, 3H), 7.42 - 7.54 (m, 1H); M+H(276.1).
    3-(2-(3-Methoxyphenoxy)-N-(thiophen-2-ylmethyl)acetamido)pyridinium chloride;Example 87.
    Prepared similarly to example 14 from 2-(3-methoxyphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide (example 99). *11 NMR (400MHz, DMSO-d6): δ, ppm: 3.70(s, 311), 4.58(s, broad, 214), 5.09(s, broad, 2H), 6.3 L (m, broad, 211), 6.51 (dd, 1H, J1=8Hz, J2=2Hz), 6.88(s, broad, 111), 6.92(m, III), 7.13( t, III, J=8.4IIz), 7.46(dd, 114.J 1=5.2Hz, J2=1.2Hz), 7.68(broad, 1H), 7.96(broad, 1H) , 8.66(dd, 2H, J1=5.2Hz, J2=1.214z); M+H(355.1).
    2-(3-methoxyphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 88.
    Prepared similarly to example 21 from 2-(3-methoxyphenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-2-amine. Room temperature 11 NMR showed a mixture of rotamers: 11 NMR (400 MHz, CDCl3 ) δ 3.74 (d, 314), 4.80 (d, 214), 5.28 (d, 2H), 6, 29 - 6.51 (m, 411), 6.86 - 6.93 (m, 214), 7.08 - 7.20 (m, 2H), 7.32 (m, III), 7.82 ( m, 1H), 8.51 (m, 1H); M+H(355.1).
    2-(2-isopropyl-5-methylphenoxy)-N-(1H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 89.
    Prepared similarly to example 21 from 2-(2-isopropyl-5-methylphenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)-111-pyrazol-5-amine. Yield 11%. 1 H NMR (400 MHz, DMSO-d6) δ 1.12 (d,./= 6.8 Hz, 611), 2.21 (s, 3H), 2.99 (hept./ - 6.8 Hz, 114), 4.57 (br s, 214), 4.98 (br s, 214), 6.23 (br s, III), 6.56 (m, 2H), 6.92 (br d , .7 = 4.1 Hz, 214), 7.08 (d, . / = 8.5 Hz, 114), 7.38 - 7.44 (m, 114), 7.78 (br s, III ), 12.90 (br s, III); M+H(370.2).
    N-((5-chlorothiophen-2-yl)methyl)-N-ethyl-2-(4-methoxyphenoxy)acetamide; Example 91. This compound was purchased from Enamine. M+H(340.1).
    N-((5-methylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide; Example 92.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-((5-methylthiophen-2-yl)methyl)aniline. Yield 57%. δ H NMR (400 MHz, CDCI 3 ) δ 2.25 (s, 3H), 2.43 (d, α7 = 1.0 Hz, 3H), 4.33 (s, 2H), 4.94 (s , 2H), 6.51 (m, 1H), 6.57 (d, J = 3.4 Hz, 1H), 6.67 (br d, J = 8.6 Hz, 2H), 7.01 ( br d, .7 = 8.2 Hz, 2H), 7.05 - 7.12 (m, 2H), 7.33 - 7.44 (m, 3H); M+H(352.1).
    N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide; Example 93. This compound was purchased from Chemdiv. M+H(339.1).
    N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide; Example 94.
    Prepared similarly to example 21 from 2-(m-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. 1 H NMR (400 MHz, CDCl3 ) δ 2.28 (s, 3H), 4.40 (br s, 211), 5.04 (br s, 2H), 6.52 (m, 2H), 6, 76 (br d, .7 = 7.4 Hz, 1H), 6.82 - 6.79 (m, 1H), 6.89 (dd, .7 = 5.1, 3.5 Hz, 1H) , 7.10 (t, .7 = 7.9 Hz, III), 7.24 (dd, .7 - 5.1, 1.2 Hz, 1H), 7.31 - 7.37 (m, 2H ), 8.37 (br s, III), 8.61 (br dd, .7 = 4.4, 1.5 Hz, 1H).; M+H(339.1).
    2-(3,4-dimethyleneoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 96. This compound was purchased from Chemdiv. M+H(353.1).
    2-(4-ethylphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 98.
    Prepared similarly to example 21 from 2-(4-ethylphenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-2-amine. *H NMR (400 MFIz, CDClj) δ 1.18 (t, δ7 = 7.6 Hz, 3H), 2.55 (q, δ7 = 7.6 Hz, 2H), 4.74 (s, 2H), 5.24 (s, 2H), 6.66 (d, J=8.7Hz, 2H), 6.85 - 6.91 (m, 2H), 7.03 (d, J=8 .7 Hz, 2H), 7.12 - 7.20 (m, 2H), 7.22 - 7.25 (m, 1H), 7.73 (ddd, .7=8.1, 7.5, 2.0 Hz, 1H), 8.49 (ddd,.7=4.9, 2.0, 0.8 Hz, 1H); M+H(353.1).
    2-(3-methoxyphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 99.
    Prepared similarly to example 21 from 2-(3-methoxyphenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. δ H NMR (400 MHz, CDCl3 ) δ 3.75 (s, 3H), 4.38 (s, 2H), 5.04 (s, 2H), 6.31 (s, 2H), 6.54 - 6.45 (m, 1H), 6.83 - 6.77 (m, 1H), 6.89 (dd, .7=5.1, 3.5Hz, 1H), 7.11 (t, J = 8.6 Hz, 1H), 7.24 (dd, .7=5.1, 1.2 Hz, 1H), 7.40 - 7.29 (m,2H), 8.37 (s, III), 8.61 (d, .7=3.1 Hz, HI); M+H(355.1).
    N-ethyl-3-phenyl-N-(thiophen-2-ylmethyl)propanamide; Example 101.
    Prepared similarly to example 21 from 3-phenylpropanoyl chloride and N-(lyophen-2-ylmethyl)ethanamine. Room temperature 1 I-NMR showed a mixture of rotamers in ~2:1 ratio: 1 H NMR (400 MI Iz, DMS()-d6) δ 1.01 (m, 311), 2.58 - 2.72 ( m, 211), 2.84 (m, 211), 3.28 (m, 211), 4.64 (m, 211), 6.92 - 7.04 (m, 211), 7.13 - 7.32 (m, 411), 7.39 - 7.45 (m, 1H); M+11(274.1).
    N-ethyl-N-(thiazol-5-ylmethyl)-2-(p-tolyloxy)acetamide; Example 102.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiazol-5-ylmethyl)ethanamine. Yield: 71%. Room temperature 'H-NMR showed a mixture of rotamers in a ratio of —3:1: 1II NMR (400 MHz, DMSO-d6) δ 0.97 (smallest) (t, .7 = 7.0 Hz, 3H), 1.12 (major) (t, .7 = 7.1 Hz, 3H), 2.21 (s, 3H), 3.29 - 3.37 (m, 211), 4.66 (s, 2H) (major), 4.77 (s, 2H), 4.81 (minor) (s, 1H), 6.77 (d, .7= 8.6 Hz, 2H), 7.05 (d, J = 8.6 Hz, 2H), 7.85 (major) (d, .7 = 0.6 Hz, 1H), 7.89 (minor) (br s, III), 8.97 (major) (d, J = 0.7 Hz, 1H), 9.06 (minor) (br s, 1H); M+H(291.1).
    (R)-N-(3-methylbutan-2-yl)-2-(3-nitrophenoxy)acetamide; Example 103.This compound was prepared in a library format. M+H(267.1).
    N-ethyl-2-phenoxy-N-(thiophen-2-ylmethyl)acetamide; Example 105.
    Prepared similarly to example 21 from 2-phenoxyacetyl chloride and N-(thiophen-2-ylmethyl)ethanamine. Room temperature fH-NMR showed a mixture of rotamers in ratio -2:1: 'll NMR (400 MHz, DMSO-d6) δ 1.01 (smallest) (t, .7 = 7.1 Hz, 3H), 1 .14 (t, .7 = 7.1 Hz, 3H), 3.29 - 3.37 (m, 2H), 4.65 (major) (br s, 2H), 4.77 (minor) (br s, 211), 4.84 (br s, 2H), 6.93 (ddd, J = 19.7, 11.9, 7.1 Hz, 3H), 7.02 (minor) (dd, .7 = 5.0, 3.6 Hz, 1H), 7.05 (major) (d, J = 2.7 Hz, 1H), 7.11 (minor) (d, J = 2.8 Hz, 1II) , 7.22 - 7.33 (m, 2H), 7.42 (major) (dd, .7=5.1, 1.1 Hz, 1H), 7.51 (minor) (dd, .7 = 5.0, 0.7 Hz, 1H); M+H(276.1).
    ((R)-N-(1-hydroxy-3-methylbutan-2-yl)-N-isopropyl-2-(m-tolyloxy)acetamide;Example 106.This compound was prepared in a library format.M+11 (294.2).
    N-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 109. This compound was purchased from Chemdiv. M+H(356.1).
    2 3,4,6-trimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 110. This compound was purchased from Princeton. M+H(377.1).
    2-(4-methoxyphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 111.
    Prepared similarly to example 21 from 2-(4-methoxyphenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. 1H NMR (400 MHz, CDCI 3 ) δ 3.74 (s, 3H), 4.36 (s, 2H), 5.04 (s, 2H), 6.67 (d, .7 = 9.0 Hz, 2H), 6.82 - 6.73 (m, 3H), 6.89 (dd,.7=5.1, 3.5Hz, 1H), 7.24 (dd, J=5.1, 1 .2 Hz, 1H), 7.39-7.28 (m, 2H), 8.35 (s, 1H), 8.61 (dd, .7=4.4, 1.7 Hz, 1H); M+II(355.1).
    3,5-Dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 115. This compound was purchased from Princeton. M+H(363.1).
    2-(3-methoxyphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 116. This compound was purchased from Chemdiv. M+H(355.1).
    N-allyl-2-(2-hydroxyphenoxy)-N-((5-methylthiophen-2-yl)methyl)acetamide; Example 117. This compound was purchased from Chembridge. M+H(318.1).
    N-(pyrazin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 122.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl N-(thiophen-2-ylmethyl)pyrazin-2-amine chloride. 111 NMR (400 MHz, DMSO-d6) δ 2.20 (s, 3H), 4.90 (br s, 211), 5.27 (br s, 2H), 6.59 (d, .7=8 .1 Hz, 2H), 6.91 (dd, J = 5.1, 3.4 Hz, 1H), 6.96 (br d, .7 = 2.5 Hz, 1H), 7.02 (d , .7=8.1 Hz, 2H), 7.41 (dd, .7=5.1, 1.3 Hz, 1H), 8.44-8.57 (m, 2H), 8.82 ( d, .7=1.1 Hz, III); M+H(340.1).
    2-(4-isopropylphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 123. This compound was purchased from Chemdiv. M+H(367.1).
    20 2-(4-Fluorphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 124.
    Prepared similarly to example 21 from 2-(4-fluorophenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. 1 H NMR (400 MHz, CDCl3 ) δ4.37 (br s, 2H), 5.04 (br s, 2H), 6.68 (br dd, .7 = 9.0, 4.1 Hz, 2H) , 6.80 (dd, J=3.5, 1.1 Hz, 1H), 6.86 - 6.95 (m, 3H), 7.23 - 7.26 (m, 1H), 7.31 - 7.37 (m, 2H), 8.36 (br s, 1H), 8.62 (br dd, .7 = 4.3, 1.9 Hz, 1H); M+H(343.1).
    N-benzyl-N-ethyl-2-(p-tolyloxy)acetamide; Example 127.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-benzylethanamine. Room temperature 'H-NMR showed a mixture of rotamers in ~2:1 ratio: *H NMR (400 MPIz, DMSO-d6) δ 0.99 (minor) (t, J = 7.1 Hz, 3H), 1 .11 (major) (t, ./= 7.1 Hz, 311), 2.21 (minor) (s, 3H), 2.23 (major) (s, 3H), 3.22 - 3.32 (m, 2H), 4.52 (major) (br s, 2H), 4.59 (minor) (br s, 2H), 4.72 (minor) (br s, 2H), 4.85 (major ) (br s, 2H), 6.72 (minor) (d, .7= 8.6 Hz, 2H), 6.83 (d, .7= 8.6 Hz, 2H), 7.04 (minor ) (d, .7 = 8.3 Hz, 2H), 7.09 (d, .7 = 8.2 Hz, 1H), 7.19 - 7.34 (m, 4H), 7.39 (br t, .7 = 7.2 Hz, 1H); M+H(284.2).
    2-(4-chlorophenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 128. This compound was purchased from Chemdiv. M+H(359.1).
    2-(4-bromophenoxy)-N-(pyridyl-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 131. This commercially available compound was purchased from Princeton.M+H(405.0).
    N-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 132. This compound was purchased from Chemdiv. M+H(372.1).
    2-(2-isopropyl-5-methylcyclohexyloxy)-N-(2-(pyridin-4-yl)ethyl)acetamide; Example 133.
    Prepared similarly to example 21 from 2-(2-isopropyl-5-methylcyclohexyloxy)acetyl chloride and 2-(pyridin-4-yl)ethanamine. 1 I NMR (400 MHz, DMSO-d6) δ 0.69 (d, J = 6.9 Hz, 3H), 0.71 - 0.83 (m, 2H), 0.84 (d, .7 = 7.1 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.89 -0.97 (m, 1H), 1.19 (ddt, .7 = 13.4 , 10.3, 3.1 Hz, 1H), 1.23 - 1.37 (m, 1H), 1.50 - 1.66 (m, 2H), 1.93 - 2.02 (m, 1H ), 2.03 - 2.14 (m, 1H), 2.77 (t, .7 = 7.0 Hz, 2H), 3.08 (td, J = 10.6.4.1 Hz, 1H ), 3.39 (dd, .7 = 13.1, 7.0 Hz, 2H), 3.75 (d, .7 = 14.8 Hz, 1H), 3.89 (d, J = 14, 8 Hz, 1H), 7.22 (dd, .7= 4.4, 1.6 Hz, 2H), 7.51 (t, .7= 5.8 Hz, 1H), 8.45 (dd, 4.4, 1.6 Hz, 211); M+11(319.2).
    N-(thiazol-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 135.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)thiazol-2-amine. Yield 74%. 1 H NMR (400 MHz, CDCl3 ) δ 2.28 (s, 3H), 4.98 (br s, 2H), 5.71 (br s, 2H), 6.80 (br d, .7=8 .5 Hz, 2H), 6.95 (dd, .7 = 5.1, 3.5 Hz, 1H), 7.00 - 7.14 (m, 3H), 7.23 (dd, .7 = 5.1, 1.2 Hz, 1H), 7.57 (d, .7 = 3.6 Hz, 1H); M+H(345.1).
    N-(cyclohexylmethyl)-2-(2,4-dimethylphenoxy)-N-(pyridin-2-yl)acetamide; Example 137. This compound was purchased from Enamine. M+H(353.2).
    N-(furan-2-ylmethyl)-N-(pyridin-2-yl)-2-(p-tolyloxy)acetamide; Example 138. This compound was purchased from Princeton. M+11(323.1).
    3,6-Dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 139. This compound was purchased from Princeton. M+11(363.1).
    2-(3-fluorphenoxy)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 142.
    Prepared similarly to example 21 from 2-(3-fluorophenoxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. 1 H NMR (400 MHz, CDCl3 ) δ 4.39 (s, 2H), 5.05 (s, 2H), 6.44 (br d, 1H), 6.52 (br d, 1H), 6. 66 (td,.7 = 8.2, 2.0 Hz, 1H), 6.80 (dd, .7=3.4, 1.0 Hz, 1H), 6.89 (dd, J = 5, 1, 3.5 Hz, 1H), 7.17 (m, II I), 7.25 (dd, J = 5.2, 1.3 Hz, 1H), 7.31 - 7.41 (m, 211), 8.38 (br s, 1H), 8.63 (br dd, J = 4.2, 1.9 Hz, 1H); M+H(343.1).
    N-ethyl-N-(thiazol-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 143.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiazol-2-ylmethyl)ethanamine. Yield: 21%. Room temperature 111 NMR showed a mixture of rotamers in ~2:1 ratio:1111 NMR (400 MHz, DMSO-d6) δ 1.01 (smallest) (t, .7 = 7.1 Hz, 3H), 1.15 (major) (t, J = 7.1 Hz, 311), 2.21 (minor) (s, 311), 2.23 (major) (s, 3H), 3.34 - 3.39 (minor) (q, J = 7.1 Hz, 2H), 3.45 (major) (q, .7= 7.1 Hz, 2H), 4.76 (major) (br s, 1H), 4 .84 (major) (br s, 1H), 4.86 (minor) (br s, 211), 4.92 (minor) (br s, 2H), 6.77 (minor) (br d, J= 8.6 Hz, 2H), 6.81 (major) (br d, .7 = 8.6 Hz, 2H), 7.06 (m, 2H), 7.66 (major) (d, J = 3 .3 Hz, HI), 7.72 (major) (d, J = 3.3 Hz, 1H), 7.74 (minor) (d, .7 = 3.3 Hz, 1H), 7.83 ( minor) (d, J=3.3 Hz, 1H); M+H(291.1).
    N-ethyl-N-(3-fluorobenzyl)-2-(p-tolyloxy)acetamide; Example 148.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl N-(3-fluorobenzyl)ethanamine chloride. Yield: 73%. Room temperature 'H-NMR showed a mixture of rotamers in ratio —2:1: '11 NMR (400 MHz, DMSO-d6) δ 0.99 (smallest) (t, J= 7.1 Hz, 3H), 1 .12 (major) (t, J= 7.1 Hz, 3H), 2.21 (minor) (s, 2H), 2.23 (major) (s, 211), 3.30 (m, 2H) , 4.53 (major) (br s, 2H), 4.61 (minor) (br s, 2H), 4.72 10 (minor) (br s, 2H), 4.88 (major) (br s , 2H), 6.72 (minor) (d, .7 = 8.6 Hz, 2H), 6.83 (major) (d, J = 8.6 Hz, 2H), 6.98 - 7.20 (m, 5H), 7.35 (td, .7 = 7.9, 6.2 Hz, 1H), 7.43 (minor) (td, .7 = 7.9, 6.2 Hz, III) ; M+H(302.1).
    3,5,6-Trimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide;15 Example 144. This compound was purchased from Princeton. M+H(377.1).
    N-((5-ethylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide; Example 151.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl20 chloride and N-((5-ethylthiophen-2-yl)methyl)aniline. Yield 60%. *H NMR (400 MHz, hCDC) δ 1.28 (t, α7=7.5Hz, 3H), 2.25 (s, 3H), 2.79 (qd, α7=7.5, 1 .0 Hz, 211), 4.33 (s, 211), 4.95 (s, 211), 6.54 (dl, .7-3.4, 1.1 Hz, HI), 6.60 ( d, .7=3.4 Hz, 1H), 6.67 (br d, .7-8.6 Hz, 2H), 7.01 (br d, .7 = 8.2 Hz, 2H), 7 .06 - 7.12 (m, 2H); 7.35 - 7.41 (m, 3H); M+H(366.1).
    N-((5-ethylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide; Example 157.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-cyclohexylpyridin-2-amine. 1 H NMR (400 MHz, DMSO-d6) δ 0.82 - 0.97 (m, 1H), 1.06-1.33 (m, 4H), 1.51 (brd, .7 = 12.8 Hz, 1H), 1.66 (brd, J = 13.3 Hz, 2H), 1.76 (br d, J = 11.5 Hz, 2H), 2.17 (s, 3H), 4.11 -4.36 (m, 3H), 6.58 (d,.7=8.6Hz, 2H), 7.00 (d, J=8.6Hz, 2H), 7.39 - 7.47 (m, 2H), 7.93 (td, .7= 7.7, 2.0 Hz, 1H), 8.56 (ddd, .7= 4.8, 2.0, 0.8 Hz, 1H ); M+H(325.2).
    N-(pyrimidin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 159.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)pyrimidin-2-amine. 1 H NMR (400 MHz, hCDC) δ 2.26 (s, 3H), 5.20(s, 211), 5.53 (s, 2H), 6.69 (d, J=8.6 Hz, 2H), 6.93 - 6.84 (m, HI), 7.04 (ddd, .7 = 17.3, 9.3, 6.5 Hz, 311), 7.18 - 7.09 (m , 2H), 8.63 (d, .7=4.8 Hz, 2H); M+H(340.1).
    2-phenoxy-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 162.
    Prepared similarly to example 21 from 2-phenoxyacetyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. δ 11 NMR (400 MHz, CDCl3 ) δ 4.41 (br s, 2H), 5.04 (br s, 211), 6.72 (d, δ7=8.1 Hz, 2H), 6.78 - 6.82 (m, 1H), 6.88 (dd, J = 5.1, 3.5 Iz, 111), 6.94 (t, .7 = 7.3 Hz, 1H), 7 .18 - 7.25 (m, 311), 7.30 - 7.40 (m, 2H), 8.37 (br s, HI), 8.61 (br s, 1H); M+H(325 ,l).
    2-(4-Fluorphenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 163. This compound was purchased from Chemdiv. M+H(343.1).
    N-(thiophen-2-ylmethyl)butan-1-amine; Example 165.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-cyclohexylpyridin-2-amine. Room temperature *H-NMR showed a mixture of rotamers in ~2:1 ratio: 1 H NMR (400 MHz, DMSO-d6) δ 0.83 (m, 3H), 1.16 - 1.28 (m, 2H ), 1.35 - 1.57 (m, 2H), 2.20 (m, 3H), 3.20 - 3.28 (m, 2H), 4.60 - 4.80 (m, 4H), 6.71 - 6.80 (m, 2H), 6.90 - 7.10 (m, 4H), 7.38 - 7.50 (m, 1H); M+H(318.1).
    2-(3-chlorophenoxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 166. This compound was purchased from Chemdiv. M+H(359.1).
    N-((3-methylthiophen-2-yl)methyl)-N-phenyl-2-(p-tolyloxy)acetamide: Example 168.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-((3-methylthiophen-2-yl)methyl)aniline. Yield 55%. δ H NMR (400 MHz, CDCI3) δ 1.87 (s, 3H), 2.25 (s, 3H), 4.33 (s, 5H), 5.02 (s, 3H), 6.65 - 6.72 (m, 3H), 6.95 - 7.08 (m, 4H), 7.11 (d, J=5.1 Hz, 1H), 7.34-7.40 (m, 3H) ; M+H(352.1).
    2-phenoxy-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide: Example 169. This compound was purchased from Chemdiv. M+H(325.1).
    (E)-3-(benzo[d][1,3]dioxol-5-yl)-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 71.
    Prepared similarly to example 6 from (E)-3-(benzo|d][1,3]dioxol-5-yl)acryloyl chloride and N-(thiophen-2-ylmethyl)-111-pyrazole -5-amine. 1 H NMR (400MHz, CDCl 3 ) δ 5.18 (br s, 211), 5.96 (s, 2H), 6.09 (br s, HI), 6.37 (br d, .7 = 14, 1 Hz, 1H), 6.75 (d, J - 8.0 Hz, 1H), 6.84 (br s, 1H), 6.87 - 6.98 (m, 3H), 7.19 (dd , .7 = 5.1, 1.2 Hz, 1H), 7.55 (d, .7 = 2.4 Hz, 1H), 7.67 (d, .7 = 15.4 Hz, 1H), 10.16 (br s, 1H); M+H(354.1).
    (E)-N-(5-methyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide;Example 72.
    Prepared similarly to example 6 from (E)-3-p-tolylacryloyl chloride and 5-methyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. 1 H NMR (400 MHz, CDCl 3 ) δ 1.92 (s, 311), 2.32 (s, 311), 5.01 (br s, 2H), 6.36 (d, .7 = 15.6 Hz, 1H), 6.83-6.91 (m, 2H), 7.09 (d, .7 = 8.0 Hz, 2H), 7.21 (dd, .7 = 5.0, 1, 4 Hz, 1H), 7.25 (d, .7= 8.3 Hz, 2H), 7.38 (s, 1H), 7.75(d, .7= 15.6 Hz, 1H);M +H(338.1).
    (E)-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide; Example 73.
    Prepared similarly to example 6 from (E)-3-p-tolylacryloyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. δ 11 NMR (400 MHz, DMSO-d6) δ 2.29 (s, 3H), 5.06 (br s, 211), 6.13 (br s, 111), 6.52 (brd,.7= 15.8 Hz, 111), 6.90 (m, 2H), 7.18 (d, .7 = 7.7 Hz, 211), 7.24 - 7.44 (m, 3H), 7.55 (d, .7 = 15.6 Hz, HI), 7.78 (br s, 1H), 12.85 (br s, 1H); M+II(324.1).
    (E)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide; Example 174.
    To a stirring solution at 0°C of (E)-3-p-tolylacryloyl chloride (362 mg, 2.000 mmol) in DCM (4.0 mL) was added pyridine (162 uL, 2.000 mmol) and then N- (thiophen-2-ylmethyl)-1H-pyrazol-4-amine (179 mg, 1000 mmol). The ice bath was removed and the reaction was stirred to completion. All volatiles were evaporated in vacuo and the residue taken up in EtOH (15.0ml) and THF (5.0ml). To this mixture was added 1.0 M NaOH (6.0 mL, 6,000 mmol) and the reaction was stirred overnight. All volatiles were evaporated in vacuo and the residue taken up in DCM. The organic layer obtained was washed with water and then brine. The resulting organic solution was dried with MgSCL and concentrated. The crude product obtained was absorbed under vacuum in Florisil with the aid of DCM (dry charge). The obtained dispersion was purified on the biotage (DCM:MeOH 1-15% 40 CV gradient, 40 g Silicycle column).
    The collected fractions were evaporated to give (E)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide (267 mg, 0.8256 mmol; 83%) as a white solid, which was judged to be less than 97% pure by 1 H-NMR and LC-MS analysis.
    Said material was then completely dissolved in a hot mixture of EtOH (5.0 mL) and DCM (2.0 mL). Upon cooling, thick white needles began to form and the process continued overnight. After decanting, the liquids were removed with a pipette and the solid obtained was washed with three aliquots of cold EtOH. The crystals obtained were then heated in hot ethanol and the volatiles were then evaporated on the rotary evaporator. This step was repeated 3 times in order to get rid of traces of DCM. The solids were then left overnight under high vacuum.
    In this way, 169 mg (0.5226 mmol, 52%) were obtained in a purity judged to be greater than 97% purity by 'H-NMR and LC-MS analysis. *H NMR (400 MHz, DMSO-d6, T = 80°C) δ 2.30 (s, 3H), 5.03 (s, 2H), 6.58 (s, 1H), 6.98 - 6 .85 (m, 2H), 7.17 (d, α/-8.1 Hz, 2H), 7.40 (ddd, α/= 41.4, 19.2, 11.8 Hz, 611); Ml 11(324.1).Example 174a: (E)-3-p-tolylacryloyl chloride.
    To a stirred suspension at 0°C of 4.22 g of the acid (26.02 mmol; 1.0 cqmol) in 50.0 mL of DCM was added 2.38 mL of oxalyl chloride (27.32 mmol ; 1.05 cqmol) and then 60 µl of DMF (0.7806 mmol; 0.03 cqmol). The ice bath was removed and the reaction was stirred at room temperature until gas evolution ceased (bubbling monitor).
    All volatiles were then evaporated on the rotary evaporator under high vacuum. 4.723 g (26.14 mmol; quant.) of a white solid were recovered. This material was used in the next step without further purification.Example 174b: N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine.
    To a stirred mixture at 0°C of 1H-pyrazol-4-amine (250 mg, 3.008 mmol) and thiophene-2-carbaldehyde (281 µL, 3.008 mmol) in methanol and acetic acid (5.0 mL, proportion 10:1) 5-ethyl-2-methylpyridine borane complex (444 uL, 3.008 mmol) was added. The ice bath was removed and the flask was attached to a bubbler to allow gas evolution and expansion. The reaction was stirred overnight at room temperature. Most of the volatiles were evaporated in vacuo. With the aid of an ice bath at 0°C, a 10 M solution of NaOH in water was carefully added. The ice bath was removed and stirring was continued for approximately 1 hour. The aqueous layer was extracted with DCM (3x), washed with brine, and dried over MgSOb and concentrated. The crude product obtained was left under vacuum to remove volatiles. The viscous oil obtained was diluted with DCM and evaporated under a gentle stream of nitrogen overnight. Solid crystals of the amine were separated and washed with three aliquots of Hex:EtOAc = 9:1. In this way, 391 mg (2.181 mmol; 72%) of the desired product was obtained in greater than 97% purity with 1 H-NMR analysis. 111 NMR (400 MHz, DMSO-d6) δ 4.21 (d, α7 = 5.6 Hz, 111), 4.92 (t, α/=6.0 Hz, 1H), 6.94 (dd ..7 = 5.1, 3.4 Hz, 1H), 7.10 - 6.99 (m, 3H), 7.36 (dd, .7= 5.1, 1.2 Hz, 1H), 12.05 (br s, 111).
    (E)-3-(benzo[d][1,3]dioxol-5-yl)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 175.
    Prepared similarly to example 6 from (E)-3-(benzo[d][1,3|dioxol-5-yl)acryloyl and N-(thiophen-2-ylmethyl)-1II-pyrazol-4 -the mine. Yield 82%. δ H NMR (400 MHz, CDCl 3 ) δ 5.04 (br s, 2H), 5.95 (s, 211), 6.33 (d, J = 15.5 Hz, 1H), 6.75 (d , .7 = 8.0 Hz, 111), 6.81 (br d, .7 = 1.3 Hz, 1H), 6.86 - 6.97 (m, 311), 7.22 (dd. 7 4.8, 1.5 Hz, III), 7.43 (br s, 2H), 7.66 (d, .7 = 15.5 Hz, 1H); M4-H(354.1).
    (E)-N-(3,5-dimethyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide; Example 176.
    Prepared similarly to example 6 from (E)-3-p-tolylacryloyl chloride and 3,5-dimethyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. 1 H NMR (400 MHz, CDCl 3 ) δ 1.89 (s, 611), 2.33 (s, 3H), 4.96 (br s, 2H), 6.28 (d, J = 15.6 Hz , 1H), 6.83 - 6.86 (m, 1H), 6.89 (dd, .7=5.1, 3.5Hz, 1H), 7.10 (d, .7=8.0 Hz, 2H), 7.22 (dd, .7 = 5.1, 1.3 Hz, 1H), 7.25 (d, .7 = 8.0 Hz, 2H), 7.75 (d, . 7 = 15.6 Hz, 1H); M+H(352.1).
    (E)-3-(benzo[d][1,3]dioxol-5-yl)-N-(5-methyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 177.
    Prepared similarly to example 6 from (E)-3-(benzo[d][1,3]dioxol-5-yl)acryloyl chloride and 5-methyl-N-(thiophen-2-ylmethyl)- 1H-pyrazol-4-amine. *H NMR (400 MHz, CDCl3 ) δ 1.91 (s, 3H), 4.99 (s, 2H), 5.96 (s, 2H), 6.21 (d, J = 15.5 Hz, 1H), 6.75 (d, .7 = 8.0 Hz, 1H), 6.80 (d, .7 = 1.7 Hz, 1H), 6.93 - 6.83 (m, 3H), 7.22 (dd, J = 5.1, 1.2 Hz, III), 7.36 (s, 1H), 7.68 (d, .7 = 15.5 Hz, III); M+H(368.1).
    (E)-3-(benzo[d)|1,3]dioxol-5-yl)-N-cyclopropyl-N-(thiophen-2-ylmethyl)acrylamide; Example 178. This commercially available compound was. M+H(302.1).
    (E)-3-(benzo[d|1,3|dioxol-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylaniide; Example 179.
    Prepared similarly to example 21 from (E)-3-(benzo[d][1,3]dioxol-5-yl)acryloyl chloride and N-(thiophen-2-ylmethyl)ethanamine. *H NMR (400 MHz, DMSO-do, T = 80°C) δ 1.12 (t, .7 = 7.1 Hz, 311), 3.50 (br q, J = 6.9 Hz, 2H ), 4.81 (br s, 2H), 6.04 (d, J = 0.5 Hz, 2H), 6.91 (d, J = 8.0 Hz, 1H), 6.94 - 7, 03 (m, 2H), 7.05 (br d, J = 3.4 Hz, III), 7.12 (br dd, .7 = 8.0, 1.5 Hz, 1H), 7.34 ( br s, 1H), 7.38 (br d, J= 5.1 Hz, 1H), 7.47 (d, .7 = 15.3 Hz, 1H); M+H(316.1).
    (E)-3-(benzo|d][1,3]dioxol-5-yl)-N-(3,5-dimethyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl) acrylamide; Example 180.
    Prepared similarly to example 6 from (E)-3-(benzo[d][1,3]dioxol-5-yl)acryloyl and 3,5-dimethyl-N-(thiophen-2-ylmethyl) chloride )-1H-pyrazol-4-amine. *H 10 NMR (400 MHz, CDCl 3 ) δ 1.90 (s, 6H), 4.95 (br s, 2H), 5.93 (s, 2H), 6.17 (d, .7 = 15, 5 Hz, 1H), 6.72 (d, .7 = 8.0 Hz, 1H), 6.79 (d, .7 = 1.7 Hz, 1H), 6.81 - 6.91 (m, 3H), 7.20 (dd, .7 = 5.1, 1.3 Hz, 1H), 7.69 (d, .7 = 15.5 Hz, 1H); M+H(382.1).
    (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide; Example 181.
    Prepared similarly to example 21 from (E)-3-p-tolylacryloyl N-(thiophen-2-ylmethyl)ethanamine chloride. Yield 82%. *H NMR (400 MHz, DMSO-d6, T = 80°C) δ 1.13 (t, .7 = 7.1 Hz, 3H), 2.33 (s, 3H), 3.51 (br q , .7 = 7.1 Hz, 2H), 4.82 (br s, 2H), 6.97 (dd, .7 = 5.0, 3.5 Hz, 1H), 7.01 - 7.11 (m, 2H), 7.21 (br d, .7 = 8.0 Hz, 2H), 7.39 (dd, .7 = 5.1, 1.2 Hz, 1H), 7.53 ( brm, 3H) M+H(286.2).
    (E)-3-(4-methoxyphenyl)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acrylamide;Example 183.
    Prepared similarly to example 6 from (E)-3-(4-methoxyphenyl)acryloyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. δ11 NMR (400 MHz, 25 DMSO-d6) δ 3.75 (s, 311), 4.98 (s, 2H), 6.43 (d, α7 = 15.6 Hz, HI), 6, 82 - 6.98 (m, 4H), 7.32 - 7.46 (m, 411), 7.52 (d, .7 = 15.6 Hz, 111), 7.73 (br s, 1H) , 12.98 (br s, III); M+H(340.1).
    (E)-3-(4-methoxyphenyl)-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 184.
    Prepared similarly to example 6 from (E)-3-(4-methoxyphenyl)acryloyl chloride and N-(thiophen-2-ylmethyl)-1FI-pyrazol-5-amine. 1 H NMR (400 MHz, CDCl3 ) δ 3.79 (s, 3H), 5.18 (br s, 2H), 6.09 (br s, 1H), 6.41 (br d, J = 15, 2 Hz, 2H), 6.81 (d, .7 = 8.7 Hz, 1H), 6.89 (dd, .7 = 5.0, 3.5 Hz, 1H), 6.95 (br d , .7 = 2.8 Hz, HI), 7.19 (dd, .7 = 5.1, 1.2 Hz, 1H), 7.32 (brd, .7-8.4 Hz, 2H), 7.52 (d,.7=2.4 Hz, III); 7.72 (d,.7=15.5 Hz, 1H); M+11(340.1).
    N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide; Example 185.
    Prepared similarly to example 6 from 3-p-tolylpropanoyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. *H NMR (400 MHz, CDCl 3 ) δ 2.28 (br s, 3H), 2.39 - 2.56 (m, 2H), 2.85 - 2.97 (m, 2H), 5.02 ( br s, 2H), 5.91 (d, .7= 2.3 Hz, 1H), 6.81 - 6.91 (m, 21 -I), 6.93 - 7.06 (m, 4H) , 7.15 - 7.22 (m, 1H), 7.45 (d, .7 = 2.4 Hz, 1H), 10.17 (brs, HI).; M+H(326.1).
    N-(3,5-dimethyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)enamamide; Example 186.
    Prepared similarly to example 6 from 3,5-dimethyl-N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine cinnamoyl chloride. Yield 67%. *H NMR (400 MHz, DMSO-d6) δ 1.76 (s, 6H), 4.77-4.96 (br m, 211), 6.33 (d, .7 - 15.7 Hz, 1 H), 6.83 (dd, .7 = 3.4, 1.2 Hz, 1H), 6.92 (dd, .7-5.1, 3.4 Hz, HI), 7.35 (dd , .7= 6.2, 2.6 Hz, 311), 7.43 (m, 311), 7.59 (d, .7-15.7 Hz, 111), 12.36 (brs, HI) ; M+H(338.1).
    N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)cinnamamide; Example 187.
    Prepared similarly to example 6 from cinnamoyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. δ H NMR (400 MHz, CDCl 3 ) δ 5.19 (br s, 1H), 6.09 (br s, 2H), 6.54 (br d, J = 15.0 Hz, 2H), 6.90 (dd, J= 5.0, 3.5 Hz, 1H), 6.96 (br d, .7= 2.5 Hz, 1H), 7.20 (dd, .7= 5.1, 1, 3 Hz, 1H), 7.30 (m, 3H), 7.37 (br s, 2H), 7.54 (d, .7 = 2.4 Hz, 1H), 7.76 (d, .7 = 15.6 Hz, 1H); M+H(310.1).
    N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)cinnamamide; Example 190.
    Prepared similarly to example 6 from cinnamoyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. Yield 38%. Room temperature *H NMR showed a mixture of rotamers: *H NMR (400 MHz, acetone-d6) δ 2.82 (d, 2H), 5.05 (d, 2H), 6.68 (d, .7= 15.6 Hz, 1H), 6.93 (d, 2H), 7.26 - 7.72 (m, 9H), 12.24 (br s, 1H); M+H(310.1).
    (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-(3,5-dimethyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acrylamide ; Example 192.
    Prepared similarly to Example 6 from (H)-3-(2,3-dihydro-111-inden-5-yl)acryloyl and 3,5-dimethyl-N-(thiophen-2-ylmethyl) chloride )-1H-pyrazol-4-amine. δ 14 NMR (400 MHz, CDCl3 ) δ 1.90 (s, 611), 2.05 (p, .7 - 7.5 Hz, 211), 2.86 (dd, .7 = 12.8, 7 .5 Iz, 4H), 4.96 (br s, 2H), 6.28 (d, .7 = 15.6 Hz, 1H), 6.82 - 6.91 (m, 211), 7, 14 (br s, 211), 7.18 - 7.25(m, 2H), 7.77 (d, .7=15.6 Hz, 1H); M+H(378.1).
    ((E)-3-(benzo[d|[1,3]dioxol-5-yl)-N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 195.
    Prepared similarly to example 21 from (E)-3-(benzo[d][1,3]dioxol-5-yl)acryloyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine . Yield 87%. Room temperature *H NMR showed a mixture of rotamers: 1 H NMR (400 MIIz, CDCl3 ) δ 5.15 (s, 2H), 5.95 (s, 2H), 6.01 (br d, III), 6 .74 (m, 2H), 6.79 - 6.95 (m, 3H), 7.14 - 7.23 (m, 1H), 7.35 (m, 1H), 7.42 (m, 1H ), 7.69 (m, 1H), 8.41 (dd, J= 2.5, 0.7 Hz, 1H), 8.62 (dd, .7=4.7, 1.6 Hz, 1H ); M+H(365.1).
    (E)-2-phenyl-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)cyclopropanecarboxamide Example 196.
    Prepared similarly to example 6 from (+/-)(E)-2-phenylcyclopropanecarbonyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. Yield 88%. *H NMR (400 MHz, DMSO-d6, T = 80°C) δ 1.19 (br m, 1H), 1.49 (m, 1H), 1.86 (br s, 1H), 2.38 (m, 1H), 4.95 (br s, 2H), 6.87 (br m, 1H), 6.96 - 6.90 (m, III), 7.02 (br d, J=1, 2 Hz, 2H), 7.10 - 7.17 (m, III), 7.18 - 7.25 (m, 2H), 7.29 (br s, 1H), 7.36-7.37 ( m, 1H), 7.58 (brs, 1H), 12.67 (brs, III); M+H(324.1).
    (E)-3-(benzo[d][1,3|dioxol-5-yl)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 197.
    Prepared similarly to example 21 from (E)-3-(bcnz.ofdII1,3]dioxol-5-yl)acryloyl and N-(thiophen-2-ylmethyl)pyridin-2-amine chloride. 11 NMR (400 MHz, CDCl3 ); δ 5.39 (d, .7=0.5 Hz, 211), 5.96 (s, 211), 6.28 (d, .7=15.4 Hz, 1H), 6.76 (d , .7 = 8.0 Hz, 1H), 6.81 (d, .7 = 1.7 Hz, 1H), 6.86 (dd, .7 = 5.1, 3.5 Hz, III), 6.91 (m, 2H), 7.06 (br d, .7 = 8.0 Hz, 1H), 7.16 (dd, .7 = 5.1, 1.3 Hz, III), 7, 23 (ddd, .7=7.5, 4.9, 1.0 Hz, HI), 7.61 - 7.75 (m, 2H), 8.59 (m, 1H); M+H(365.1).
    2-phenoxy-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acetamide; Example 199.
    Prepared similarly to example 6 from 2-phenoxyacetyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. 1 H NMR (400 MHz, CDCl3 ) δ 4.62 (br s, 2H), 5.07 5 (br s, 2H), 6.08 (br s, 1H), 6.83 (br d, .7 = 8.0 Hz, 1H), 6.87 - 6.96 (m, 3H), 7.18 - 7.25 (m, 3H), 7.52 (d, J=2.5 Hz, 1H) ; M+H(314.1).
    (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 200.
    Prepared similarly to example 6 from (E)-3-(2,3-dihydro-1H-inden-5-yl)acryloyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol- 5-amine. δ11 NMR (400 MHz, CDCl3 ) δ 2.03 (p, .7 = 7.5 Hz, 2H), 2.84 (m, 4H), 5.17 (s, 2H), 6.07 (br s, 1H), 6.48 (br d, J = 15.5 Hz, 1H), 6.88 (br dd, J= 5.0, 3.5 Hz, 1H), 6.93 (br d, 1H), .7= 2.7 Hz, 1H), 7.08 - 7.24 (m, 4H), 7.47 (d, .7 = 2.4 Hz, HI), 7.76 (d, .7= 15.5 Hz, 1H), 11.35 (br s, 1H); M+H(350.1).
    (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-(5-methyl-1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 201.
    Prepared similarly to example 6 from (E)-3-(2,3-dihydro-111-inden-5-yl)acryloyl and 5-methyl-N-(thiophen-2-ylmethyl)-chloride 1 H-pyrazol-4-amine. δ111 NMR (400MHz, CDCl3 ) δ 1.93 (s, 3H), 2.03 (p, δ7 = 7.5 Hz, 211), 2.85 (δ, / ~ 7.5 Hz, 4H), 5.01 (br s, 211), 6.37 (d, .7 = 15.5 Hz, HI), 6.83 - 6.90 (m, 211), 7.13 (br s, 211), 7.17 - 7.23 (m, 2H), 7.40 (br s, 111), 7.77 (d, J - 15.6 Hz, HI); Ml 11(364.1).
    N-(bicyclo[2,2,1]heptan-2-yl)-N-(1H-pyrazol-5-yl)einamamide; Example 203.
    Prepared similarly to example 6 from cinnamoyl chloride and N-(bicyclo[2,2,1]heptan-2-yl)-1H-pyrazol-5-amine. δ 0.80 - 0.87 (m, 1H), 1.00 - 1.08 (m, 1H), 1.30 - 1.35 (m, 1H), 1 .35 - 1.48 (m, 1H), 1.54 - 1.48 (m, 1H), 1.68 - 1.78 (m, 1H), 1.89 - 1.78 (m, 1H) , 2.10 -2.13 (m, 1H), 2.92-2.99 (m, 1H), 4.60 (m, 1H), 6.18 - 6.25 (m, 2H), 7 .21 - 7.33 (m, 5H); 7.59 - 7.69 (m, 2H); M+H(308.2).
    N-ethyl-N-(thiophen-2-ylmethyl)cinnamamide; Example 204.
    Prepared similarly to example 21 from cinnamoyl chloride and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'H-NMR showed a mixture of rotamers in ~2:1 ratio: 'iT NMR (400 MHz, I)MSO-d6) δ 1.10 (m, 311), 3.41 (minor) (br q , ,J ~ 7.0 Hz, 211), 3.54 (highest) (br q, J = 6.9 Hz, 2H), 4.73 (highest) (br s, 2H), 4.97 (smallest) ) (br s, 211), 6.93 - 7.01 (m, 1H), 7.08 (m, 1H), 7.13 (major) (d, J = 15.4 Hz, 1H), 7 .28 (minor) (d, .7 = 15.4 Hz, III), 7.42 (m, 4H), 7.56 (m, 111), 7.71 (m, 2H); M+H(272.1).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-ethyl-N-(thiazol-5-ylmethyl)acetamide; Example 205.
    Prepared similarly to example 21 from 2-(2,3-dihydro-H1-inden-5-yloxy)acetyl chloride and N-(thiazol-5-ylmethyl)ethanamine. Room temperature 11-NMR showed a mixture of rotamers in a ratio of ~4:1: 1H NMR (400 MHz, DMSO-d6) δ 0.99 (smallest) (t, J = 7.0 Hz, 3H), 1 .14 (major) (t, ./ 7.1 Hz, 311), 1.99 (p, .7 = 7.4 Hz, 2H), 2.70 - 2.86 (m, 411), 3, 22 - 3.41 (m, 211), 4.68 (major) (br s, 211), 4.77 (br s, 2H), 4.83 (minor) (br s, 211), 6.66 (dd, .7 = 8.2, 2.5 Hz, 1H), 6.76 (br s, 111), 7.09 (d, .7 - 8.2 Hz, 1H), 7.86 ( major) (s, 1H), 7.91 (minor) (s, 1H), 8.99 (major) (s, 111), 9.09 (minor) (s, 1H); M+H(317.1).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-ethyl-N-(thiazol-5-ylmethyl)acetamide; Example 212.
    Prepared similarly to example 21 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and N-(thiazol-2-ylmethyl)ethanamine. Room temperature 'El-NMR showed a mixture of rotamers in ~2:1 ratio: 'H NMR (400 MHz, DMSO-d6) δ 1.01 (smallest) (t,.7=7.1 Hz, 3H), 1.15(major) (t,. 7=7.1 Hz, 311), 1.99 (m, 2H), 2.67 - 2.88 (m, 4H), 3.36 (minor) (q , .7=7.1 Hz, 2H), 3.46 (highest) (q, .7 = 7.1 Hz, 2H), 4.77 (highest) (br s, 2H), 4.83 (highest ) (br s, 2H), 4.85 (minor) (br s, 2H), 4.92 (minor) (s, 1H), 6.63 (minor) (dd, .7= 8.2, 2 .3 Hz, 1H), 6.67 (major) (dd, .7 = 8.2, 2.5 Hz, 1H), 6.75 (minor) (br d, .7 = 1.8 Hz, 1H ), 6.78 (major) (br d, .7 = 2.0 Hz, 1H), 7.08 (t, .7 = 8.3 Hz, 1H), 7.67 (major) (d, , 7= 3.3 Hz, 1H), 7.72 (major) (d, .7= 3.3 Hz, 1FI), 7.74 (minor) (d, .7 = 3.3 Hz, 1H), 7.83 (minor) (d, J=3.2 Hz, 1H); M+H(317.1).
    2-(benzo[d][1,3|dioxol-5-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 217.
    Prepared similarly to example 21 from 2-(benzo[d][1,3]dioxol-5-yloxy)acetyl chloride and N-(thiophen-2-ylmethyl)aniline. δ H NMR (400 MHz, CDCl 3 ) δ 5.93 (s, 2H), 6.10 (d, J=15.5 Hz, 1H), 6.73 (dd, δ7 = 4.8, 3, 2 Hz, 2H), 6.87 (m, 3H), 7.05 - 7.14 (m, 2H), 7.21 (dd,.7=5.1, 1.2 Hz, 1H), 7 .33 - 7.44 (m, 3H); 7.65 (d, J =15.5 Hz, 1H); M+11(368.1).
    N-aliI-N-(thiophen-2-ylmethyl)cinnamamide; Example 218. This compound was purchased from Enamine. M+11(284.1).
    (+/-) (E)-N-ethyl-2-phenyl-N-(thiophen-2-ylmethyl)cyclopropanecarboxamide; Example 220.
    Prepared similarly to example 6 from (+/-) (E)-2-phenylcyclopropanecarbonyl chloride and N-(thiophen-2-ylmethyl)ethanamine. 1 I NMR (400 MHz, DMSO-d6, T = 80°C) δ 1.19 (br m, 111), 1.49 (m, 1H), 1.86 (br s, 1H), 2, 34-2.42 (m, 1H), 4.95 (br s, 2H), 6.87 (br d, .7 = 3.4 Hz, 1H), 6.90 - 6.96 (m, 1H ), 7.02 (br d, .7 = 7.2 Hz, 2H), 7.10 - 7.17 (m, 1H), 7.18-7.25 (m, 2H), 7.30 ( br s; 1H), 7.35 -7.39 (m, 1H), 7.58 (s, 1H), 12.67 (brs, 1H); M+H(286.1).
    (E)-N-(bicyclo[2,2,1]hcptan-2-yl)-N-(1H-pyrazol-5-yl)-3-p-tolylacrylamide;Example 223.
    Prepared similarly to example 6 from (E)-3-p-tolylacryloyl chloride and N-(bicyclo[2,2,1]heptan-2-yl)-1H-pyrazol-5-amine. δ11 NMR (400 MHz, CDCl3 ) δ 0.84 (m, 1H), 1.08 - 0.99 (m, 1H), 1.25 - 1.54 (m, 4H), 1.64 - 1 .78 (m, 1H), 1.78 - 1.89 (m, 1H), 2.10 (br s, 1H), 2.30 (s, 3H), 2.95 (br s, 1H), 4.51 - 4.68 (m, 1H), 6.17 (d, .7= 15.5 Hz, 1H), 6.21 (d, J= 2.3 Hz, 1H), 7.05 ( d, .7=8.1 Hz, 2H), 7.19 (d, .7=8.1 Hz, 2H), 7.58 -7.67 (m, 2H); M+H(321.2).
    N-(bicyclo[2,2,1|heptan-2-yl)-2-(2,3-dihydro-11-inden-5-yloxy)-N-(1H-pyrazol-5-yl)acethamide; Example 229.
    Prepared similarly to example 6 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and N-(bicyclo[2,2,1]heptan-2-yl)-1H -pyrazol-5-amine. 1 H NMR (400 MHz, CDCl3 ) δ 0.78 -0.88 (m, 1H), 0.94-1.09 (m, 1H), 1.27 - 1.50 (m, 4H), 1 .62-1.77 (m, 1H), 1.77 - 1.89 (m, 1H), 1.96 - 2.03 (m, 2H), 2.09 (br s, 1H), 2. 78 (m, 4H), 2.95 (br s, 1H), 4.36 (m, 2H), 4.46 - 4.60 (m, III), 6.19 (d, .7 = 2, 4 Hz, 1H), 6.58 (dd, .7 = 8.2, 2.5 Hz, 1H), 6.68 (br d, J = 2.3 Hz, 1H), 7.01 (d, .7 = 8.2 Hz, 1H), 7.59 (d, .7 = 2.4 Hz, 1H), 11.11 (brs, 1H); M+H(351.2).
    N-(bicyclo[2,2,1]hept-5-en-2-ylmethyl)-N-(1H-pyrazol-5-yl)-2-(p-tolyloxy)acetamide; Example 230.
    Prepared similarly to example 6 from 2-(p-tolyloxy)acetyl chloride and N-(bicyclo[2,2,1]hept-5-en-2-ylmethyl)-1H-pyrazol-5-amine (endo and exo mixture). *H NMR (400 MHz, CDCl 3 ) δ 0.53 (m, 1H), 1.04 - 1.50 (m, 3H), 1.57 - 1.82 (m, 1H), 2.22 (s , 3H), 2.32 - 2.43 (m, 1H), 2.73 (br s, 1H), 2.80 (br s, 1H), 3.44 - 3.89 (m, 2H), 4.53 - 4.57 (m, 2H), 5.78 - 5.86 (m, 1H), 5.96 - 6.05 (m, 1H), 6.05 - 6.13 (m, 1H ), 6.13 - 6.22 (m, 1H), 6.71 (m, 2H), 6.99 (d, .7=8.3 Hz, 2H), 7.53 -7.57 (m , 1H), 11.17 (brs, 1H); M+H(338.2).
    2-(cyclohexyloxy)-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)acetamide; Example232.
    Prepared similarly to example 6 from 2-(cyclohexyloxy)acetyl chloride and N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. δ 11 NMR (400 MHz, CDCl3 ) δ 1.09 - 1.33 (m, 6H), 1.69 (m, 211), 1.87 (m, 2H), 3.29 (br s, HI) , 4.07 (brs s, 2H), 5.04 (brs, 211), 6.03 (brs s, 1H), 6.86 - 6.94 (m, 2H), 7.19 (dd, .7 = 5.0, 1.3 Hz, 1H), 7.51 (d, .7 =2.4 Hz, HI); M+H(320.1).
    N-(bicyclo[2,2,1]heptan-2-yl)-2-(cyclohexyloxy)-N-(πi-pyrazol-5-yl)acetamide;Example 233.
    Prepared similarly to example 6 from 2-(cyclohexyloxy)acetyl chloride and N-(bicyclo[2,2,1]hcptan-2-yl)-1H-pyrazol-5-amine. 1 H NMR (400 MHz, hCDC) δ 0.76 (ddd, .7 = 13.1, 5.2, 2.9 Hz, 1H), 0.93 - 1.03 (m, 1H), 1, 07-1.54 (m, 10H), 1.60 - 1.92 (m, 6H), 2.08 (br s, 1H), 2.93 (br s, 1H), 3.19 - 3 .29 (m, 1H), 3.78 - 3.93 (m, 2H), 4.43 - 4.54 (m, 1H), 6.15 (d, J = 2.4 Hz, 1H), 7.61 (d, J = 2.4 Hz, III); M+H(318.2).
    3,4,6-Trimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 235. This compound was purchased from Princeton. M+H(377.1).
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-ethyl-N-((5-methylthiophen-2-yl)methyl)acetamide; Example 236.
    Prepared similarly to example 21 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetyl chloride and N-((5-methylthiophen-2-yl)methyl)ethanamine. Room temperature *H-NMR showed a mixture of rotamers in ~2:1 ratio: 1II NMR (400 MHz, DMSO-d6) δ 1.00 (smallest) (t, .7 = 7.1 Hz, 3H), 1 .13 (major) (t, .7 = 7.1 Hz, 3H), 1.92 - 2.09 (m, 2H), 2.38 (major) (s, 2H), 2.41 (minor) (s, 3H), 2.78 (m, 4H), 3.25 - 3.38 (m, 2H), 4.54 (major) (br s, 2H), 4.65 (minor) (br s , 2H), 4.75 (br s, 2H), 6.56 - 6.71 (m, 2H), 6.73 (minor) (d, .7 = 1.6 Hz, 1H), 6.77 (major) (d, .7= 2.0 Hz, 1H), 6.81 (major) (d, .7= 3.3 Hz, 111), 6.87 (minor) (d, .7 = 3.3 Hz, 1H), 7.09 (m, III); M+H(330.1).
    (E)-N-phenyl-N-(thiophen-2-ylmethyl)-3-p-tolylacrylamide; Example 237.
    Prepared similarly to example 21 from (E)-3-p-tol-ylacryloyl chloride and N-(thiophen-2-ylmethyl)aniline. 1 H NMR (400 MHz, CDCl3 ) δ 2.31 (s, 311), 5.14 (s, 2H), 6.23 (d, .7 = 15.6 Hz, 1H), 6.82 - 6 .92 (m, 2H), 7.05 - 7.13 (m, 4H), 7.16 - 7.24 (m, 3H), 7.33 -7.44 (m, 3H), 7.72 (d,.7 = 15.6 Hz, 1H); M+H(334.1).
    N-phenyl-N-(thiophen-2-ylmethyl)cinnamamide; Example 238.
    Prepared similarly to example 21 from cinnamoyl chloride and N-(thiophen-2-ylmethyl)aniline. 1 H NMR (400 MHz, DMSO-d6) δ 5.14 (br s, 2H), 6.29 (br d, .7 = 15.4 Hz, 1H), 6.84 (m, 1H), 6 .89 (dd, J= 5.1, 3.4 Hz, 1H), 7.14 - 7.23 (m, 2H), 7.30 - 7.51 (m, 9H), 7.60 (d ,.7 = 15.6 Hz, 1H); M+H(320.1).
    N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)cinnamamide; Example 239.
    Prepared similarly to example 21 from cinnamoyl chloride and N-(thiophen-2-ylmethyl)pyridin-2-amine. δ H NMR (400 MHz, DMSO-d6) δ 5.34 (br s, 2H), 6.64 (br d, .7 = 15.5 Hz, 1H), 6.88 (dd, .7 = 5 .0, 3.5 Hz, 1H), 6.92 (br dd, .7 = 3.4, 1.2 Hz, 1H), 7.28 - 7.41 (m, 6H), 7.48 - 7.55 (m, 2H), 7.62 (d, J=15.5Hz, 1H), 7.83 - 7.91 (m, 1H), 8.53 (ddd, .7=4.8 , 1.9, 0.9 Hz, 1H); M+H(321,1).QA
    (+/-) (E)-N,2-diphenyl-N-(thiophen-2-ylmethyl)cyclopropane/earboxamide; Example 240.
    Prepared similarly to example 21 from (-I-/-)(E)-2-phenylcyclopropanecarbonyl chloride and N-(lyophen-2-ylmethyl)aniline. *11 NMR (400 MHz, CDCl3 ) δ 1.07 (m, 1H), 1.57 - 1.64 (m, HI), 1.69 (m, 111), 2.58 (m, 1H), 5.06 (s, 211), 7.04 - 7.24 (m, 511), 7.26 - 7.32 (m, 311); M+H(334.1).
    3,5-Dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 241. This compound was purchased from Princeton. M+H(363.1).
    N-(bicyclo[2,2,1|heptan-2-yl)-N-(1H-pyrazol-5-yl)-3-p-tolylpropanamide;Example 242.
    Prepared similarly to example 6 from 3-p-tolylpropanoyl chloride and N-(bicycloph2,2,1]heptan-2-yl)-1H-pyrazol-5-amine. *H NMR (400 MHz, CDCl3 ) δ 0.72 (m, 111), 0.91 - 1.00 (m, 1H), 1.24 - 1.49 (m, 5H), 1.57 - 1 .78 (m, 2H), 2.06 (m, III). 2.26 (s, 3H), 2.28 - 2.37 (m, 2H), 2.76 - 2.90 (m, 3H), 4.41 - 4.52 (m, 1H), 6, 02 (d, .7 = 2.4 Hz, 211), 6.95 (d, J = 8.1 Hz, 2H), 7.00 (d, .7 = 7.9 Hz, 1H), 7, 53 (d, .7= 2.4 Hz, 1H), 11.40 (brs, 1H); M+H(324.2).
    (E)-N-allyl-3-(7-chlorobenzo[d]fl,3]dioxol-5-yl)-N-(thiophen-2-ylmethyl)acrylamide;Example 243.This compound was purchased from Enamine . M+H(362.1).
    N-(pyridin-3-yl)-N-(thiophen-2-ylmethyl)cinnamamide; Example 244.
    Prepared similarly to example 21 from cinnamoyl chloride and N-(thiophen-2-ylmethyl)pyridin-3-amine. *H NMR (400 MHz, DMSO-d6) δ 5.19 (br s, 2H), 6.32 (br s, III), 6.81 - 6.97 (m, 2H), 7.28 - 7 .39 (m, 3H), 7.39 - 7.52 (m, 4H), 7.59 - 7.68 (m, 2H), 8.37 (br d, .7 = 2.3 Hz, 1H ), 8.55 (br d, .7 = 3.6 Hz, 1H); M+H(321.1).
    3,6-dimethyl-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide;Example 249.
    (E)-N-ethyl-3-(4-(imidazo[1,2-a]pyridin-2-ylmethoxy)phenyl)-N-(thiophen-2-ylmethyl)acrylamide; Example 254. This compound was purchased from Enamine. M+H(418.2).
    (E)-3-(benzo[d][1,3]dioxol-5-yl)-N,N-bis(thiophen-2-ylmethyl)aerylamide; Example 255. This compound was purchased from Enamine. M+H(384.1).
    N-(cyclohexylmethyl)-N-ethyl-2-(p-tolyloxy)acetamide; Example 256.
    Prepared similarly to example 21 from 2-(p-tolyloxy)acetyl chloride and N-(cyclohexylmethyl)ethanamine. Room temperature '1-I-NMR showed a mixture of rotamers in ~2:1 ratio: '11 NMR (400 MHz, DMSO-d6) δ 0.78 - 1.28 (m, 811), 1.53 - 1 .69 (m, 6H), 2.22 (s, 311), 3.11 (t, 6.8 Hz, 211), 3.22 - 3.38 (m, 211), 4.67 (minor) (s, 211), 4.74 (major) (s, 211), 6.74 - 6.82 (m, 2H), 7.02 -7.11 (m, 2H); M+11(290.2).
    If not commercially available or otherwise described, all secondary amines were prepared by reductive amination similar to example 6a or 21b using one of the standard reducing agents and general conditions known to those skilled in the art such as: NaBIU, LiAIH4, Na( OAc).3BH (STAB), Na(CN)BH3, 2-picolino borane complex, 5-ethyl-2-methylpyridine borane (PEMB) or their equivalents, and DCM (dichloromethane), DCE (dichloroethane), Et2Ü (ether diethyl), THF (tetrahydrofuran), dioxane, MeOH, EtOH, MeCN, AcOH alone or in binary or tertiary combinations thereof. All acids used are commercially available. Condensation between the acid and the amine was mediated by a condensation reagent such as EDCI (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide)), DCC (N,W-dicyclohexylcarbodiimide), DIC (M,7V' -diisopropylcarbodiimide), HATU (2-(1H-7-azabenzotriazol-1-yl)- 1,1,3,3-tetramethyl uronium hexafluorophosphate Methananium), PyBOP (benzotriazol-1-yl-oxytripyrrolidinephosphonium hexafluorophosphate), CD1 (carbonyldiimidazole) , 2-chloro-1-methylpyridinium iodide, T3P (propylphosphonic anhydride), according to well-established synthesis protocols in the literature. One skilled in the art can readily derive the synthesis of the present compounds from the descriptions below in accordance with the methods and principles discussed above.
    2-(benzo[d][1,3]dioxol-5-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 5. To a microwave flask was added 2-(benzo[d][1,3]dioxol-5-yloxy)acetic acid (195 mg, 1.0 mmol) in DCM (1.0 mL), followed by N-(thiophen-2-ylmethyl)aniline (190 mg, 1.0 mmol), EDC (230 mg, 1.2 mmol) and HOBt (270 mg, 2.0 mmol) in DCM (2.0 mL ) and DMF (2.0 mL). The microwave vial was capped and reacted under microwave irradiation (Emrys Optimizer reactor) at 100°C for 10 minutes. The compound was purified by HPLC; the clear fractions were combined and concentrated. The final compound was recrystallized from ethanol and water, yielding 169 mg (0.46 mmol, 46%). δ11 NMR (400 MHz, DMSO-d6) δ 4.36 (s, 2H), 5.00 (s, 211), 5.94 (s, 2H), 6.15 (br d, .7 = 6 .2 Hz, III), 6.45 (br s, III), 6.75 (d, .7=8.5 Hz, HI), 6.83 (br s, 111), 6.90 (dd, .7= 5.1.3.4 Hz, III), 7.22 - 7.29 (m, 211), 7.33 - 7.46 (m, 4H); M+H(368.1). N-(thiophen-2-ylmethyl)aniline; Example 5a.To a round bottom flask cooled to 0°C were added aniline (3.0 g, 30 mmol) and thiophene-2-carbaldehyde (3.4 g, 30 mmol) in methanol and acetic acid (30.0 ml, 10:1), followed by 2-picoline borane complex (3.2 g, 30 mmol). The ice bath was removed and the flask was attached to a bubbler to allow gas evolution and expansion. The reaction was stirred overnight at room temperature. Most of the volatiles were evaporated in vacuo. With the aid of an ice bath at 0°C, 10% HCl (150 mL) was added to the residue and stirred for 2 hours at room temperature. About 60 mL of a 10 M solution of NaOII in water was added under cooling to make the solution alkaline. The aqueous layer was extracted with DCM (3 times), washed with brine, and dried over MgSO4 s) and concentrated. The crude product was absorbed under vacuum in Florisil with the aid of DCM (dry charge). The obtained dispersion was purified by column chromatography (Biotage system; hex:EtOAc 25-100% gradient 30 CV, 80 g silica column Silicycle). The collected fractions were evaporated to yield 5.68 g (29.87 mmol; 99%), which was judged to be over 97% pure by 1H-NMR analysis.
    2-(2,3-dihydro-1H-inden-5-yloxy)-N-ethyl-N-(thiophen-2-ylmethyl)acetamide; Example 10.
    Prepared similarly to example 5 from 2-(2,3-dihydro-1H-inden-5-yloxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. 1 H NMR (400 MHz, DMSO-d6) δ 1.98 (p, J = 7.4 Hz, 2H), 2.77 (dt, J = 14.6, 7.4 Hz, 4H), 4, 49 (s, 2H), 4.87 (s, 2H), 6.54 (dd, J = 8.2, 2.5 Hz, III), 6.64 (d,./= 2.0 Hz, 1H), 6.88 (d, ./ = 2.4 Hz, 1H), 6.94 (dd, J = 5.1, 3.4 Hz, III), 7.06 (d, ./ = 8 .2 Hz, III), 7.45 (dd, J = 5.1, 1.2 Hz, 1H), 7.62 (s, 2H), 12.98 (s, III); M+H(316.1).
    2-(2-hydroxy-4-methylphenoxy)-N-(1H-pyrazol-5-yl)-N-(thiophen-2-ylmethyl)-acetamide;Example 11.
    Prepared similarly to example 5 from 2-(2-hydroxy-4-methylphenoxy)acetic acid and N-(thiophen-2-ylmethyl)-1H-pyrazol-5-amine. Yield 10%. *H NMR (400 MHz, DMSO-d6) δ 12.88 (s, 1H), 9.01 (s, 1H), 7.77 (s, 1H), 7.45 - 7.35 (m, 1H ), 6.93 - 6.90 (m, 211), 6.65 - 6.62 (m, 1H), 6.60 - 6.59 (m, 1H) 6.48 - 6.45 (m, 1H) 1H), 6.21 (s, 1H), 4.98 (s, 211), 4.56 (s, 2H), 2.14 (s, 311); M+H (344.1).
    N-ethyl-2-(2-hydroxy-4-methylphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 19.
    Prepared similarly to example 5 from 2-(2-hydroxy-4-methylphenoxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine Yield 59%. δ H NMR (400 MHz, DMSO-d6) δ 9.28 (major) (s, 1H), 9.27 (minor) (s, 1H), 7.49 (minor) (dd, .7 = 5, 1, 1.2 Hz, 1H), 7.42 (major) (dd, .7=5.1, 1.2 Hz, 1H), 7.09 - 7.06 (minor) (m, 1H), 7.06 - 7.05 (major) (m, 1H), 7.02 - 7.00 (minor) (m, 1H), 6.96 - 6.94 (major) (m, 1H), 6, 78 (major) (d, J = 8.1 Hz, 1H), 6.74 (minor) (d, .7 = 8.1 Hz, 1H), 6.63 - 6.62 (m, 1H), 6.52 - 6.50 (m, 1H), 4.80 (minor) (s, 2H), 4.79 (major) (s, 2H), 4.74 (minor) (s, 2H), 4 .65 (major) (s, 2H), 3.35 - 3.28 (m, 2H), 2.16 (s, 3H), 1.11 (major) (t, J= 7.2Hz, 3H) , 1.01 (smallest) (t, .7=7.2Hz, 3H); M+H (306.1).
    N-phenyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 26.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ H NMR (400 MHz, DMSO-d6) δ 2.20 (s, 3H), 4.39 (s, 2H), 5.00 (s, 2H), 6.63 (br d, .7 = 8 .2 Hz, 211), 6.83 (br s, II1), 6.91 (dd, .7-5.1, 3.4 Hz, 1H), 7.03 (d, .7=8.2 Hz, 2H), 7.20-7.31 (m, 211), 7.33 - 7.49 (m, 411); M+H(338.1).
    2-(2,3-dihydrobenzo[b|[1,4]dioxin-6-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 29.
    Prepared similarly to example 5 from 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yloxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. 1 H NMR (400 MHz, DMSO-d6) δ 4.16 (tdd, α7= 5.6, 3.6, 2.2 Hz, 4H), 4.33 (s, 2H), 5.00 ( s, 2H), 6.23 (d, .7 = 9.0 Hz, 211), 6.70 (d, .7 = 8.6 Hz, 1H), 6.82 (s, III), 6, 90 (dd, .7=5.1, 3.4Hz, 1H), 7.28 - 7.21 (m, 2H), 7.47-7.34 (m, 4H); M+H(382.1).
    2-(3-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 31.
    Prepared similarly to example 5 from 2-(3-methoxyphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ H NMR (400 MHz, DMSO-d6) δ 3.69 (s, 3H), 4.42 (s, 2H), 5.01 (s, 2H), 6.31 (m, 2H), 6, 50 (dd, .7= 8.2, 1.7 Hz, 1H), 6.83 (br s, 1I-I), 6.91 (dd, .7= 5.1, 3.4 Hz, 1H ), 7.13 (t, J = 8.1 Hz, 1H), 7.21 - 7.32 (m, 2H), 7.33 - 7.52 (m, 411); M+H(354.1).
    2-(4-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 33.
    Prepared similarly to example 5 from 2-(4-methoxyphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ H NMR (400 MHz, DMSO-d6) δ 3.67 (s, 311), 4.36 (s, 2H), 5.00 (s, 2H), 6.68 (br d, .7 = 8 .7 Hz, 2H), 6.77 - 6.85 (m, 3H), 6.91 (dd, .7 = 5.1, 3.4 Hz, HI), 7.23 - 7.29 (m , 2H), 7.33 -7.44 (m, 4H); M+11(354.1).
    2-(4-Fluorphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 37.
    Prepared similarly to example 5 from 2-(4-fluorophenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ 11 NMR (400 MHz, DMSO-d6) δ 4.43 (s, 211), 5.00 (s, 211), 6.72 - 6.87 (m, 311), 6.91 (dd, . 7=5.1, 3.4 Hz, 111), 7.01 -7.14 (m, 2H), 7.23 -7.31 (m, 211), 7.34 - 7.47 (m, 4H); M+H(342.1).
    2-(benzo|d]|1,3|dioxol-5-yloxy)-N-ethyl-N-(thiophen-2-ylmethyl)acetamide; Example 40.
    Prepared similarly to example 5 from 2-(benzo|d][1,3]dioxol-5-yloxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'bl NMR showed a mixture of rotamers in a ratio ~2:1: 'li NMR (400 MHz, DMSO-d6) δ 0.98 - 1.14 (m, 3H), 3.22 - 3.37 (m, 3H), 4.59 - 4.80 (m, 4H), 5.96 (s, 2H), 6.29 - 6.39 (m, 1H), 6.59 - 6.63 (m , 1H), 6.78-6.81 (m, 1H), 6.95 (dd, .7=5.1, 3.4Hz, 1H), 7.01-7.10(m, 2H ), 7.41 -7.51 (m, 1H); M+H(320.1).
    N-ethyl-2-(3-methoxyphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 42.
    Prepared similarly to example 5 from 2-(3-methoxyphenoxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio ~2:1: 'H NMR (400 MHz, DMSO-d6) δ 0.98 - 1.14 (m, 3H), 3.25 - 3.36 (m, 2H), 3.69 (m, 3H), 4.61 - 4.76 (m, 2H), 4.80 (br s, 2H), 6.38 - 6.56 (m, 3H) , 6.88 - 7.22 (m, 3H); 7.37 - 7.53 (m, 1H); M+H(306.1).
    N-phenyl-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide; Example 46.
    Prepared similarly to example 5 from 2-(m-tolyloxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ 11 NMR (400 MHz, DMSO-d6) δ 2.22 (s, 3H), 4.39 (s, 211), 4.99 (s, 211), 6.51 (br d, .7 = 12 .5 Hz, 2H), 6.71 (br d, .7 = 7.5 Hz, 1 H), 6.82 (br s, H l), 6.89 (dd, .7 = 5.1, 3.4 Hz, HI), 7.09 (t, .7 = 7.8 Hz, 1H), 7.22 - 7.27 (m, 2H), 7.33 - 7.52 (m, 4H) ; MlH(338.1).
    N-ethyl-N-(furan-3-ylmethyl)-2-(p-tolyloxy)acetamide; Example 48.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-(furan-3-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio ~2:1: *11 NMR (400 MHz, DMSO-d6) δ 1.06 (m, 3H), 2.22 (br d, 3H), 3 .18 - 3.32 (m, 2H), 4.34 (m, 2H), 4.78 (s, 2H), 6.3 - 6.50 (m, 1H), 6.78 (m, 211 ), 7.07 (br dd, .7 = 8.3, 3.8 Hz, 2H), 7.59 (br d, .7 = 1.4 Hz, 1II), 7.62 - 7.72 ( m, 1H); M+H(266.1).
    N-ethyl-2-(4-methoxyphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 49.
    Prepared similarly to example 5 from 2-(4-methoxyphenoxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio ~2:1: *H NMR (400 MIIz, DMSO-d6) δ 0.95 - 1.14 (m, 3H), 3.24 - 3.38 (m, 2H), 3.66 - 3.68 (m, 311), 4.61 - 4.75 (m, 4H), 6.80 - 6.84 (m, 4H), 6.89 - 7 .10 (m, 2H), 7.33 - 7.52 (m, 1H); M+11(306.1).
    N-ethyl-N-(thiophen-2-ylmethyl)-2-(o-tolyloxy)acetamide; Example 52.This compound was prepared in a library format. M+H(290.1).
    2-(3-Fluorphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 53.
    Prepared similarly to example 5 from 2-(3-fluorophenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. 111 NMR (400 MHz, DMSO-d6) δ 4.48 (br s, 2H), 5.00 (br s, 211), 6.62 (m, 2H), 6.75 (td,.7=8 .3, 2.0 Hz, 1H), 6.84 (brs, III), 6.91 (dd, .7 = 5.1, 3.4 Hz, 1H), 7.22-7.32 (m , 311), 7.34 - 7.50 (m, 4H); M+11(342.1).
    2-(benzo|d][1,3]dioxol-5-yloxy)-N-ethyl-N-(furan-3-ylmethyl)acetamide; Example 56.
    Prepared similarly to example 5 from 2-(benzo[d][1,3]dioxol-5-yloxy)acetic acid and N-(furan-3-ylmethyl)ethanamine. Room temperature 'll NMR showed a mixture of rotamers in a ratio ~2:1 'H NMR (400 MHz, DMSO-d6) δ 0.97 - 1.13 (m, 3H), 3.27 (m, 2H) , 4.30 - 4.36 (m, 2H), 4.74 (br s, 211), 5.95 (m, 2H), 6.28 - 6.50 (m, 2H), 6.61 ( m, 1H), 6.79 (m, 1H), 7.59 (br d, J=1.4Hz, 1H), 7.63 - 7.73 (m, 1H); M+H(304, l).
    N-ethyl-3-(4-methoxyphenyl)-N-(thiophen-2-ylmethyl)propanamide; Example 57.
    Prepared similarly to example 5 from 3-(4-methoxyphenyl)propanoic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'il NMR showed a mixture of rotamers in a ratio ~2:1: 'H NMR (400 MIIz, DMSO-d6) δ 0.96 - 1.05 (m, 3H), 2.55 - 2.65 (m, 2H), 2.71 - 2.81 (m, 2H), 3.21 - 3.31 (m, 2H), 3.70 (s, 3H), 4.60 - 4.68 (m, 2H ), 6.81 (d, J - 8.7 Hz, 2H), 6.90 - 7.02 (m, 2H), 7.07 - 7.20 (m, 2H), 7.38 - 7, 46 (m, 1H); M+H(304.1).
    N-ethyl-N-(thiophen-2-ylmethyl)-2-(m-tolyloxy)acetamide; Example 58.
    Prepared similarly to example 5 from 2-(m-tolyloxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 1 H NMR showed a mixture of rotamers in a ~2:1 ratio: 1 11 NMR (400 MHz, DMSO-d6) δ 1.01 (smallest) (t, ./ = 7.1 Hz, 3H), 1.14 (major) (t, .7 = 7.1 Hz, 3H), 2.25 (minor) (s, 311), 2.26 (major) (s, 3H), 3.27 - 3, 45 (m, 2H), 4.65 (major) (s, 211), 4.76 (minor) (s, 211), 4.81 (s, 2H), 6.63 - 6.81 (m, 2H), 3H), 6.92-7.20 (m, 311), 7.55 7.38 (m, 111); M+H(290.1).
    N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 61.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-(thiophen-2-ylmethyl)pyridin-2-amine. δ 11 NMR (400 MHz, DMSO-d6) δ 2.18 (s, 3H), 4.75 (s, 211), 5.19 (s, 2H), 6.58 - 6.61 (m, 211), 6.86 - 6.89 (m, 211), 7.00 (m, 2H), 7.29 (ddd, J = 7.4, 4.9, 0.9 Hz, 1H), 7.37 (dd, .7= 4.8, 1.5 Hz, 1H), 7.45 (br d, .7 = 8.1 Hz, HI), 7.85 (ddd, .7= 8.1, 7 .5, 2.0 Hz, HI), 8.44 (ddd, .7=4.9, 1.9, 0.8 Hz, 1H); M+H(339.1).
    N-ethyl-2-(2-hydroxyphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 62.
    Prepared similarly to example 5 from 2-(2-hydroxyphenoxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. Yield 33%. Room temperature 'H NMR showed a mixture of rotamers in a ~2:1 ratio: 'H NMR (400 MHz, DMSO-d6) δ 9.31 (s, 1H), 7.50 (minor) (dd, .7 = 5.2, 1.2 Hz, 1H), 7.42 (major) (dd, .7 = 5.2, 1.2 Hz, 1H), 7.11 - 7.10 (minor) (m, 1H), 7.06 - 7.05 (major) (m, III), 7.03 - 7.01 (minor) (m, III), 6.96 - 6.94 (major) (m, III) , 6.89 - 6.79 (m, 3H), 6.73 - 6.69 (m, 1H), 4.85 (minor) (s, 2H), 4.84 (major) (s, 2H) , 4.76 (minor) (s, 211), 4.66 (major) (s, 2H), 3.37 - 3.27 (m, 2H), 1.13 (major) (t, .7 = 7.0 Hz, 3H), 1.01 (t, .7 = 7.0 Hz, 3H); M+H (292.1).
    2-(4-ethylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 63.
    Prepared similarly to example 5 from 2-(4-ethylphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ PI NMR (400 MHz, DMSO-d6) δ 1.12 (t, δ7 = 7.6 Hz, 3H), 2.53 (q, δ7 = 7.6 Hz, 211), 4.39 ( br s, 2H), 5.00 (br s, 2H), 6.65 (br d, .7 = 8.2 Hz, 2H), 6.83 (br s, 111), 6.91 (dd, .7 = 5.1, 3.4 Hz, 111), 7.06 (d, .7 = 8.6 Hz, 211), 7.22 - 7.31 (m, 211), 7.33 - 7 .49 (m, 4H); M+11(352.1),
    2-(3,4-dimethylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 65.
    Prepared similarly to example 5 from 2-(3,4-dimethylphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ11 NMR (400 MHz, DMSO-d6) δ 2.11 (s, 311), 2.14 (s, 3H), 4.36 (br s, 211), 5.00 (br s, 2H), 6.44 (br d, 7 = 7.6 Hz, 1H), 6.53 (br s, III), 6.83 (s, 1 H), 6.91 (dd, 7= 5.1, 3 .4 Hz, 111), 6.97 (d, 7 = 8.2 Hz, 1H), 7.23 - 7.28 (m, 5 211), 7.35 - 7.47 (m, 411); MH 1(352.1).
    2-(benzo[d][1,3]dioxol-5-yloxy)-N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)acetamide;Example 67.
    Prepared similarly to example 5 from 2-(benzo[d][1,3]dioxol-5-yloxy)acetic acid and N-(thiophen-2-ylmethyl)pyridin-2-amine. *H NMR (400 MHz, DMSO-d6) δ 4.74 (br s, 2H), 5.20 (br s, 2H), 5.94 (s, 211), 6.16 (dd, 7 = 8 .5, 2.6 Hz, 1H), 6.42 (d, 7 = 2.5 Hz, III), 6.74 (d, 7 = 8.5 Hz, 1H), 6.89 (m, 2H ), 7.31 (dd, 7 = 7.4, 4.9, 0.9 Hz, 1H), 7.38 (dd, 7 = 4.8, 1.5 Hz, 1H), 7.47 ( d, 7 = 8.1 Hz, 1H), 7.78 - 7.95 (m, 1H), 8.46 (ddd, 7 = 4.8, 1.9, 0.7 Hz, 1H); M+H(369.1).
    2-(3-Chlorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 68.
    Prepared similarly to example 5 from 2-(3-chlorophenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. 11 NMR (400 MHz, DMSO-d6) δ 4.50 (br s, 2H), 5.00 (br s, 2H), 6.74 (brd, 7 = 7.5 Hz, 1H), 6, 83 (br s, 2H), 6.91 (dd,7=5.1, 3.4Hz, 1H), 6.98 (ddd, 20 7=7.9, 1.9, 0.8Hz, 1H), 7.21-7.31 (m, 311), 7.33-7.51 (m, 4H); M+H(358.1).
    N-ethyl-3-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)propanamide; Example 69.
    Prepared similarly to Example 5 from 3-(4-Nuorphenyl)propanoic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 11 NMR 25 showed a mixture of rotamers in a ratio ~2:1: 14 NMR (400 MHz, DMSO-d6) δ 1.12 - 0.93 (m, 3H), 2.57 - 2, 70 (m, 2H), 2.83 (br dd, 7= 16.5, 8.7 Hz, 2H), 3.22 - 3.33 (m, 2H), 4.61 (major) (br s , 2), 4.68 (minor) (br s, 12), 6.89 - 7.02 (m, 2H), 7.02 -7.12 (m, 2H), 7.18 - 7.33 (m, 2H), 7.36 - 7.47 (m, 1H); M+H (292.1).
    2-(2-hydroxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 71.
    Prepared similarly to example 5 from 2-(2-hydroxyphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ H NMR (400 MHz, DMSO-d6) δ 4.39 (br s, 2H), 5.02 (br s, 2H), 6.63 - 6.86 (m, 5H), 6.91 (dd , J = 5.1, 3.4 Hz, 1H), 7.26 (m, 2H), 7.35 - 7.46 (m, 4H), 9.15 (s, 1H); M+H(340.1).
    N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 73.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-(thiophen-2-ylmethyl)pyridin-2-amine. 111 NMR (400 MHz, DMSO-d6) δ 2.20 (s, 3H), 4.77 (br s, 2H), 5.03 (br s, 2H), 6.61 (d, .7= 8.1 Hz, 2H), 6.95 (dd, .7= 5.0, 1.3 Hz, 1H), 7.02 (d, .7= 8.1 Hz, 2H), 7.25 ( br dd,.7= 2.9, 1.1 Hz, 1H), 7.30 (ddd,.7= 7.4, 4.9, 0.9 Hz, 1H), 7.42-7.48 (m, 211), 7.81 -7.90 (m, 1H), 8.45 (ddd,.7=4.8, 1.9, 0.8 Hz, 1H); M+H(339.1).
    N-ethyl-N-(furaπ-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 74.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-(furan-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in a ratio ~1:1 11 NMR (400 MHz, DMSO-d6) δ 0.91 - 1.09 (m, 3H), 2.20 (s, 3H) , 3.24 - 3.34 (m, 211), 4.49 - 4.54 (m, 211), 4.76 - 4.84 (m, 2H), 6.28 -• 6.39 (m , 1H), 6.43 (br d, .7 = 1.3 Hz, 1H), 6.84 - 6.70 (m, 2H), 7.05 (br d, .7 = 7.9 Hz , 2H), 7,567.66 (m, III); M+11(274.1).
    N-ethyl-N-(thiophen-2-ylmethyl)-3-o-tolylpropanamide; Example 77.
    Prepared similarly to example 5 from 3-o-tolylpropanoic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ~2:1 ratio: '11 NMR (400 MHz, DMSO-d6) δ 1.02 (m, 3H), 2.21 (minor) (s, 3H) 2.28 (major) (s, 311), 2.52 - 2.65 (m, 211), 2.75 - 2.88 (m, 2H), 3.23 - 3.32 (m, 2H) , 4.62 (major) (s, 2H), 4.68 (minor) (br s, 2H), 6.89 - 7.04 (m, 2H), 7.04 - 7.20 (m, 4H ), 7.37 - 7.48 (m, 111); M+H(288.1).
    2-(2-Fluorphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 78.
    Prepared similarly to example 5 from 2-(2-fluorphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. *H NMR (400 MHz, DMSO-d6) δ 4.53 (br s, 2H), 5.00 (br s, 211), 6.82 - 6.95 (m, 4H), 7.06 (m , 111), 7.18 (ddd, .7 = 11.8, 8.0, 1.6 IIz, 1II), 7.26 - 7.31 (m, 2H), 7.36 - 7.47 ( m, 4H); M+11(342.1).
    N-phenyl-N-(thiophen-2-ylmethyl)-2-(o-tolyloxy)acetamide; Example 81.
    Prepared similarly to example 5 from 2-(o-tolyloxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. 11 NMR (400 MHz, DMSO-d6) δ 2.06 (s, 3H), 4.46 (br s, 2H), 4.99 (br s, 2H), 6.57 (br d, .7 = 7.9 Hz, 1H), 6.80 (m, 2H), 6.89 (dd, .7 = 5.1, 3.4 Hz, 114), 7.06 (m, 2H), 7, 20 - 7.29 (m, 2H), 7.32 - 7.46 (m, 411); M+H(338.1).
    N-ethyl-2-(3-fluorphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 84.
    Prepared similarly to example 5 from 2-(3-fluorophenoxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ~2:1 ratio: 11 NMR (400 MHz, DMSO-d6) δ 1.01 (smallest) (t, .J 7.1 Hz, 3H), 1 .14 (major) (t, .7= 7.1 Hz, 3H), 3.27 - 3.38 (m, 211), 4.65 (major) (br s, 2H), 4.76 (minor ) (br s, 211), 4.88 (minor) (br s, 2H), 4.90 (major) (br s, 2H), 6.70 - 6.83 (m, 311), 6.95 (major) (dd, J=5.1, 3.4 Hz, 1H), 7.03 (minor) (dd, J=5.0, 3.5 Hz, 1H), 7.05 (major) ( dd, .7 = 3.4, 1.0 Hz, 1H), 7.12 (minor) (d, .7 = 2.6 Hz, 1H), 7.30 (m, 1H), 7.42 ( major) (dd, .7^5.1, 1.2 Hz, 1H), 7.51 (minor) (dd, .7=5.1, 1.1 Hz, 1H); M+H(294.1).
    2-(benzo[d][1,3]dioxol-5-yloxy)-N-ethyl-N-(furan-2-ylmethyl)acetamide; Example
    Prepared similarly to example 5 from 2-(benzo[d][1,3]dioxol-5-yloxy)acetic acid and N-(furan-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in a ~1:1 ratio 11 NMR (400 MHz, DMSO-d6) δ 0.9310 - 1.10 (m, .7 = 56.3, 7.1 Hz , 3H), 3.25 - 3.34 (m, 211), 4.50 - 4.54 (m, 2H), 4.75 - 4.82 (m, 2H), 5.95 (s, 2H ), 6.30 - 6.45 (m, 3H), 6.61 (dd, .7= 9.5, 2.5 Hz, 1H), 6.80 (d, .7= 8.5 Hz, 1H), 7.57-7.68 (m, 1H); M+H(304.1).
    2-(2-chlorophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 95.
    Prepared similarly to example 5 from 2-(2-chlorophenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. 1 H NMR (400 MHz, DMSO-d6) δ 4.57 (br s, 2H), 5.00 (br s, 211), 6.84 (br s, 2H), 6.88 - 6.97 ( m, 2H), 7.21 - 7.27 (m, 1H), 7.28 - 7.33 (m, 2H), 7.36 - 7.47 (m, 5H); M+H(358.1).
    2-(4-isopropylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 97.
    Prepared similarly to example 5 from 2-(4-isopropylphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ11 NMR (400 MHz, DMSO-d6) δ 1.15 (d, α7 = 6.9 Hz, 6H), 2.80 (sept, α7 = 6.9 Hz, III), 4.39 ( br s, 2H), 5.00 (br s, 211), 6.66 (br d, .7 = 8.4 Hz. 2H), 6.83 (br s, III), 6.91 (dd, .7 = 5.1, 3.4 Hz, 1H), 7.10 (d, .7 = 8.6 Hz, 25 2H), 7.24 - 7.30 (m, 2H), 7.35 - 7.47 (m, 4H); M+H(366.1).
    N-ethyl-3-(3-fluorophenyl)-N-(thiophen-2-ylmethyl)propanamide; Example 100.
    Prepared similarly to example 5 from 3-(3-fluorophenyl)propanoic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ratio ~2:1: 11 NMR (400 MHz, DMSO-d6) δ 0.96 - 1.08 (m, 3H), 2.58 - 2.73 (m, 2H), 2.86 (br dd, J= 16.4, 8.4 Hz, 2H), 3.23 - 3.31 (m, 2H), 4.60 - 4.71 (m, 2H), 6.91 - 7.03 (m, 2H), 7.07 - 7.17 (m, 2H), 7.20 - 7.37 (m, 2H), 7.36 - 7.48 ( m, 1H); M+H(292.1).
    N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)propanamide; Example 104.
    Prepared similarly to example 5 from 2-(p-tolyloxy)propanoic acid and N-(thiophen-2-ylmethyl)pyridin-2-amine. δ H NMR (400 MHz, CDCl3 ) δ 1.53 (d, J = 6.6 Hz, 3H), 2.24 (s, 3H), 5.00 (q, .7 = 6.6 Hz, 1H ), 5.23 (br s, 2H), 6.57 - 6.64 (m, 2H), 6.85 - 6.87 (m, 211), 6.97 (br d, J = 8.2 Hz, 2H), 7.04 (br d, .7 = 8.0 Hz, 1H), 7.16 - 7.24 (m, 2H), 7.65-7.73 (m, 1H), 8.47 (dd,.7=5.0, 1.3 Hz, III); M+H(353.1).
    N-ethyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)propanamide; Example 107.
    Prepared similarly to example 5 from 2-(p-tolyloxy)propanoic acid and N-(thiophen-2-ylmethyl)ethanamine. '11 NMR showed a mixture of rotamers in a ~2:1 ratio: '11 NMR (400 MHz, DMSO-d6) δ 0.95 (smallest) (t, .7 = 7.0 Hz, 311), 1, 10 (major) (t, J = 7.1 Hz, 311), 1.36 - 1.43 (m, 3H), 2.20 (minor) (s, 311), 2.22 (major) (s , 3H), 3.21 (minor) (q, .7 = 7.0 Hz, 2H), 3.38 (major) (q, .7 = 7.0 Hz, 211), 4.61 (major) (d, .7 = 15.1 Hz, 111), 4.67 (smallest) (d, .7 = 15.0 Hz, III), 4.78 (major) (d, .7 = 16.5 Hz , 1H), 4.86 (minor) (d, J = 16.4 Hz, 1H), 5.15 (major) (q, .7 = 6.4 Hz, 1H), 5.22 (minor ) (q, .7 = 6.3 Iz, III), 6.69 (minor) (d, .7 = 8.6 Hz, 211), 6.75 (major) (d, .7 = 8, 6 Hz, 2H), 6.89 - 7.12 (m, 411), 7.41 (major) (dd, J = 5.1, 1.3 Hz, 1H), 7.51 (minor) (dd , J = 5.1, 1.3 Hz, 1H); M+II(353.1).
    N-benzyl-N-phenyl-2-(p-tolyloxy)acetamide; Example 108.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-benzylaniline. 1 H NMR (400 MHz, DMSO-d6) δ 2.19 (s, 3H), 4.43 (br s, 2H), 4.86 (br s, 2H), 6.63 (d, ./ = 8.2 Hz, 2H), 7.02 (d, J=8.2 Hz, 2H), 7.14 - 7.40 (m, 10H); M+H(332.1).
    N-ethyl-3-(3-fluorophenyl)-N-(thiophen-2-ylmethyl)propanamide; Example 112.
    Prepared similarly to example 5 from 3-(3-fluorophenyl)propanoic acid and N-(thiophen-2-ylmethyl)ethanamine. 'li NMR showed a mixture of rotamers in ~2:1 ratio: 'H NMR (400 MHz, DMSO-d6) δ 1.01 (m, 3H), 2.60 - 2.74 (m, 2H), 2.81 - 2.91 (m, 2H), 3.23 - 3.33 (m, 2H), 4.61 (major) (br s, 2H), 4.69 (minor) (br s, 2H ), 6.91-7.15(m, 4H), 7.24-7.34 (m, 1H), 7.39 (major) (dd,J=5.1, 1.2Hz, 1H) , 7.45 (minor) (dd, α/= 3.8, 2.5 Hz, 1H); M+H(292.1).
    N-ethyl-N-(thiophen-2-ylmethyl)-3-m-tolylpropanamide; Example 113.
    Prepared similarly to example 5 from 3-m-tolylpropanoic acid and N-(thiophen-2-ylmethyl)ethanamine. 'H NMR showed a mixture of rotamers in a ratio ~2:1: 'II NMR (400 MHz, DMSO-d6) δ 0.96 - 1.06 (m, 3H), 2.25 (s, 311), 2.56 - 2.69 (m, 211), 2.72 - 2.86 (m, 211), 3.21 - 3.31 (m, 2H), 4.61 (major) (br s, 211 ), 4.67 (minor) (br s, 214), 6.89 - 7.06 (m, 5H), 7.14 (br t, ./ = 7.4 Hz, 1H), 7.39 ( major) (dd,./5.1, 1.3 Hz, 114), 7.45 (minor) (dd, .7=4.8, 1.6 Hz, 114); M+H(288.1).
    N-phenyl-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 114.
    Prepared similarly to example 5 from benzofuran-2-carboxylic acid and N-(thiophen-2-ylmethyl)aniline. δ H NMR (400 MHz, DMSO-d6) δ 5.21 (br s, 2H), 6.44 (br s, 1H), 6.87 - 6.90 (m, 1H), 6.91 (dd , 5.0, 3.5 Hz, 1H), 7.16 - 7.25 (m, 3H), 7.33 - 7.41 (m, 4H), 7.42 - 7.46 (m, 2H ), 7.54 - 7.60 (m, 1H); M+H(334.1).
    N-(2-ethylhexyl)-3-(4-hydroxyphenyl)propanamide; Example 118.
    Prepared similarly to example 5 from 3-(4-hydroxyphenyl)propanoic acid and 2-ethylhexan-1-amine. δ H NMR (400 MHz, DMSO-d6) δ 0.79 (t, .7 = 7.4 Hz, 311), 0.86 (t, .7 = 6.9 Hz, 3H), 1.06 - 1.39 (m, 1011), 2.30 (dd, .7 = 8.5, 6.9 Hz, 2H), 2.67 (t, .7 = 7.7 Hz, 211), 2.89 -3.01 (m, 2H), 6.63 (d, .7 = 8.5 Hz, 2H), 6.96 (d, .7 = 8.6 Hz, 2H), 7.64 (t, J=5.8 Hz, 1H), 9.11 (s, 1H); M+H(278.2).
    N-ethyl-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 119.
    Prepared similarly to example 5 from benzofuran-2-carboxylic acid and N-(thiophen-2-ylmethyl)ethanamine. *H NMR (400 MHz, DMSO-d6) δ 1.23 (brs, 311), 3.53 (brs, 2H), 4.84 (brs, 2H), 7.00 (dd, .7=5 .1, 3.4 Hz, III), 7.14 (brs, 1H), 7.31 - 7.37 (m, 1H), 7.42 - 7.52 (m, 3H), 7.66 (br dd, .7 = 8.3, 0.8 lz, 111), 7.76 (ddd, .7 = 7.8, 1.3, 0.7 Hz, 1 H); M+11(286.1).
    2-(4-cyanophenoxy)-N-ethyl-N-(thiophen-2-ylmethyl)acetamide; Example 120.
    Prepared similarly to example 5 from 2-(4-cyanolenoxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. 'li NMR showed a mixture of rotamers in a ratio -2:1: 1H NMR (400 MHz, DMSO-d6) δ 1.01 (minor) (t, J = 7.1 Hz, 3H), 1.15 ( major) (t, J = 7.1 Hz, 3H), 3.30 - 3.34 (m, 2H), 4.65 (major) (br s, 2H), 4.76 (minor) (br s , 211), 4.96 (minor) (br s, 2H), 4.99 (major) (br s, 211), 6.95 (major) (dd, J = 5.1, 3.4 Hz, HI), 7.03 (minor) (dd, J - 5.1, 3.5 Hz, HI), 7.06 (major) (dd, J 7-7 3.4, 1.0 Hz, 1H) , 7.13 (mcnor) (d, .7-2.5 Hz, 1H), 7.22 7.3 I (m, HI), 7.34-7.45 (m, 2H), 7.45 - 7 .56 (m, 1H); M+11(301.1).
    N-(1-methyl-1H-imidazol-2-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide;Example 121.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and 1-methyl-N-(thiophen-2-ylmethyl)-1H-imidazol-2-amine. *H NMR (400 MHz, CD3OD) δ 2.24 (s, 3H), 3.22 (s, 3H), 4.38 (s, 2H), 5.04 (br s, 2H), 6.67 (br d, .7 = 8.5 Hz, 211), 6.88 (br d, J 7 3.5 Hz, 1H), 6.91 - 6.96 (m, 211), 7.04 (br d, .7=8.4 Hz, 2H), 7.08 (br s, HI), 7.36 (brd, .7 = 5.1 Hz, 1H); M+11(342.1).
    3-(3,5-difluorophenyl)-N-(2-ethylhexyl)propanamide; Example 125.
    Prepared similarly to example 5 from 3-(3,5-difluorophenyl)propanoic acid and 2-ethylhexan-1-amine. 111 NMR (400 MHz, DMSO-d6) δ 0.78 (t, .7 = 7.4 Hz, 3H), 0.84 (t, .7 = 6.9 Hz, 3H), 1.06 - 1.32 (m, 10H), 2.40 (t, .7 = 7.4 Hz, 2H), 2.83 (t, .7 = 7.4 Hz, 2H), 2.94 (m, 2H ), 6.88 - 6.97 (m, 2H), 7.01 (tt, .7 = 9.5, 2.4 Hz, 1H), 7.69 (t, .7 = 5.6 Hz, 111); M+11(298.2).
    N-ethyl-3-(4-methoxyphenyl)-N-(thiophen-2-ylmethyl)propanamide; Example 126.
    Prepared similarly to example 5 from 3-(4-methoxylenyl)propanoic acid and N-(thiolen-2-ylmethyl)ethanamine. 'll NMR showed a mixture of rotamers in a ratio —2:1: *H NMR (400 MHz, DMSO-d6) δ 1.01 (m, 311), 2.64 (m, 2H), 2.75 - 2.89 (m, 2H), 3.24 - 3.33 (m, 2H), 3.71 (m, 3H), 4.65 (m, 211), 6.70 - 6.84 (m, 3H), 6.91 - 7.04 (m, 2H), 7.12 - 7.22 (m, III), 7.42 (m, 1H); M+H(304.1).
    (R)-2-(3-chloroeneoxy)-N-(3-methylbutan-2-yl)acetamide; Example 129.
    Prepared similarly to example 5 from 2-(3-chlorophenyloxy)acetic acid and (R)-3-methylbutan-2-amine. δ 11 NMR (400 MHz, DMSO-d6) δ 0.77 - 0.85 (m, 6H), 1.01 (d, α7 =6.8 Hz, 3H), 1.54-1.73 ( m,.7=6.7 Hz, 1H), 3.58 - 3.73 (m, 1H), 4.52 (s, 211), 6.92 (m, 1H), 7.01 (m, 1H), 2H), 7.27-7.36 (m, 1H), 7.81 (br d, .7=8.7 Hz, 1H); M+H(256.1).
    N-ethyl-2-(2-fluorphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 134.
    Prepared similarly to example 5 from 2-(2-fluorophenoxy)acetic acid and N-(thiophen-2-ylmethyl)ethanamine. *H NMR (400 MHz, DMSO-d6) δ 0.97 - 1.18 (m, 3H), 3.27-3.35 (m, 2H), 4.71 (m, 2H), 4.96 (m, 2H), 6.89-7.14 (m, 5H), 7.21 (m, 1H), 7.39-7.54 (m, 1H); M+H(294.1).
    N-(2-ethylhexyl)-3-m-tolylpropanamide; Example 136.
    Prepared similarly to example 5 from 3-m-tolylpropanoic acid and 2-ethylhexan-1-amine. δ H NMR (400 MHz, DMSO-d6) δ 0.79 (t, .7 = 7.4 Hz, 3H), 0.85 (t, J = 6.9 Hz, 3H), 1.09 - 1 .36 (m, 9H), 2.35 (m, 2H), 2.75 (br t, .7 = 7.6 Hz, 2H), 2.95 (m, 2H), 6.94-7, 03 (m, 311), 7.13 (t,.7=7.5 Hz, III), 7.67 (t,.7=5.7 Hz, 1H); M+11(276.2).
    N-(2-ethylhexyl)-3-(3-fluorophenyl)propanamide; Example 140.
    Prepared similarly to example 5 from 3-(3-fluorophenyl)propanoic acid and 2-ethylhexan-1-amine. 11 NMR (400 MHz, DMSO-d6) δ 0.78 (t, .7 = 7.4 Hz, 3H), 0.85 (t, .7 = 6.8 Hz, 3H), 1.05 - 1.36 (m, 10H), 2.39 (t, .7=7.5Hz, 2H), 2.82 (t, J=7.5Hz, 2H), 2.95 (t, .7 = 6.1 Hz, 211), 6.94-7.10 (m, 3H), 7.23 - 7.33 (m, 1H), 7.69 (t, .7 = 5.6 Hz, 1 H); M+H(280.2).
    2-(4-(hydroxymethyl)phenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 141.5
    Prepared similarly to example 5 from 2-(4-(hydroxymethyl)phenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. *H NMR (400 MHz, DMSO-d6) δ 4.29 - 4.52 (m, 4H), 5.00 (br s, 2H), 6.70 (br d, J = 8.2 Hz, 211 ), 6.78 - 6.87 (m, 1H), 6.88 - 6.95 (m, 1H), 7.14 - 7.24 (dd, .7 = 13.9, 8.7 Hz, 211), 7.24 - 7.32 (m, 2H), 7.34 - 7.48 (m, 4H); M+H(354.1).
    N-cidohexyl-N-phenyl-2-(p-tolyloxy)acetamide; Example 146.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-cyclohexylaniline. δ 11 NMR (400 MHz, DMSO-d6) δ 1.03 - 0.78 (m, 311), 1.28 (m, 2H), 1.50 (d, .7 = 12.5 Hz, 111) , 1.72 (dd,.7=35.6, 12.4Hz, 4H), 2.18 (s, 3H), 4.12 (s, 211), 4.36 15 (t, .7= 12.0 Hz, 1H), 6.58 (d, .7 = 8.6 Hz, 211), 7.00 (d, .7-8.3 Hz, 211), 7.32 (d, .7 = 6.4 Hz, 2H), 7.52 - 7.40 (m, 3H); M+H(324.2).
    N-(2-ethylhexyl)-3-phenylpropanamide; Example 147.
    Prepared similarly to example 5 from 3-phenylpropanoic acid and 2-ethylhexan-1-amine. 111 NMR (400 MHz, DMSO-d6) δ 0.77 (t, .7 = 7.4 Hz, 3H), 0.84 (t, .7 = 6.9 Hz, 311), 1.35 - 1.05 (m, 9H), 2.35 (m, 211), 2.78 (1, .7 - 7.7 Hz, 2H), 3.01 - 2.87 (m, 2H), 7, 30 - 7.10 (m, 5H), 7.66 (t, .7 = 5.7 Hz, 111); M+11(261.2).
    2-(6-methyl-4-oxo-4H-chromen-2-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 149.
    Prepared similarly to example 5 from 2-(6-methyl-4-oxo-4H-chromen-2-yloxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. δ 11 NMR (400 MHz, DMSO-d6) δ 2.33 (s, 3H), 5.21 (s, 211), 6.46 (s, 111), 6.91 (m, 211), 7, 09 (br d, .7 = 8.0 Hz, 1H), 7.22 (m, 3H), 7.33 - 7.26 (m, 2H), 7.44 (dd, .7 = 3.9 , 2.5 Hz, 1H), 7.52 (br d, .7 = 8.5 Hz, 1H), 7.68(s, 1H); M+H(406.1).
    N-ethyl-3-(4-oxo-3,4-dihydroquinazolin-2-yl)-N-(thiophen-2-ylmethyl)propanamide;Example 150.
    Prepared similarly to example 5 from 3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 1 H NMR showed a mixture of rotamers in a ratio —2:1 1 H NMR (400 MHz, DMSO-d6): 1 II NMR (400 MHz, DMSO-d6) δ 1.05 (m, 3H), 3.00 - 2.79 (m, 4H), 3.29 - 3.43 (m, 2H), 4.69 (d, J = 75.4 Hz, 2H), 7.13 - 6.80 ( m, 2H), 7.56 - 7.25 (m, 3H), 7.80 - 7.70 (m, 1H), 8.05 (d, .7=7.9 IIz, 1H), 12, 19 (s, 1H); M+11(342.1).
    2-(4-hydroxyphenoxy)-N"phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 152.
    Prepared similarly to example 5 from 2-(4-hydroxyphenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. 1 I NMR (400 MHz, DMSO-d6) δ 4.29 (s, 2H), 4.98 (s, 211), 6.64 - 6.49 (m, 4H), 6.82 (br s , 111), 6.88 (dd, .7 = 5.1, 3.4 Hz, 1H), 7.25-7.19 (m, 211), 7.39 (m, 4H), 8.91 (s, 1H); M+H(340.1).
    2-(4-cyanophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 153.
    Prepared similarly to example 5 from 2-(4-cyanophenoxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. *H NMR (400 MHz, DMSO-d6) δ 4.57 (s, 2H), 4.98 (s, 2H), 6.82 (s, 1H), 6.97 - 6.87 (m, 3H), 7.28 (d, .7=7.0 Hz, 2H), 7.47 - 7.34 (m, 4H), 7.71 (d, J - 8.9 Hz, 211); M+11(349.1).
    N-(2-ethylhexyl)-3-(thiophen-2-yl)propanamide; Example 155.
    Prepared similarly to example 5 from 3-(thiophen-2-yl)propanoic acid and 2-ethylhexan-1-amine. *H NMR (400 MHz, DMSO-d6) δ 0.78 (t, .7 - 7.4 Hz, 3H), 0.84 (t, J = 6.9 Hz, 3H), 1.35 - 1 .09 (m, 10H), 2.40 (t, J = 7.4 Hz, 2H), 3.02 - 2.90 (m, 4H), 6.81 (m, 1H), 6.89 ( dd, J=5.1, 3.4Hz, 1H), 7.27 (dt, J=5.1, 0.9Hz, 1H), 7.73 (br t, J=5.5Hz, 1H ); M+H(268.2).
    N-propyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide; Example 156.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-(thiophen-2-ylmethyl)propan-1-amine. δ11 NMR (400 MHz, DMSO-d6) δ 0.89 - 0.75 (m, 311), 1.53 - 1.31 (m, 2H), 2.17 (s, 3H), 3.66 - 3.52 (m, 2H), 4.30 (br s, 2H), 6.58 (d, J = 8.1 Hz, 2H), 7.00 (d, .7 = 8.2 Hz, 2H), 7.51 - 7.35 (m, 5H); M+H(304.1).
    N-(pyridin-2-yl)-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide; Example 158.
    Prepared similarly to example 5 from 3-p-tolylpropanoic acid and N-(thiophen-2-ylmethyl)pyridin-2-amine. *H NMR (400 MHz, DMSO-d6) δ 2.20 (s, 3H), 2.50 (m, 211), 2.75 (t, .7 = 7.7 Hz, 2H), 5.13 (br s, 211), 6.83 - 6.76 (m, 111), 6.85 (dd, .7 = 5.1, 3.4 Hz, 1H), 6.98 (m 411), 7 .31 - 7.20 (m, 211), 7.35 (dd, .7 = 5.1, 1.3 Hz, HI), 7.85 - 7.75 (m, 1H), 8.46 ( ddd, .7-4.8, 2.0, 0.8 Hz, III); M+H(337.1).
    N-(2-ethylhexyl)-3-(3-methoxyphenyl)propanamide; Example 160.
    Prepared similarly to example 5 from 3-(3-methoxyphenyl)propanoic acid and 2-ethylhexan-1-amine. NMR (400 MHz, DMSO-d6) δ 0.77 (t, J = 7.4 Hz, 3H), 0.83 (t, .7 = 6.9 Hz, 3H), 1.34 - 1.07 (m, 10H), 2.35 (t, J=1J Hz, 2H), 2.75 (t, .7 = 7.6 Hz, 2H), 2.98 - 2.88 (m, 2H), 3.70 (s, 3H), 6.79 - 6.68 (m, 3H), 7.19 - 7.11 (m, 1H), 7.66 (t, .7-5.7 Hz, 1H); M+11(292.2).
    2-(benzyloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 161.
    Prepared similarly to example 5 from 2-(benzyloxy)acetic acid and N-(thiophen-2-ylmethyl)aniline. 1 H NMR (400 MHz, DMSO-d6) δ 3.84 (br s, 2H), 4.41 (br s, 2H), 4.97 (br s, 2H), 6.80 (dd, .7 = 3.4, 1.1 Hz, 1H), 6.88 (dd, .7 = 5.1, 3.4 Hz, 1H), 7.17 -7.10 (m, 2H), 7.38 - 7.19 (m, 8H), 7.40 (dd, 5.1, 1.3 Hz, 1H); M+H(338.1).
    N-isopropyl-N-phenyl-2-(p-tolyloxy)acetamide; Example 164.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-isopropylaniline. *H NMR (400 MHz, DMSO-d6) δ 0.97 (t, J = 6.3 Hz, 6H), 2.17 (s, 3H), 4.13 (s, 2H), 4.76 ( m, 1H), 6.58 (d, .7= 8.5 IIz, 211), 7.00 (d, .7= 8.4 Hz, 2H), 7.33 (d, .7= 6, 6 Hz, 2H), 7.57 - 7.39 (m, 3H); M+11(284.2).
    N-phenyl-N-(pyridin-4-ylmethyl)-2-(p-tolyloxy)acetamide; Example 167.
    Prepared similarly to example 5 from 2-(p-tolyloxy)acetic acid and N-(pyridin-4-ylmethyl)aniline. id NMR (400 MHz, DMSO-d6) δ 2.19 (s, 311), 4.49 (br s, 2H), 4.88 (br s, 211), 6.63 (d, .7= 8.4 Hz, 211), 7.02 (dd, J = 8.7, 0.6 Hz, 2H), 7.23 (d, .7 = 6.0 Iz, 211), 7.46 - 7.29 (m, 5H); 8.46 (dd, .7-4.4, 1.6 Hz, 2H); M+H(333.2).
    N-ethyl-2-methyl-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)propanamide; Example 170.
    Prepared similarly to example 5 from 2-methyl-2-(p-tolyloxy)propanoic acid and N-(thiophen-2-ylmethyl)ethanamine. 1 H NMR (400 MHz, DMSO-d6) δ 0.89 (m, 311), 1.62 - 1.42 (m, 6H), 2.20 (m, 3H), 3.20 (minor) ( q, J - 6.9 Hz, 2H), 3.63 (major) (q, .7 = 6.9 Hz, 2H), 4.63 (major) (s, 2H), 5.04 (minor) (s, 2H), 6.62 (major) (d, J = 8.5 Hz, 2H), 6.74 (minor) (d, .7 = 8.5 Hz, 2H), 7.11 - 6 .87 (m, 4H), 7.40 (dd, .7 = 5.1, 1.2Hz, 1H); M+H(318.1).
    2-(2-hydroxy-4-methylphenoxy)-N-(1H-pyrazol-4-yl)-N-(thiophen-2-ylmethyl)acetamide;Example 182.
    Prepared similarly to example 5 from 2-(2-hydroxy-4-methylphenoxy)acetic acid and N-(thiophen-2-ylmethyl)-1H-pyrazol-4-amine. 1 H NMR (400 MHz, DMSO-d6): δ 2.15 (s, 3H), 4.47 (s, 2H), 4.88 (br s, 2H), 6.47 (ddd, J=8 .1, 2.1, 0.6 Hz, 1H), 6.60 (d, .7= 2.0 Hz, 1H), 6.66 (d, .7= 8.1 Hz, 1H), 6 .88 (br dd, 3.4, 1.1 Hz, 1H), 6.94 (dd, .7= 5.1, 3.4 Hz, 1H), 7.44 (m, 2H), 7, 78 (br s, 1H), 9.10 (br s, 1H), 13.00 (br s, 1H); M+H(344.1). 2-(2-Hydroxy-4-methylphenoxy)acetic acid; Example 182a.A a stirred solution at 0°C of ethyl 2-(2-hydroxy-4-methylphenoxy)acetate (1.20 g, 5.82 mmol) in methanol (10.0 mL) and water (6. 0 mL), was added to 10.0 M solution of NaOH (3.0 mL, 30.0 mmol). The ice bath was then removed and the reaction was warmed to room temperature with stirring until the reaction was complete. The mixture was poured into a mixture of water (20.0 mL) and 6.0 M 11Cl (6.0 mL), and the product was collected by filtration and dried under vacuum yielding 692 mg of 2-(2-hydroxy acid). -4-methylphenoxy)acetic acid as a white solid in 70% yield. Ethyl 2-(2-hydroxy-4-methylphenoxy)acetate; Example 182b.To a stirred solution at 0°C of ethyl 2-(2-methoxy-4-methylphenoxy)acetate (2.73 g, 12.17 mmol) in DCM (25.0 mL) was added dropwise. -drop a 1.0M solution of BBr3 in DCM (18.27 mmol, 18.3 mL). The reaction was stirred for 1 hour then cooled to -78°C and quenched with water. After warming to room temperature, the solution was extracted three times with EtOAc and the combined organic layers were washed with brine and then dried Na2SIXj. The organic layer obtained was concentrated by rotary evaporation and then absorbed in Elorisil with the aid of EtOAc and all volatiles were evaporated in the rotary evaporator. The powder obtained was loaded onto a chromatography column and purified with a hexane/ethyl acetate gradient (Biotagc system). After evaporating the solvent from the desired fractions, 1.623 g of ethyl 2-(2-hydroxy-4-methylphenoxy]acetate was recovered in 71% yield.
    (E)-N-ethyl-3-(4-methoxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide; Example 188.
    Prepared similarly to example 5 from (E)-3-(4-methoxyphenylacrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in a ratio ~2:1 : *H NMR (400 MHz, DMSO-d6) δ 1.03 - 1.11 (m, 3H), 3.34 - 3.60 (m, 211), 3.77 (s, 3H), 4, 70 (major) (s, 2H), 4.93 (minor) (s, 2H), 6.85 - 7.23 (m, 5H), 7.33 - 7.57 (m, 2H), 7, 60 - 7.68 (m, 2H); M+II(302.1).
    (E)-N-ethyl-N-(furan-3-ylmethyl)-3-p-tolylaerylamide; Example 189.
    Prepared similarly to example 5 from (E)-3-p-tolylacrylic acid and N-(furan-3-ylmethyl)ethanamine. Room temperature 'll NMR showed a mixture of rotamers in a ratio ~1.5:1: 'll NMR (400 MHz, DMSO-d6) δ 1.02 - 1.12 (m, 3H), 2.30 (s , 311), 3.37 (minor) (br q, ./ = 7.0 Hz, 2H), 3.47 (major) (br q, ./ = 6.8 Hz, 2H), 4.38 ( major) (s, 211), 4.55 (minor) (s, 211), 6.39 (br s, 1H), 6.97 7.27 (m, 311), 7.37 - 7.75 ( m, 511); M+H(270.1).
    (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-o-tolylaerylamide; Example 191.
    Prepared similarly to example 5 from (E)-3-o-tolylacrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ratio -1.5:1: *H NMR (400 MHz, DMSO-d6) δ 1.01 - 1.21 (m, 311), 2.36 - 2 .40 (m, 311), 3.42 (minor) (br q, .7 = 6.9 Hz, 2H), 3.54 (major) (br q, .7 = 6.9 Hz, 2H), 4.73 (major) (br s, 2H), 4.96 (minor) (br s, 2H), 6.89 - 7.16 (m, 3H), 7.22 - 7.29 (m, 311 ), 7.40 - 7.46 (m, 1H), 7.65 - 7.89 (m, 2H); M+H(286.1).
    (E)-3-(benzo[d][1,3]dioxol-5-yl)-N-ethyl-N-(furan-3-ylmethyl)acrylamide; Example 193.
    Prepared similarly to example 5 from (E)-3-(benzo[d][1,3]dioxol-5-yl)acrylic acid and N-(furan-3-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio -1.5:1: '11 NMR (400 MHz, DMSO-d6) δ 1.02 - 1.13 (m, 3H), 3.37 (smallest ) (br q, J = 6.9 Hz, 1H), 3.48 (major) (br q, J = 6.9 Hz, 1H), 4.38 (major) (br s, 1H), 4, 56 (minor) (br s, 1H), 6.06 (s, 2H), 6.40 (br s, 1H), 6.91 - 7.17 (m, 311), 7.37 - 7.53 (m, 211), 7.58 - 7.66 (m, 211); M+H(300.1).
    (E)-3-(2,3-dihydrobenzofuran-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide;Example 194.
    Prepared similarly to example 5 from (E)-3-(2,3-dihydrobenzofuran-5-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio -2:1: 'll NMR (400 MHz, DMSO-d6) δ 1.03 - 1.14 (m, 3H), 3.20 (br t, .7=9.2 Hz, 2H), 3.39 (minor) (br q, .7 = 6.9 Hz, 2H), 3.51 (major) (br q, .7 = 6.9 Hz, 2H), 4.57 (t, .7= 8.7 Hz, 2H), 4.71 (major) (br s, 2H), 4.94 (minor) (br s, 2H), 6.78 ( d, .7= 8.2 Hz, 1H), 6.88 - 7.02 (m, 2H), 7.06 (br s, 1H), 7.34 -7.56 (m, 3H), 7.61 - 7.72 (m, 1H); M+11(3 14.1).
    (E)-3-(2,3-dihydrobenzo|b]|1,4]dioxin-6-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide;Example 198.
    Prepared similarly to example 5 from (E)-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in a ~2:1 ratio: 1 H NMR (400 MI Iz, DMSO-d6) δ 1.00 (smallest) (br t, .7 = 7.0 Hz, 1 H), 1.12 (major) (br t, .7=7.1 Hz, 211), 3.30 (m, 2H), 4.18 (m, 411), 4.63 (major) (br s, 1H), 4.73 (br s, 211), 4.74 (minor) (br s, 2H), 6.31 - 6.50 (m, 211), 6.71 - 6.77 (m , 1H), 6.89 -7.15 (m, 2H), 7.42 (major) (dd,.7 = 5.1, 1.2 Hz, 1H), 7.50 (minor) (d, α7=4.1Hz, 1H); M+H(330.1).
    N-ethyl-5-methyl-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 202.
    Prepared similarly to example 5 from 5-methylbenzofuran-2-carboxylic acid and N-(thiophen-2-ylmethyl)ethanamine. 11 NMR (400 MHz, DMSO-d6) δ 1.22 (br s, 3H), 2.41 (br s, 3H), 3.53 (br s, 2H), 4.83 (br s, 2H) , 6.99 (dd,./= 5.1, 3.4 Hz, 1H), 7.13 (br s, 111), 7.23 - 7.30 (m, 1H), 7.38 (br s, 1H), 7.47 (br d, α7 = 4.5 Hz, 1H), 7.50 - 7.56 (m, 2H); M+11(300.1).
    N-ethyl-N-(thiophen-2-ylmethyl)-3-p-tolylpropanamide; Example 206.
    Prepared similarly to example 5 from 3-p-tolylpropanoic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in ~2:1 ratio: 1H NMR (400 MHz, DMSO-d6) δ 0.96-1.05 (m, 311), 2.25 (s, 3I -I), 2.56 - 2.66 (m, 2H), 2.71 - 2.88 (m, 2H), 3.23 - 3.32 (m, 2H), 4.61 (major) ( br s, 211), 4.67 (minor) (br s, 2H), 6.90 - 7.02 (m, 2H), 7.03 - 7.16 (m, 411), 7.39 (major ) (dd, .7 = 5.1, 1.2 Hz, II), 7.44 (minor) (dd, .7-4.8, 1.5 Hz, 111); M 111(288.1).
    (E)-N-ethyl-3-(4-fluorophenyl)-N-(thiophen-2-ylmethyl)aerylamide; Example 207.
    Prepared similarly to example 5 from (E)-3-(4-fluorophenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 1 H NMR showed a mixture of rotamers in a ~2:1 ratio: 1 H NMR (400 MHz, DMSO-d6) δ 1.04-1.14 (m, 3H), 3.41 (minor) ( br q, .7=7.1 Hz, 2H), 3.53 (major) (br q, .7=7.1 Hz, 2H), 4.73 (major) (br s, 2H), 4, 97 (minor) (br s, 2H), 6.90 - 7.02 (m, 1H), 7.03 - 7.31 (m, 4H), 7.40-7.45 (m, 1H), 7.51 - 7.60 (m, III), 7.71 - 7.86 (m, 2H); M+H(290.1).
    (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-ethyl-N-(furan-3-ylmethyl)acrylamide;Example 208.
    Prepared similarly to example 5 from (E)-3-(2,3-dihydro-1H-inden-5-yl)acrylic acid and N-(furan-3-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio ~2:1: '14 NMR (400 MHz, DMSO-d6) δ 1.03 - 1.14 (m, 3H), 2.02 (p, J = 7.5 Hz, 2H), 2.86 (m, 4H), 3.38 (minor) (br q, J = 7.0 Hz, 2H), 3.49 (major) (br q,.7 = 7.0 Hz, 2H), 4.39 (major) (br s, 214), 4.57 (minor) (br s, 2H), 6.40 (dd, .7 = 1.7, 0, 7 Hz, 1H), 7.05 (major) (d, .7 = 15.3 Hz, 1H), 7.15 (minor) (d, .7 = 15.5 Hz, 1H), 7.25 ( br d, .7 = 7.7 Hz, III), 7.35 - 7.69 (m, 511); M+H(296.2).
    (E)-N-ethyl-3-(5-methylthiophen-2-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 209.
    Prepared similarly to example 5 from (E)-3-(5-methylthiophen-2-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ratio ~1.5:1: 11 NMR (400 MHz, DMSO-d6) δ 1.03 - 1.12 (m, 3H), 2.46 (br s, 3H), 3.35 - 3.52 (m, 2H), 4.71 (major) (br s, 211), 4.87 (minor) (br s, 2H), 6.62 (major) (d, .7=15.1 Hz, III), 6.75 (minor) (d, J=14.9 Hz, 1H), 6.82 (br d, .7=2.1 Hz, 111) , 6.90-7.12 (m, 2H), 7.23-7.29 (m, 1H), 7.39 - 7.46 (m, 1H), 7.56-7.67 (m, 1H), 111); M+11(292.1).
    (E)-3-(benzo|d]|1,3|dioxol-5-yl)-N-ethyl-N-(furan-2-ylmethyl)acrylamide; Example 210.
    Prepared similarly to example 5 from (E)-3-(benzo[d][1,3]dioxol-5-yl)acrylic acid and N-(furan-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in ~1:1 ratio: 1 H NMR (400 MHz, DMSO-do) δ 1.10 - 0.94 (m, 3H), 3.38 (br q, .7 = 6.5 Hz, 1H), 3.52 (br q, J= 6.8 Hz, 1H), 4.59 (br s, 1H), 4.75 (br s, 1H), 6, 06 (s, 2H), 6.30 - 6.42 (m, 2H), 6.93 (d, J=8.0 Hz, 1H), 7.00 (br d,.7 = 15.3 Hz , 0.5H), 7.11 - 7.20 (m, 1.511), 7.40 - 7.48 (m, 211), 7.60 (br d, .7 = 13.6 Hz, HI); M+11(300.1).
    (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide;Example 211.
    Prepared similarly to example 5 from (E)-3-(2,3-dihydro-1H-inden-5-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio of -2:1: *H NMR (400 MHz, DMSO- do) δ 1.03 - 1.14 (m, 3H), 2.02 (p, J = 7.4 Hz, 2H), 2.87 (m, 4H), 3.40 (minor) (br q, J = 7.0 Hz, 2H), 3.52 (major) (br q, .7 = 7.0 Hz, 211), 4.72 (major) (br s, 2H), 4.95 (minor) (br s, 2H), 6.93 - 7.01 (m, 1H), 7, 08 (br s, 1H), 7.21 - 7.28 (m, 1H), 7.35 - 7.69 (m, 4H); M+11(312.1).
    N-ethyl-5-methoxy-N-(thiophen-2-ylmethyl)benzofuran-2-carboxamide; Example 213.
    Prepared similarly to example 5 from 5-methoxy benzofuran-2-carboxylic acid and N-(thiophen-2-ylmethyl)ethanamine. 'iT NMR (400 MHz, DMSO-d6) 1.22 (br s, 3H), 3.53 (br s, 2H), 3.79 (s, 3H), 4.83 (br s, 2H), 6.99 (dd, .7= 5.1, 3.4 Hz, 1H), 7.04 (dd, .7= 9.0, 2.7 Hz, 1H), 7.14 (br s, 1H ), 7.24 (d, .7 = 2.4 Hz, 1H), 7.38 (br s, 1H), 7.47 (br d, .7 = 4.8 Hz, III), 7.56 (br d, .7 = 9.0 Hz, HI); M+H(3 16.1).
    (E)-N-ethyl-3-(3-hydroxy-4-niethoxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide;Example 214.
    Prepared similarly to example 5 from (E)-3-(3-hydroxy-4-methoxyphenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 1 H NMR showed a mixture of rotamers in ~2:1 ratio: * H NMR (400 MHz, DMSO-d6) 6 1.03 - 1.14 (m, 3H), 3.40 (minor) ( br q, .7= 7.0 Hz, 2H), 3.50 (major) (br q, 7.0 Hz, 2H), 3.80 (s, 3H), 4.71 (major) (br s , 2H), 4.92 (minor) (br s, 2H), 6.76 - 7.25 (m, 6H), 7.32 - 7.54 (m, 2H), 9.06 (s, 1H ); M+H(318.1).
    (E)-N-ethyl-N-(furan-2-ylmethyl)-3-p-tolylacrylamide; Example 215.
    Prepared similarly to example 5 from (E)-3-p-tolylacrylic acid and N-(furan-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ratio -1:1: 'll NMR (400 MHz, DMSO-d6) δ 0.99 - 1.09 (m, 3H), 2.32 (s, 3H ), 3.39 (q, .7=6.9 Hz, 1H), 3.52 (q, J=7.0 Hz, 1H), 4.60 (br s, II I), 4.75 ( br s, 1H), 6.43 - 6.29 (m, 1H), 7.13 - 7.03 (m, 0.511), 7.20 - 7.25 (m, 2.5H), 7.43 - 7.56 (m, 1H), 7.57 - 7.62 (m, 3H); M+H(270.1).
    (E)-N-ethyl-3-(2-fluorophenyl)-N-(thiophen-2-ylmethyl)acrylamide; Example 216.
    Prepared similarly to example 5 from (E)-3-(2-fluorophenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ratio -2:1: *H NMR (400 MHz, DMSO-d6) δ 1.05 - 1.15 (m, 3H), 3.42 (minor) ( br q, .7 = 7.2 Hz, 2H), 3.53 (major) (br q, .7 = 7.0 Hz, 2H), 4.74 (major) (br s, 2H), 4, 96 (minor) (br s, 2H), 6.93 - 7.03 (m, 1H), 7.06 - 7.10 (m, 1H), 7.15 - 7.37 (m, 3H), 7.39 - 7.51 (m, 2H), 7.62 - 7.71 (m, 1H), 7.84 - 7.96 (m, 1H); M+H(290.1).
    (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-m-tolylaerylamide; Example 219.
    Prepared similarly to example 5 from (E)-3-m-tolylacrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 1 II NMR showed a mixture of rotamers in a ratio of -2:1: 1 I NMR (400 MIIz, DMSO-d6) δ 1.04 -1.15 (m, 311), 2.33 (br s , 3H), 3.41 (minor) (br q, .7 = 7.1 Hz, 211), 3.53 (major) (br q, .7 = 7.0 Hz, 211), 4.73 ( major) (br s, 211), 4.96 (minor) (br s, 2H), 6.92 - 7.02 (m, 1H), 7.05 - 7.33 (m, 411), 7, 38 - 7.58 (m, 411); M+H(286.1).
    (E)-N-ethyl-3-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)aerylamide; Example 221.
    Prepared similarly to example 5 from (E)-3-(3-methoxyphenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 'H NMR showed a mixture of rotamers in a ratio ~2:1: *1-1 NMR (400 MHz, DMSO-dó) δ 1.04 - 1.14 (m, 3I-I), 3.41 (minor) (br q, .7 = 6.8 Hz, 2H), 3.54 (major) (br q, J= 7.0 Fiz, 2H), 3.77 - 3.80 (m, 3H) , 4.73 (major) (br s, 2H), 4.97 (minor) (br s, 2H), 6.90 - 7.03 (m, 2H), 7.06 - 7.19 (m , 2H), 7.22 - 7.36 (m, 3H), 7.40 - 7.45 (m, 111), 7.47 - 7.57 (m, 1H); M+H(302.1).
    (E)-3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide;Example 222.
    Prepared similarly to example 5 from (E)-3-(2,2-diluorbenzo[d][1,3]dioxol-5-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in ~2:1 ratio: 1 H NMR (400 MHz, DMSO-d6) δ 1.06 (smallest) (br t, .7 = 7.0 Hz, 311) , 1.11 (major) (br t, .7= 7.0 Hz, 3H), 3.40 (minor) (br q, J = 6.8 Hz, 2H), 3.53 (major) (br q, .7 = 7.0 Hz, 2H), 4.73 (major) (br s, 2H), 4.97 (minor) (br s, 2H), 6.92 - 7.03 (m, III ), 7.08 (br s, 1H), 7.16 (major) (d, .7 = 15.4 Hz, 1H), 7.33 (minor) (d, .7 = 15.3 Hz, 1H ), 7.37 - 7.63 (m, 4H), 7.95 (br d, .7 = 17.3 Hz, HI); M+H(352.1).
    (E)-1N-ethyl-3-(3-thiorphenyl)-N-(thiophen-2-ylmethyl)acrylamide; Example 224.
    Prepared similarly to example 5 from (E)-3-(3-fluorophenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in ~2:1 ratio: 11 NMR (400 MHz, DMSO-d6) δ 1.06 (smallest) (br t, .7= 7.1 Hz, 3H) , 1.12 (major) (br t, .7 = 7.1 E1z, 3H), 3.41 (minor) (br q, .7= 6.8 Hz, 211), 3.54 (major) ( br q, .7= 7.0 Hz, 2H), 4.73 (major) (br s, 2H), 4.98 (minor) (br s, 211), 6.94 - 7.03 (m, III), 7.08 (d, .7 = 3.4 Hz, III), 7.16 - 7.26 (m, 1.614), 7.34 - 7.49 (m, 2.414), 7.49 - 7.61 (m, 214), 7.62 - 7.72 (m, 114); M+H(290.1).
    (E)-N-ethyl-3-(5-methylfuran-2-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 225.5
    Prepared similarly to example 5 from (E)-3-(5-methylfuran-2-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in ~2:1 ratio: 14 NMR (400 MHz, DMSO-d6) δ 0.98 - 1.23 (m, 3H), 2.30 (minor) ( br s, 314), 2.33 (major) (br s, 3H), 3.36 - 3.51 (m, 2H), 4.71 (major) (br s, 2H), 4.86 (minor ) (br s, 214), 6.23 (br s, 114), 6.62 - 6.80 (m, 2H), 6.94 -10 7.08 (m, 2H), 7.28 - 7 .45 (m, 214); M+H(276.1).
    (E)-3-(4-cyanophenyl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide; Example 226.
    Prepared similarly to example 5 from (E)-3-(4-cyanophenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR 15 showed a mixture of rotamers in a ratio ~2:1: 14 NMR (400 MHz, DMSO-d6) δ 1.09 (m, 3H), 3.41 (minor) (br q, .7 = 7.0 Hz, 211), 3.55 (major) (br q, .7 = 7.0 Hz, 2H), 4.74 (major) (br s, 2H), 4.99 (minor ) (br s, 214), 6.94 - 7.01 (m, 1H), 7.06 - 7.10 (m, 114), 7.24 - 7.52 (m, 2H), 7.56 - 7.65 (m, 114), 7.85 - 7.97 (m, 414); M+H(297.1).
    20 (E)-N-ethyl-3-(thiophen-2-yl)-1N-(thiophen-2-ylmethyl)aerylamide; Example 227.
    Prepared similarly to example 5 from (E)-3-(thiophen-2-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature '11 NMR showed a mixture of rotamers in a ratio —2:1: 41 NMR (400 MHz, DMS()-d6) δ 1.01 - 1.17 (m, 314), 3.37 - 3, 53 (m, 214), 4.72 (major) (br s, 211), 4.90 (minor) (br s, 211), 6.79 25 (major) (d, .7-15.2 Hz , 0.611), 6.88 - 7.02 (m, 1.411), 7.06 - 7.14 (m, 211), 7.39 - 7.53 (m, 214), 7.60 - 7.77 (m, 2H); M+H(278.1).
    (E)-3-(2-cyanophenyl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide; Example 228.
    Prepared similarly to example 5 from (E)-3-(2-cyanophenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in ~2:1 ratio: *H NMR (400 MHz, DMSO-d6) δ 1.05 - 1.16 (m, 311), 3.43 (minor) ( br q, .7 = 7.0 Hz, 2H), 3.56 (major) (br q, .7 = 7.0 Hz, 2H), 4.75 (major) (br s, 2H), 5, 00 (minor) (br s, 2H), 6.90 - 7.04 (m, 1H), 7.05 - 7.15 (m, 1H), 7.34-7.62 (m, 3H), 7.72 -7.84 (m, 2H), 7.91 (br d, .7 = 7.8 Hz, 1H), 8.11-8.19 (m, 1H); M+H(297, 1).
    (E)-3-(2,3-dihydro-1H-inden-5-yl)-N-ethyl-N-(furan-2-ylmethyl)aerylamide; Example 231.
    Prepared similarly to example 5 from (E)-3-(2,3-dihydro-1H-inden-5-yl)acrylic acid and N-(furan-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in ~1:1 ratio: *H NMR (400 MHz, DMSO-d6) δ 0.98 - 1.12 (m, 3H), 2.02 (p, J = 7.4 Hz, 2H), 2.87 (m, 411), 3.38 (br q, .7 = 6.8 Hz, III), 3.53 (br q, .7 = 6.8 Hz , HI), 4.60 (br s, 1H), 4.75 (br s, 1H), 6.30 - 6.42 (m, 2H), 7.06 (d, .7 = 15.3 Hz , 0.5H), 7.20 - 7.29 (m, 1.5H), 7.42 (br s, 1H), 7.46 - 7.55 (m, 1H), 7.57 - 7, 67 (m, 2H); M+H(296.2).
    3-(2,3-dihydro-1H-inden-5-yl)-N-ethyl-N-(thiophen-2-ylmethyl)propanamide; Example 234.
    Prepared similarly to example 5 from 3-(2,3-dihydro-1H-inden-5-yl)propanoic acid and N-(thiolen-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in a ratio ~2:1:1 H NMR (400 MHz, DMSO-d6) δ 0.95 - 1.08 (m, 3H), 1.93 - 2.02 ( m, 2H), 2.55 - 2.66 (m, 2H), 2.73 - 2.83 (m, 6H), 3.22 - 3.32 (m, 2H), 4.61 (major) (br s, 2H), 4.67 (minor) (br s, 2H), 6.90 - 7.14 (m, 5H), 7.39 (major) (dd, .7= 5.1, 1 .3 Hz, 1H), 7.45 (minor) (dd, .7=4.9, 1.5 Hz, 1H); M+H(314.2).
    (E)-N-ethyl-N-(thiophen-2-ylmethyl)-3-(thiophen-3-yl)acrylamide; Example 245.
    Prepared similarly to example 5 from (E)-3-(thiophen-3-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature '11 NMR showed a mixture of rotamers in a ~2:1 ratio: '11 NMR (400 MHz, DMSO-d6) δ 1.01 - 1.11 (m, 3H), 3.38 (minor) ( br q, .7 = 6.7 Hz, 2H), 3.49 (major) (br q, J = 6.7 Hz, 2H), 4.70 (major) (br s, 2H), 4.92 (minor) (br s, 2H), 6.91 - 7.13 (m, 3H), 7.37 - 7.43 (m, 1H), 7.49 - 7.61 (m, 3H), 7 .84 - 7.89 (m, 1H); M+H(278.1).
    (E)-3-(3-cyanophenyl)-N-ethyl-N-(thiophen-2-ylmethyl)acrylamide; Example 246.
    Prepared similarly to example 5 from (E)-3-(3-cyanophenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in ~2:1 ratio: 1 H NMR (400 MHz, DMSO-d6) δ 1.06 (smallest) (br t, .7= 7.1 Hz, 3H) , 1.13 (major) (br t, J = 7.0 Hz, 3H), 3.40 (minor) (br q, .7 = 6.9 Hz, 2H), 3.56 (major) (br q, .7= 7.0 Hz, 2H), 4.74 (major) (br s, 2H), 5.00 (minor) (br s, 2H), 6.94-7.01 (m, 1H ), 7.06-7.11 (m, 1H), 7.31 (major) (d, .7=15.5 Hz, 1H), 7.40-7.48 (m, III), 7, 53 (minor) (d, .7 = 19.1 Hz, III), 7.57-7.67 (m, 2H), 7.83 (br d, .7 = 7.7 Hz, III), 8 .03 (br t, .7 = 9.0 Hz, 1H); 8.33 (br d, 12.7 Hz, 1H); M+H(297.1).
    (E)-N-ethyl-3-(4-hydroxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide; Example 247.
    Prepared similarly to example 5 from (E)-3-(4-hydroxyphenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 1 IT NMR showed a mixture of rotamers in ~2:1 ratio: 111 NMR (400 MHz, DMSO-d6) δ 1.00 - 1.18 (m, 3H), 3.40 (minor) (br q, .7=7.3 Hz, 211), 3.50 (major) (br q, .7 = 7.3 Hz, 2H), 4.71 (major) (br s, 211), 4.92 (minor) (br s, 2H), 6.78 (br d, .7 = 8.4 Hz, 2H), 6.83 - 7.04 (m, 2H), 7.06 (br d, J = 3.0 Hz, 1H), 7.39 - 7.57 (m, 4H), 9.85 (s, III); M+H(288.1).
    (E)-N-ethyl-3-(1-methyl-1H-pyrrol-2-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 248.
    Prepared similarly to example 5 from (E)-3-(1-methyl-1H-pyrrol-2-yl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature '14 NMR showed a mixture of rotamers in a ratio —2:1: 'H NMR (400 MHz, DMSO-d6) δ 1.10 (br s, 3H), 3.46 (br s, 2H), 3.69 (s, 3H), 4.71 (major) (br s, III), 4.89 (minor) (br s, 1H), 6.07 (br s, 1H), 6.71 ( br d, J = 17.0 Hz, 2H), 6.91 - 7.07 (m, 3H), 7.40 - 7.55 (m, 2H); M+H(275.1).
    (E)-N-ethyl-3-(1-methyl-1H-pyrrol-2-yl)-N-(thiophen-2-ylmethyl)acrylamide; Example 250.
    Prepared similarly to example 5 from 2-(4-cyanophenoxy)acetic acid and N-(thiocyan-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in a ratio —2:1: '11 NMR (400 MHz, DMSO-d6) δ 1.01 (smallest) (br t, J = 7.1 Fiz, III), 1.15 (major) (br t, J = 7.1 Hz, 2H), 3.30 - 3.36 (m, 2H), 4.64 (major) (br s, 2H), 4.76 ( minor) (br s, 2H), 5.01 (minor) (br s, 2H), 5.03 (major) (br s, 2H), 6.89 - 7.16 (m, 4H), 7, 42 (major) (dd, J= 5.1, 1.2 Hz, 1H), 7.51 (minor) (dd, J= 5.1, 1.1 Hz, 1H), 7.73 - 7, 83 (m, 2H); M+H(301.1).
    (E)-N-ethyl-3-(2-methoxyphenyl)-N-(thiophen-2-ylnictyl)acrylamide; Example 251.
    Prepared similarly to example 5 from (E)-3-(2-methoxyphenyl)acrylic acid and N-(thiophon-2-ylmethyl)ethanamine. Room temperature 11 NMR showed a mixture of rotamers in ~2:1 ratio: *11 NMR (400 MHz, DMSO-d6) δ 1.03 - 1.15 (m, 311), 3.42 (minor) ( br q, .7= 6.9 Hz, 2H), 3.51 (major) (br q, 6.7 Hz, 2H), 3.84 (minor) (br s, 311), 3.86 (major ) (br s, 311), 4.72 (highest) (br s, 211), 4.92 (smallest) (br s, 211), 6.90 - 7.02 (m, 211), 7.03 - 7.26 (m, 311), 7.32 - 7.48 (m, 2H), 7.67 - 7.94 (m, 211); M 111(302.1).
    (E)-N-ethyl-3-(3-hydroxyphenyl)-N-(thiophen-2-ylmethyl)acrylamide; Example 252.
    Prepared similarly to example 5 from (E)-3-(3-hydroxyphenyl)acrylic acid and N-(thiophen-2-ylmethyl)ethanamine. Room temperature 1II NMR showed a mixture of rotamers in a ratio ~2:1: 'H NMR (400 MHz, DMSO-d6) δ 1.04 - 1.14 (m, 3H), 3.41 (minor) (br q, .7=7.0 Hz, 2H), 3.52 (major) (br q, .7 = 7.2 Hz, 2H), 4.72 (major) (br s, 2H), 4.94 (minor) (br s, 2H), 6.79 (br d, .7 = 7.9 Hz, 1H), 6.93 - 7.25 (m, 611), 7.37 - 7.54 (m , 2H), 9.55 (br s, 1H); M+H(288,1).Example 253.
    Prepared similarly to example 5 from and N-(thiophen-2-ylmethyl)ethanamine. Room temperature *H NMR showed a mixture of rotamers in ~2:1 ratio: *H NMR (400 MHz, DMSO-d6); M+H(2,1). δ H NMR (400 MHz, dmso) δ 1.01 (dt, .7 = 18.8, 7.1 Hz, 3H), 2.71 (dt, .7 = 17.8, 7.5 Hz, 2H ), 2.93 (qf = 7.8 Hz, 2H), 3.31 - 3.24 (m, 2H), 4.60 (s, 1H), 4.69 (s, 1H), 7.02 - 6.91 (m, 2H), 7.51 - 7.37 (m, 311), 7.72 (d, .7 = 8.3 Hz, 2H). Scheme 3
    If not commercially available or otherwise described, all secondary amines were prepared by reductive amination similar to example 6a or 21b using one of the standard reducing agents and general conditions known to those skilled in the art such as: NaBIlj, IJAIH4, Na( OAc)}BH (STAB), Na(CN)B113, 2-picolino borane complex, 5-ethyl-2-methylpyridine borane (PEMB) or their equivalents, and DCM (dichloromethane), DCE (dichloroethane), Et2Ü (ether diethyl), THF (tetrahydrofuran), dioxane, MeOH, EtOH, MeCN, AcOH alone or in binary or tertiary combinations thereof, all phenols or alcohols employed are commercially available. One skilled in the art can readily derive the synthesis of the present compounds from the following descriptions in accordance with the methods and principles discussed above.
    2-(3-cyanophenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 44. To a microwave flask was added 3-hydroxybenzonitrile (60 mg, 0.50 mmol) in DMF (1.0 mL), followed by K2CO3 (140 mg, 1.0 mmol) and 2-bromo- N-phenyl-N-(thiophen-2-ylmethyl)acetamide (150 mg, 0.5 mmol) in DMF (4.0 mL). The microwave vial was capped and reacted under microwave irradiation (Emrys Optimizer reactor) at 120°C for 10 minutes. The compound was purified by HPLC; the clear fractions were combined and concentrated, yielding 101 mg (0.29 mmol, 58%). NMR (400 MHz, DMSO-d6) δ 4.57 (s, 2H), 5.00 (s, 2FI), 6.84 (br s, 1H), 6.91 (dd, J=5.1, 3.4 Hz, 1H), 7.15 (br d, J = 7.9 Hz, 1H), 7.23 - 7.33 (m, 3H), 7.34 - 7.52 (m, 6H) ; M+H(349.1).2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 44a.A a stirred suspension at 0°C of N-(thiophen-2-ylmethyl)aniline (3.51 g, 18.53 mmol) and sodium bicarbonate (1.71 g, 20.38 mmol) in dimethylformamide (15.0 mL), bromoacetyl chloride (1.54 mL, 18.53 mmol) was added. The ice bath was removed and the flask was connected to a bubbler to allow gas evolution and expansion. The reaction was stirred overnight at room temperature. Most of the volatiles were evaporated in vacuo, then the residue was taken up in dichloromethane and washed first with water and then brine. The resulting organic layer was dried with MgSO4 and concentrated. The crude product obtained was absorbed under vacuum in Florisil with the aid of DCM (dry charge). The obtained dispersion was purified by column chromatography (Biotage system, hex:EtOAc 1-20% 30 CV gradient, 40 g silica column Silicycle). The collected fractions were evaporated to give 4.51 g of 2-bromo-N -phenyl-N-(thiophen-2-ylmethyl)acetamide (14.55 mmol; 78%), which was judged to be greater than 97% pure by 1 H-NMR analysis.
    N-ethyl-2-(2-hydroxy-5-methylphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 27.
    Prepared similarly to example 44 from 2-bromo-N-ethyl-N-(thiophen-2-ylmethyl]acetamide and 4-methylbenzene-1,2-diol. Yield 10%. *11 NMR showed a mixture of rotamers in a ~2:1 ratio: 1 H NMR (400 MHz, DMSO-d6) δ 9.06 (highest) (s, 1H), 9.04 (smallest), (s, III), 7.51 (smallest) ) (dd, J = 5.1, 1.2 Hz, 1H), 7.43 (major) (dd, .7= 5.1, 1.2 Hz, 1H), 7.11 - 7.01 ( minor) (m, 1H), 7.06 - 7.05 (major) (m, 1H), 7.03 - 7.01 (minor) (m, 1H), 6.96 - 6.94 (major) (m, 1H), 6.69 - 6.61 (m, 3H), 4.83 (minor) (s, 214), 4.82 (major) (s, 214), 4.76 (minor) ( s, 214), 4.66 (major) (s, 211), 3.36 - 3.30 (m, 214), 5 2.16 (major) (s, 311), 2.14 (minor) ( s, 311), 1.12 (major) (t, 7=7.1 Hz, 311) 1.02 (minor) (t,7=7.1 Hz, 3H); M+H (306.1) .
    N-ethyl-2-(3-fluoro-4-methylphenoxy)-N-(thiophen-2-ylmethyl)acetamide; Example 32.
    Prepared similarly to example 44 from 2-bromo-N-ethyl-N-(thiophen-2-ylmethyl)acetamide and 3-fluoro-4-methylphenol. Yield 31%. 'H NMR showed a mixture of rotamers in a ~2:1 ratio: 'H NMR (400 MHz, DMSO-d6) δ 1.00 (smallest) (t, J = 7.1 Hz, 3H), 1.13 (major) (t, J= 7.1 Hz, 3H), 2.14 (br s, 314), 3.22 - 3.40 (m, 214), 4.64 (major) (s, 2H) , 4.75 (minor) (s, 214), 4.84 (m, 214), 6.61 - 6.80 (m, 214), 6.87 - 7.20 (m, 314), 7, 42 (major) (dd, J = 5.1, 1.2 Hz, 114); 7.51 (minor) (d, J = 4.0 Hz, 1H); M+H 15 (308.1).
    2-(3-fluoro-4-methylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 55.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and 3-fluoro-4-methylphenol. δ H NMR (400 MHz, DMSO-d6) δ 2.11 (d, 7 = 1.6 20 Hz, 314), 4.42 (br s, 214), 4.98 (br s, 214), 6 .52 (dd, , /= 26.4, 10.2 Hz, 214), 6.81 (br s, 114), 6.89 (dd, 7 = 5.1, 3.4 Hz, 1H), 7.10 (t, 7 = 8.8 Hz, 1H), 7.28 - 7.21 (m, 211), 7.46 - 7.33 (m, 414); M+H (356.1).
    2-(4-fluoro-3-methylphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 64.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and 4-fluoro-3-methylphenol. *H NMR (400 MHz, DMSO-d6) δ 2.14 (d, 7 = 1.8 Hz, 3H), 4.38 (br s, 2H), 4.98 (br s, 2H), 6, 54 (br d, J= 8.5 Hz, 1H), 6.64 (br s, 1H), 6.82 (br s, 1H), 6.89 (dd, J= 5.1, 3.4 Hz, 1H), 6.97 (t, .7 = 9.1 Hz, 1H), 7.28 - 7.21 (m, 2H), 7.48 - 7.32 (m, 4H); M+H (356.1).
    5 2-(5-methylpyridin-2-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 75.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and 5-methylpyridin-2-ol. δ H NMR (400 MHz, DMSO-d6) δ 2.17 (s, 3H), 4.57 (br s, 2H), 4.96 (br s, 2H), 6.71 (d, J=8 .4 Hz, 1H), 6.81 (br s, 1H), 6.89 (dd, .7= 5.1, 3.4 Hz, 1H), 7.31 - 7.24 (m, 2H) , 7.46 - 7.32 (m, 4H), 7.50 (dd, .7 = 8.4, 2.0 Hz, 1H), 7.87 10 (brs, 1H); M+H (339.1).
    2-(3-fluoro-4-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetinide; Example 76.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and 3-fluoro-4-methoxyphenol. δ H NMR (400 MHz, DMSO-d6) δ 3.74 (s, 3H), 15 4.39 (br s, 2H), 4.98 (br s, 2H), 6.50 (br s, J = 8.6 Hz, HI), 6.69 (br d, .7 = 13.2 Hz, 1H), 6.81 (br s, 1 H), 6.89 (dd, J= 5.1, 3.4 Hz, 1H), 7.01 (t, J=9.5 Hz, 1H), 7.26 (m, 2H), 7.46 -7.32(m, 4H); M+H (372.1).
    2-(6-methylpyridin-2-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 83.20
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and 6-methylpyridin-2-ol. 11 NMR (400 MHz, DMSO-d6) δ 2.29 (s, 3H), 4.55 (br s, 2H), 4.96 (br s, 2H), 6.60 (d, .7= 8.2 Hz, HI), 6.79 (m, 2H), 6.89 (dd, .7 = 5.1, 3.4 Hz, HI), 7.31 (d, .7 = 7.2 Hz, 2H), 7.47 - 7.34 (m, 4H), 7.55 (dd, J = 8.2, 7.3 Hz, HI); M+H (339.1).
    2-(6-methylpyridin-3-yloxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 90.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and 6-methylpyridin-3-ol. *H NMR (400 MPIz, DMSO-d6) δ 2.25 (s, 3H), 4.59 (br s, 2H), 4.95 (br s, 2H), 6.63 (br s, 1H) , 6.79 (m, 2H), 6.88 (dd, J = 5.1, 3.4 Hz, 1H), 7.31 -7.24 (m, 2H), 7.47-7.33 (m, 4H), 7.91 (d, α/ = 5.2 Hz, 1H); M+H (339.1).
    N-phenyl-N-(thiophen-2-ylmethyl)-2-(4-(trifluoromethyl)phenoxy)acetamide; Example 130.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and 4-(trifluoromethyl)phenol. 11 NMR (400 MHz, DMSO-d6) δ 4.55 (s, 2H), 4.98 (br s, 2H), 6.82 (br s, 1H), 6.89 (dd, J = 5 .1, 3.4 Hz, 1H), 6.94 (br d, ./= 8.2 Hz, 2H), 7.28 (br d, J= 7.0 Hz, 2H), 7.46 - 7.35 (m, 4H); 7.60 (br d, α/= 8.6 Hz, 2H); M+H (392.1).
    N-phenyl-N-(thiophen-2-ylmethyl)-2-(thiophen-2-yloxy)acetamide; Example 145.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiophen-2-ylmethyl)acetamide and thiophen-2-ol. 1 H NMR (400 MHz, DMSO-d6) δ 4.43 (br s, 2H), 4.99 (br s, 2H), 6.13 (br s, 1H), 6.65 (dd,./ = 5.7, 3.8 Hz, 1H), 6.71 (dd, ./= 5.8, 1.5 Hz, 1H), 6.81 (br s, 1H), 6.89 (dd , J = 5.1, 3.4 Hz, III), 7.25 - 7.20 (m, 211), 7.44 - 7.33 (m, 4H); M+H(330.1).
    2-(4-allyl-2-methoxyphenoxy)-N-phenyl-N-(thiophen-2-ylmethyl)acetamide; Example 154.
    Prepared similarly to example 44 from 2-bromo-N-phenyl-N-(thiocyan-2-ylmethyl)acetamide and 4-allyl-2-methoxyphenol. 1II NMR (400 MHz, DMSO-d6) δ 3.25 (m, 2H), 3.68 (s, 311), 4.43 - 4.26 (m, 2H), 5.08 - 4.96 ( m, 4H), 5.90 (m, 1H), 6.59 (br s, 2H), 6.74 (br s, 111), 6.81 (br s, III), 6.89 (dd, J = 5.1, 3.4 Hz, 1H), 7.26 - 7.20 (m, 2H), 7.40 (m, 411); M+H (394.1). The patents and publications listed herein describe the general technique and are hereby incorporated by reference in their entirety and for all purposes to the same extent as if each were specifically and individually indicated to be incorporated as reference. In the event of any conflict between a cited reference and this descriptive report, the descriptive report will prevail. In describing embodiments of the present application, specific terminology is employed for the sake of clarity. However, this invention is not intended to be limited to the specific terminology selected. Nothing in this specification should be considered as limiting the scope of the present invention. All examples presented are representative and not limiting. The above-described embodiments may be modified or varied without departing from the invention, as understood by those skilled in the art in light of the foregoing teachings.
    权利要求:
    Claims (12)
    [0001]
    1. Non-medical method for modulating Transient Receptor Channel Potential of Melastatin 8 (TRPM8) characterized in that it comprises contacting the receptor with a compound having structural formula (I):
    [0002]
    2. A non-medical method of modulating the cooling sensation of a composition comprising combining the composition with a compound of Structural Formula (I):
    [0003]
    3. A non-medical method of inducing a feeling of cooling in a human or animal which comprises bringing the human or animal into contact with a compound of Structural Formula (I):
    [0004]
    Non-medical method according to claim 1, characterized in that the compound or a salt thereof is used in vitro or in vivo.
    [0005]
    5. Non-medical method according to any one of claims 1 to 3, characterized in that the compound, or a salt thereof, is a TRMP8 receptor agonist.
    [0006]
    6. Composite, characterized by being selected from a group
    [0007]
    7. Compound, according to claim 6, characterized in that it has the structure of
    [0008]
    8. Non-medical method according to any one of claims 1 to 3, characterized in that R2a, R2b, R3, R4, R5 and R6 are all hydrogens.
    [0009]
    9. Non-medical method according to any one of claims 1 to 3, characterized in that a) X1-X2 is O-CH2, O-CH(CHs) or O-CH(CH2CHs); or b) X1-X2 is CH2-CH2 or CH=CH.
    [0010]
    10. Non-medical method, according to any one of claims 1 to 3, characterized in that the compound is selected from a group
    [0011]
    A non-medical method according to any one of claims 1 to 3, characterized in that the compound is in a composition further comprising at least one carrier, wherein the composition is an ingestible composition or personal care composition; or a food or drink; or a textile product or packaging material; or wherein the composition is in the form of a solid, semi-solid, plaster, solution, suspension, lotion, cream, foam, gel, paste, emulsion or a combination thereof; or wherein the compound in the composition is in a concentration ranging from 0.0001 ppm to 100,000 ppm.
    [0012]
    12. Non-medical method, according to claim 11, characterized in that the compound is in a concentration ranging from 1 ppm to 500 ppm.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6598219B2|2019-10-30|Compounds useful as TRPM8 activity regulators
    US11028052B2|2021-06-08|Compounds useful as modulators of TRPM8
    JP6322673B2|2018-05-09|Sweetness modifier
    TWI595838B|2017-08-21|Sweet flavor modifier
    TWI639385B|2018-11-01|Sweet flavor modifier
    同族专利:
    公开号 | 公开日
    US9394287B2|2016-07-19|
    RU2608109C2|2017-01-13|
    AU2011323245B2|2016-01-21|
    MY165612A|2018-04-18|
    JP6598219B2|2019-10-30|
    JP5990526B2|2016-09-14|
    US10016418B2|2018-07-10|
    JP2014503486A|2014-02-13|
    MX340488B|2016-07-08|
    US20180289704A1|2018-10-11|
    MX2013005001A|2013-08-08|
    WO2012061698A3|2012-08-02|
    CN108484589A|2018-09-04|
    CN103201279A|2013-07-10|
    US20130324557A1|2013-12-05|
    CA2816983A1|2012-05-10|
    EP2635572A2|2013-09-11|
    RU2013125846A|2014-12-10|
    JP2016172769A|2016-09-29|
    EP2635572B1|2018-10-17|
    BR112013011188A2|2016-07-05|
    DE202011111014U1|2018-05-02|
    WO2012061698A9|2013-01-10|
    WO2012061698A2|2012-05-10|
    US10953007B2|2021-03-23|
    MX359640B|2018-10-04|
    JP6175163B2|2017-08-02|
    AU2011323245A1|2013-05-02|
    JP2017165774A|2017-09-21|
    US20160317532A1|2016-11-03|
    EP3470407A1|2019-04-17|
    EP2635572A4|2014-04-02|
    ZA201303421B|2015-02-25|
    DE202011110963U1|2017-11-07|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US335251A|1886-02-02|Baking-pan |
    US4753674A|1981-10-20|1988-06-28|Ube Industries, Ltd.|Herbicidal composition containing a phenoxyalkylamide derivative and method for controlling weeds by the use of the same|
    US4404018A|1982-06-23|1983-09-13|Velsicol Chemical Corporation|Furfuryl amides of phenoxyphenoxyalkanoic acids and herbicidal use|
    JPH0142257B2|1982-08-10|1989-09-11|Ube Industries|
    GB8316779D0|1982-09-07|1983-07-27|Ici Plc|Process|
    JPH0259806B2|1985-01-16|1990-12-13|Tokuyama Soda Kk|
    CS276621B6|1988-12-22|1992-07-15|Univ Slovenska Tech|N-substituted-2,6-dialkyl anilides and process for preparing thereof|
    US5084466A|1989-01-31|1992-01-28|Hoffmann-La Roche Inc.|Novel carboxamide pyridine compounds which have useful pharmaceutical utility|
    DK0471612T3|1990-08-14|1999-02-22|Hoechst Marion Roussel Inc|New 19-nor carbon chain steroids comprising an amide group at the 11-beta position, process for their preparation, the|
    JPH03275657A|1989-07-05|1991-12-06|Kanegafuchi Chem Ind Co Ltd|Cinnamic acid amide derivative|
    CA2020437A1|1989-07-05|1991-01-06|Yoshihide Fuse|Cinnamamide derivative|
    US5214204A|1991-07-19|1993-05-25|Abbott Laboratories|Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity|
    US5403843A|1991-08-12|1995-04-04|Takeda Chemical Industries, Ltd.|Pyrrolopyrimidinyalglutaminate derivatives and their use|
    JPH0625276A|1992-05-13|1994-02-01|Tanabe Seiyaku Co Ltd|Acylaminosugar derivative and its production|
    EP0650974A1|1993-10-28|1995-05-03|Tanabe Seiyaku Co., Ltd.|Acylaminosaccharide derivative and process for preparing the same|
    JPH07133226A|1993-11-11|1995-05-23|Tanabe Seiyaku Co Ltd|Phylactic agent|
    ITFI940095A1|1994-05-23|1995-11-23|Molteni & C|PHOTODYNAMIC CONJUGATES WITH BIOCIDE PROPERTIES|
    DE69514367T2|1994-08-11|2000-07-27|Banyu Pharma Co Ltd|SUBSTITUTED AMID DERIVATIVES|
    US5780473A|1995-02-06|1998-07-14|Bristol-Myers Squibb Company|Substituted biphenyl sulfonamide endothelin antagonists|
    IL118631A|1995-06-27|2002-05-23|Tanabe Seiyaku Co|Pyridazinone derivatives and processes for their preparation|
    EP0847268B1|1995-08-29|2001-09-12|V. Mane Fils S.A.|Refreshing compositions|
    AU1619497A|1996-02-07|1997-08-28|Banyu Pharmaceutical Co., Ltd.|Substituted amide derivatives|
    AU1619297A|1996-02-07|1997-08-28|Banyu Pharmaceutical Co., Ltd.|Substituted amide derivatives|
    IL123986A|1997-04-24|2011-10-31|Organon Nv|Serine protease inhibiting antithrombotic agents and pharmaceutical compositions comprising them|
    DE19838138A1|1997-08-25|1999-03-04|Novartis Ag|New isoxazole-5-one derivatives|
    NZ503809A|1997-12-19|2002-04-26|Schering Ag|Ortho-anthranilamide derivatives as anti-coagulants|
    DK1073623T3|1998-04-20|2007-06-25|Ortho Mcneil Pharm Inc|Substituted amino acids such as erythropoietin mimetics|
    US6310078B1|1998-04-20|2001-10-30|Ortho-Mcneil Pharmaceutical, Inc.|Substituted amino acids as erythropoietin mimetics|
    DE60023492T2|1999-05-17|2006-07-20|Novo Nordisk A/S|GLUCAGON ANTAGONISTS / INVERSE AGONISTS|
    TWI262185B|1999-10-01|2006-09-21|Eisai Co Ltd|Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives|
    ECSP003699A|1999-10-08|2002-04-23|Smithkline Beecham Corp|FAB I INHIBITORS|
    US6306911B1|2000-02-07|2001-10-23|Ortho-Mcneil Pharmaceutical, Inc.|Substituted amino acids as neutral sphingomyelinase inhibitors|
    US6468576B1|2000-06-23|2002-10-22|Nestec S.A.|Frozen slush liquid concentrate and method of making same|
    GB0023983D0|2000-09-29|2000-11-15|Prolifix Ltd|Therapeutic compounds|
    FR2815032B1|2000-10-10|2003-08-08|Pf Medicament|NOVEL AMINOPHENYL PIPERAZINE OR AMINO PHENYL PIPERIDE DERIVATIVES PRENYL TRANSFERASE PROTEIN INHIBITORS AND PREPARATIONS THEREOF|
    CA2438318A1|2001-02-16|2002-08-29|Aventis Pharmaceuticals Inc.|Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands|
    WO2002080899A1|2001-03-30|2002-10-17|Eisai Co., Ltd.|Remedial agent for digestive disease|
    DE10115994A1|2001-03-30|2002-10-10|Wella Ag| acrylamide derivatives and colorants containing these compounds|
    DE20110355U1|2001-06-22|2001-08-30|Wella Ag| acrylamide derivatives and colorants containing these compounds|
    DE20111037U1|2001-07-04|2001-08-30|Wella Ag| acrylamide derivatives and colorants containing these compounds|
    DE10206354A1|2002-02-14|2003-08-28|Aventis Pharma Gmbh|Use of inhibitors of the sodium-dependent chloride-bicarbonate exchanger for the treatment of thrombotic and inflammatory diseases|
    CA2497901A1|2002-09-06|2004-03-18|Takeda Pharmaceutical Company Limited|Furan or thiophene derivative and medicinal use thereof|
    MXPA05003054A|2002-09-20|2005-05-27|Pfizer Prod Inc|Amide and sulfonamide ligands for the estrogen receptor.|
    WO2004063147A1|2003-01-10|2004-07-29|Novo Nordisk A/S|Salts and solvates of glucagon antagonists|
    CA2519429C|2003-03-17|2013-08-06|Affinium Pharmaceuticals, Inc.|Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics|
    WO2004085420A1|2003-03-24|2004-10-07|Vicore Pharma Ab|Bicyclic compounds useful as angiotensin ii agonists|
    JP2005272476A|2003-04-09|2005-10-06|Japan Tobacco Inc|Heteroaromatic pentacyclic compound and medicinal use thereof|
    RU2005134659A|2003-04-09|2007-05-27|Джапан Тобакко Инк. |HETEROAROMATIC PENTACYCLIC COMPOUND AND ITS APPLICATION IN MEDICINE|
    AU2004247389C1|2003-06-13|2010-05-27|Laboratorios S.A.L.V.A.T., S.A.|New benzamides as PPARY modulators|
    GB0314079D0|2003-06-18|2003-07-23|Astrazeneca Ab|Therapeutic agents|
    SI1656139T1|2003-07-21|2011-12-30|Merck Serono Sa|Aryl dicarboxamides|
    US20060045953A1|2004-08-06|2006-03-02|Catherine Tachdjian|Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers|
    GB0325644D0|2003-11-04|2003-12-10|Avidex Ltd|Immuno ihibitory pyrazolone compounds|
    CA2568914C|2004-06-04|2013-09-24|Affinium Pharmaceuticals, Inc.|Therapeutic agents, and methods of making and using the same|
    EP1838690A2|2004-12-21|2007-10-03|Devgen N.V.|Compounds with kv4 ion channel activity|
    CA2592092A1|2004-12-22|2006-06-29|Pfizer Limited|Nonnucleoside inhibitors of hiv-1 reverse transcriptase|
    JP2006232706A|2005-02-23|2006-09-07|Dai Ichi Seiyaku Co Ltd|Phenetylamine derivative and medicine by using the same|
    GB0506133D0|2005-03-24|2005-05-04|Sterix Ltd|Compound|
    WO2006138350A2|2005-06-15|2006-12-28|Anormed Inc.|Chemokine receptor binding compounds|
    WO2007017093A1|2005-08-04|2007-02-15|Bayer Healthcare Ag|Substituted 2-benzyloxy-benzoic acid amide derivatives|
    US20070259354A1|2005-10-11|2007-11-08|Senomyx, Inc.|Optimized trpm8 nucleic acid sequences and their use in cell based assays and test kits to identify trpm8 modulators|
    KR101423785B1|2005-10-21|2014-07-25|액테리온 파마슈티칼 리미티드|Piperazine derivatives as antimalarial agents|
    WO2007054480A1|2005-11-08|2007-05-18|N.V. Organon|2--acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor|
    WO2007076055A2|2005-12-22|2007-07-05|Entremed, Inc.|Compositions and methods comprising proteinase activated receptor antagonists|
    DE102006012251A1|2006-03-15|2007-11-08|Grünenthal GmbH|Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments|
    US8318720B2|2006-07-20|2012-11-27|Affinium Pharmaceuticals, Inc.|Acrylamide derivatives as Fab I inhibitors|
    US20080090242A1|2006-09-29|2008-04-17|Schering Corporation|Panel of biomarkers for prediction of fti efficacy|
    DE102006049452A1|2006-10-17|2008-05-08|Grünenthal GmbH|Substituted tetrahydropyrolopiperazine compounds and their use in medicaments|
    DE102006060598A1|2006-12-21|2008-06-26|Merck Patent Gmbh|New tetrahydrobenzoisoxazole compounds are mitotic motor protein Eg5 modulators useful to treat and prevent cancer, and to treat e.g. monocyte leukemia, glioblastoma, colon carcinoma, myelotic leukemia and lymphatic leukemia|
    US20090023798A1|2007-06-15|2009-01-22|Pharmacyclics, Inc.|Thiohydroxamates as inhibitors of histone deacetylase|
    WO2009011336A1|2007-07-18|2009-01-22|Taisho Pharmaceutical Co., Ltd.|Quinoline compounds|
    TW200922558A|2007-09-28|2009-06-01|Mitsubishi Tanabe Pharma Corp|Indazole acrylic and amide compound|
    WO2010051048A1|2008-02-20|2010-05-06|The Wistar Institute|Microrna modulators and method for identifying and using the same|
    CA2728769A1|2008-07-04|2010-01-07|Bruno Villoutreix|Nitrogen heterocycle derivatives as proteasome modulators|
    ES2659421T3|2008-08-26|2018-03-15|Basf Se|Detection and use of low molecular weight modulators of the cold menthol receptor TRPM8|
    WO2010080397A1|2008-12-18|2010-07-15|Janssen Pharmaceutica Nv|Sulfamides as trpm8 modulators|
    DE102010002558A1|2009-11-20|2011-06-01|Symrise Ag|Use of physiological cooling agents and agents containing such agents|
    EP2521724B1|2009-12-11|2016-11-23|Nono Inc.|Agents and methods for treating ischemic and other diseases|
    MY165612A|2010-11-05|2018-04-18|Senomyx Inc|Compounds useful as modulators of trpm8|
    EP2481727A1|2011-01-28|2012-08-01|Dompe S.p.A.|TRPM8 receptor antagonists|
    EP2958897B1|2013-02-19|2019-01-09|Senomyx, Inc.|Compounds useful as modulators of trpm8|
    ES2850999T3|2014-03-14|2021-09-02|Raqualia Pharma Inc|Azaspiro derivatives as TRPM8 antagonists|
    BR112018006471A2|2015-10-01|2018-10-09|Senomyx Inc|compounds useful as trpm8 modulators|MY165612A|2010-11-05|2018-04-18|Senomyx Inc|Compounds useful as modulators of trpm8|
    EP2481727A1|2011-01-28|2012-08-01|Dompe S.p.A.|TRPM8 receptor antagonists|
    JP2014527511A|2011-06-24|2014-10-16|アムジエン・インコーポレーテツド|TRPM8 antagonists and their use in therapy|
    EP2723718A1|2011-06-24|2014-04-30|Amgen Inc.|Trpm8 antagonists and their use in treatments|
    US8952009B2|2012-08-06|2015-02-10|Amgen Inc.|Chroman derivatives as TRPM8 inhibitors|
    JP6882144B6|2012-12-12|2021-06-23|シムライズ アーゲー|Compositions and cosmetic compositions|
    US10182584B2|2012-12-12|2019-01-22|Symrise Ag|Cooling preparations|
    DE202012013357U1|2012-12-12|2016-07-29|Symrise Ag|preparations|
    EP2958897B1|2013-02-19|2019-01-09|Senomyx, Inc.|Compounds useful as modulators of trpm8|
    WO2014172871A1|2013-04-25|2014-10-30|Syngenta Participations Ag|Dihydrobenzofuran derivatives as insecticidal compounds|
    EP2832234A1|2013-07-30|2015-02-04|IMAX Discovery GmbH|Imidazo[1,2-a]pyridine-ylmethyl-derivatives and their use as flavoring agents|
    EP2979682B1|2014-07-30|2018-09-05|Symrise AG|A fragrance composition|
    EP3297676A2|2015-05-22|2018-03-28|Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt |Combination of trpm8-agonist and nachr-agonist for treatment of obesity and related disorders and for weight reduction|
    AU2016281346B2|2015-06-23|2020-01-02|Kissei Pharmaceutical Co., Ltd.|Pyrazole derivative, or pharmaceutically acceptable salt thereof|
    BR112018006471A2|2015-10-01|2018-10-09|Senomyx Inc|compounds useful as trpm8 modulators|
    BR112018006584B1|2015-10-02|2021-07-27|Firmenich Sa|PERFUME EMITTING DEVICE|
    JP6799671B2|2016-08-09|2020-12-16|シムライズ アーゲー| A mixture containing -3-benzo [1,3] dioxol-5-yl-N, N-diphenyl-2-propeneamide.|
    JPWO2018117166A1|2016-12-21|2019-10-31|キッセイ薬品工業株式会社|Thiazole derivative or pharmacologically acceptable salt thereof|
    EP3615679A4|2017-05-03|2021-02-17|Firmenich Incorporated|Methods for making high intensity sweeteners|
    US20200188289A1|2017-05-15|2020-06-18|Firmenich Sa|Compositions comprising essential oils|
    WO2019012071A1|2017-07-14|2019-01-17|Firmenich Sa|Cooling composition|
    DE202017107872U1|2017-07-14|2018-04-18|Firmenich Sa|cooling composition|
    JP2020531552A|2017-08-31|2020-11-05|ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ|Use of physiological cooling active ingredients, and compositions containing such active ingredients|
    CA3078909A1|2017-10-16|2019-04-25|Takasago International Corporation|Cool-sensation imparter composition containing 2,2,6-trimethylcyclohexanecarboxylic acid derivative|
    BR112020003233A2|2017-12-20|2020-08-18|Firmenich S.A.|compositions for oral care|
    CN110143893A|2018-02-14|2019-08-20|复旦大学|A kind of compound, Its Preparation Method And Use that can combine alpha-synuclein aggregation body by force|
    EP3806661A1|2018-08-10|2021-04-21|Firmenich Incorporated|Antagonists of t2r54 and compositions and uses thereof|
    EP3689324A1|2019-02-04|2020-08-05|Symrise AG|New cooling agents and preparations comprising them|
    EP3860369A1|2019-03-28|2021-08-11|Firmenich SA|Flavor system|
    EP3861004A1|2019-04-04|2021-08-11|Firmenich SA|Mogroside compounds and uses thereof|
    CN113423287A|2019-06-28|2021-09-21|弗门尼舍有限公司|Fat mixtures, emulsions thereof and related uses|
    WO2021043842A1|2019-09-05|2021-03-11|Firmenich Sa|Flavanone derivatives and their use as sweetness enhancers|
    WO2021094268A1|2019-11-11|2021-05-20|Firmenich Sa|Gingerol compounds and their use as flavor modifiers|
    WO2021118864A1|2019-12-13|2021-06-17|Firmenich Incorporated|Taste modifying compositions and uses thereof|
    WO2021119035A1|2019-12-13|2021-06-17|Firmenich Incorporated|Taste modifying compositions and uses thereof|
    WO2021126570A1|2019-12-18|2021-06-24|Firmenich Incorporated|Taste modifying compositions and uses thereof|
    WO2021126569A1|2019-12-18|2021-06-24|Firmenich Incorporated|Taste modifying compositions and uses thereof|
    WO2021175751A1|2020-03-05|2021-09-10|Firmenich Sa|11-oxo-cucurbitanes and their use as flavor modifiers|
    WO2021198199A1|2020-03-31|2021-10-07|Firmenich Sa|Flavor composition|
    WO2021209345A1|2020-04-17|2021-10-21|Firmenich Sa|Amino acid derivatives and their use as flavor modifiers|
    WO2021233973A1|2020-05-22|2021-11-25|Firmenich Sa|Compositions for reducing salty taste and uses thereof|
    WO2021244953A1|2020-06-03|2021-12-09|Firmenich Sa|Compositions for reducing off tastes and uses thereof|
    WO2021259945A1|2020-06-24|2021-12-30|Firmenich Sa|Sweetening compositions and uses thereof|
    WO2022013163A1|2020-07-14|2022-01-20|Firmenich Sa|Reduction of undesirable taste notes in oral care products|
    WO2022020435A1|2020-07-24|2022-01-27|Firmenich Incorporated|Savory taste enhancement via transmembrane region binding|
    法律状态:
    2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2019-07-02| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
    2019-09-17| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-06-01| B350| Update of information on the portal [chapter 15.35 patent gazette]|
    2021-09-21| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
    2021-11-16| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2022-01-04| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/11/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
    优先权:
    申请号 | 申请日 | 专利标题
    US41063410P| true| 2010-11-05|2010-11-05|
    US61/410,634|2010-11-05|
    US201161443490P| true| 2011-02-16|2011-02-16|
    US61/443,490|2011-02-16|
    PCT/US2011/059312|WO2012061698A2|2010-11-05|2011-11-04|Compounds useful as modulators of trpm8|
    [返回顶部]